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1 General definition and properties 
Nanoparticles are defined as objects with a size range between 1and 200 nm, independently 
of their material, shape, charge or other physicochemical characteristics. Cholesterol 
particles (e.g. LDL, HDL), exosomes and viruses can be considered natural nanoparticles, 
whereas engineered nanoparticles (as illustrated in Figure 1) can be made of inorganic 
materials (such as gold, silica, iron, etc.) or organic materials (such as liposomes and other 
lipid based nanoparticles, dendrimers and other polymeric nanoparticles, albumin-based 
nanoparticles or modified viruses and exosomes).1,2 
 
Figure 1: Nano-sized objects can be made of different materials, both organic and inorganic. Reproduced from:  Nano and 
microcarriers to improve stem cell behaviour for neuroregenerative medicine strategies: Application to Huntington's 
disease. Biomaterials (2016).3 
Nanomedicine is the medical application of nanotechnologies for the treatment and 
diagnosis of diseases, with a particular focus on cancer therapy.4–11 Nanomedicines have 
been and are being explored in various technological, biotechnological and pharmacological 
settings, including in drug delivery.4 In fact, nano-sized materials are often used as drug 
carriers to encapsulate smaller hydrophilic and hydrophobic drugs or biologicals, with the 
aim of increasing drug biodistribution and targeting, and reducing eventual side effects. A 
part from the traditional role as drug carriers, nano-sized materials have also been used for 
imaging and diagnostic purposes, for instance in magnetic resonance imaging, or as antigen 
or adjuvant carriers for the development of synthetic vaccines.12 
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1.1 Nano-sized materials for drug delivery 
Nanomaterials have been showed to be promising drug delivery systems because they can 
be easily engineered in many ways. Several characteristics of nanomaterials such as size, 
material, shape, surface charge, hydrophobicity, roughness and elasticity can be tailored in 
order to meet various needs. Moreover, the surface of nanomedicines can be engineered 
by adding fluorescent or other labels for imaging strategies, or by introducing functional 
groups to reduce clearance and increase biodistribution,7 as well as for active targeting 
purposes (as illustrated in Figure 2). Another important characteristic of nanomedicines is 
that they can encapsulate different types of hydrophilic and hydrophobic drugs and they 
can be designed to control their release profile.13 This high engineering potential can be 
exploited to control the distribution and behaviour of nanomedicines in biological 
environments. In fact, by tuning the design of nanomaterials we can in principle tailor 
parameters such as their serum-protein interactions, sequestration by the immune system, 
blood circulation time, biodistribution and cellular recognition and internalization.13  
In this first Chapter, I will discuss in more detail some of the key features of nanomaterials 
for nanomedicine applications, such as their small size, functionalization capabilities and 
easy tailoring and I will highlight how these characteristics make them promising carriers 
for drug delivery.  
 
Figure 2: Nanomedicines can encapsulate several compounds, such as contrast agents for imaging purposes and 
hydrophilic or hydrophobic drugs for therapy. Nanomedicines can also be used to transport biologicals (larger drugs such 
as peptides or RNA and DNA based drugs) and protect them from enzymatic degradation. They can be functionalized in 
many ways, for instance by adding targeting moieties for recognition by specific cells or polymers such as PEG for reducing 
opsonisation and clearance by the immune system. Reproduced from: Cancer nanotechnology: opportunities and 
challenges. Nature Reviews Cancer (2005).6 
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2 The biological interactions of nanomedicines 
The potential of nanotechnology derives from the fact that nano-sized objects represent a 
link between bulk materials and molecular structures. When approaching the nanoscale, 
the number of atoms on the surface of a material becomes significant and this can confer 
different physical and chemical properties to nano-sized materials compared to their 
bulk.14,15 Furthermore, the small size of nanomaterials results in a high surface area to 
volume ratio, and this makes nanoparticles very reactive and prone to interact with their 
surroundings, including biomolecules, cells and organisms. For these reasons, nanoparticles 
are very interesting for nanomedicine since they could potentially interact at cellular level 
in new ways compared to standard small molecular drugs.  The way natural nano-sized 
objects, such as albumin, cholesterol and virus particles16 interact with cells clearly shows 
this potential: natural nanoparticles are recognized by specific cell receptors at the plasma 
membrane, they are internalized by cells using the cell endocytic machinery, and their 
internalization and processing by the cell is precisely regulated. Similarly, engineered 
nanomaterials exploit the cellular machinery to be internalized by cells. In fact, since the 
cell membrane blocks diffusion of complexes larger than ~1 kDa, nanomedicines need to be 
transported into cells using energy dependent mechanisms,17 unlike many small drugs 
present in the market. This enables nanomedicines to potentially overcome problems 
associated with the passive diffusion of drugs through cell membranes, such as their 
indiscriminate internalization in different cell types and organs, which is often associated 
with several side effects. Moreover, the possibility of engineering nanomedicines to interact 
with cell receptors opens up new strategies for targeting specific cell types and organs. So 
far, several receptors have been associated with the uptake of nanomaterials. 18,19 The initial 
recognition of nanomedicines at the plasma membrane can also affect their subsequent 
processing by cells, including their final localization in the cell. However, still little is known 
about the recognition of nanomaterials by receptors at the plasma membrane and about 
the molecular mechanisms leading to their uptake and intracellular processing.20–23 A better 
understanding of these processes can help to design smarter nanomedicines and to achieve 
a better targeting.24  
Another important consequence of the high reactivity of nano-sized objects is the formation 
of the so called biomolecular ‘corona’.25–28 When a nanomedicine (or any nano-size 
material) after administration enters in contact with a biological environment (for example, 
with blood, interstitial fluids or extracellular matrices), its surface is rapidly covered by 
various biomolecules, leading to the formation of a corona (Figure 3). The prevailing 
hypothesis describes an inner layer of tightly bound biomolecules (‘hard corona’) with a 
long residence time on the nanoparticle, and an outer layer of weakly bound biomolecules 
(‘soft corona’), which instead have a high exchange rate with the surrounding 
environment.29 Nanoparticle physico-chemical characteristics, such as size, shape, charge, 
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hydrophobicity, rigidity and surface characteristics affect the composition of the 
corona.5,12,13,23,34–36 Moreover, the presence of a corona alters particle size, stability and 
surface properties and confers a new biological identity to the nanomaterial.25 In fact, the 
corona can determine the way particles are recognized and processed by cells5,12,13,23,34–36 
and can modulate their pharmacological and toxicological profile, as well as their 
therapeutic or diagnostic functions.19,25,30 This means that the characteristics of the medium 
in which nanomedicines are dispersed can dramatically change the corona composition, 
thus the biological responses to nanomedicines.31–33 For this reason, even when testing 
nanomedicines in vitro, one should always take into account the source, concentration and 
composition of the dispersant used.  
 
Figure 3: The corona is a layer of biomolecules adsorbed on the surface of nano-sized objects once they are introduced in 
a biological environment. It has been shown that this layer can mediate the interaction of nanomedicines with cells. 
Adapted from: Biomolecular coronas provide the biological identity of nano-sized materials. Nature Nanotechnology 
(2012).25
Even though several studies in vivo and in vitro37–40 have characterized the corona of several 
nanomedicines, a clear picture on how the corona composition affects the biological 
behaviour of nanomedicines is still missing.26 Several works in literature have demonstrated 
that different corona components can specifically be recognized by cellular 
receptors.19,30,41,42 More recent examples showed that the presence or absence of a corona 
can also determine a different uptake mechanisms for the same nanomedicine.43,44 As it is 
emerging that the biomolecular corona mediates the interaction of the nanomaterials with 
cells, the control of its composition can potentially be exploited as a novel strategy to direct 
nanomedicines towards specific targets. For example, nanomaterials can be designed to 
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form a corona that can initiate targeted receptor-mediated cellular binding and 
internalization.30,41,42,45. Another emerging way to exploit the biomolecular corona is to use 
it as a fingerprint of serum proteins for the early detection of disease markers for diagnostic 
purposes.46 Overall, further studies are necessary to fully understand how the corona 
mediates the interaction of nanomedicines with cells and organs. 
3 The biodistribution of nanomedicines 
Nanomedicines have proved to have longer blood circulation times compared to other 
drugs. Generally speaking, increasing blood circulation time leads to an increased 
probability that a drug will recognize and end up in the target tissue. A series of biological 
factors can influence drug biodistribution.5,13 As mentioned, once circulating in blood, 
nanomedicines adsorb several biomolecules on their surface, including opsonins and other 
proteins which can be recognized by the MPS (mononuclear phagocytic system), leading to 
their fast clearance and transport to the spleen or lymph nodes. Nanomedicines and drugs 
smaller than 5 nm can also be eliminated by renal clearance through the reticuloendothelial 
system, or they can end up in leaky tissues by extravasation. In order to limit this clearance, 
nanomedicine characteristics can be tailored to gain a “stealth effect” and increase their 
blood circulation times.47  
For example controlling the size of nanomaterials can affect their biodistribution. As 
mentioned above, very small particles (1-5 nm) have a high renal clearance and can easily 
spread in different organs since they can cross the endothelial tight junctions. In tumour 
microenvironments a small size can be an advantage, since it allows a rapid and uniform 
penetration in the tissue compared to larger sizes. On the other hand, bigger particles (>200 
nm) can be more easily recognized by the MPS (mononuclear phagocytic system) after 
deposition of opsonins and complement proteins on their surface and are cleared from the 
blood. Moreover they can be sequestered by sinusoids in the spleen and fenestra of liver, 
which are approximately 150–200 nm in diameter. Thus, mid-range particles (20-100 nm) 
on the one hand can avoid renal clearance and leakage into capillaries, and on the other 
hand are not recognized by the MPS as easily as bigger objects.7,13  
Nanoparticle shape also affects their biodistribution. Non-spherical particles seem to be 
cleared rapidly by renal filtration when their shortest dimension is small enough to allow it, 
whereas - as mentioned - larger particles are cleared more efficiently by the MPS.48 
Similarly, spherical nanoparticles penetrate and accumulate in tumours less rapidly than 
disc-shaped or rod-like nanoparticles.23,49  
Nanoparticle charge can also influence biodistribution. Positively charged nanoparticles can 
easily interact with cells and matrices due to electrostatic interactions, therefore they tend 
to have lower blood circulation times than neutral or negatively charged particles. However, 
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once cationic particles reside in a tissue, due to their charge, they can also strongly interact 
with membranes and matrices, thus distributing less efficiently throughout the tissue itself.5 
It must be stressed that the charge of nanomedicines can vary greatly when dispersed in 
complex biological environments as a consequence of corona formation. For example, many 
nano-sized objects with a mild-negative or positive-charge tend to neutrality after 
adsorption of serum proteins on their surfaces. Therefore a careful analysis of the final 
charge of nanomedicines once introduced in biological context should be carried out in 
order to be able to predict  possible outcomes based on their final charge.5,13,23 
Some studies have tried to summarise (as illustrated in Figure 4) how size, shape and charge 
affect nanomedicine biodistribution, and introduced the concept of “geometrical targeting” 
as a novel strategy to exploit these effects for improving drug delivery.47 
 
Figure 4: Nanoparticle size (a), shape (b) and surface charge (c) dictate biodistribution among the different organs. 
Reproduced from: Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature 
Biotechnology (2015).47 
The surface of nanomedicines can be engineered by adding functional groups to reduce 
clearance and increase their biodistribution.7,50 For example, grafting hydrophilic polymers 
such as polyethylene glycol (PEG) on the surface of nanomedicines, a process called 
PEGylation, has been proved to be an effective strategy to increase the residence time of 
nanomedicines in the blood (Figure 5).51,52 In fact, PEGylation can reduce the amount of 
biomolecules bound on the surface of nanomedicines after administration,53,54 therefore 
reducing their opsonisation and recognition by the MPS. Not only the presence of PEG, but 
also its density and length are fundamental to control the interactions with biomolecules: 
increasing the PEG length, for instance, reduces protein adsorption on the surface of 
nanomedicines and can change affinity for certain classes of biomolecules, like 
apolipoproteins.55 
Next to PEGylation, many other strategies are being investigated in order to limit the 
interactions of nanomedicines (and drugs in general) with serum proteins and the immune 
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system when they reach systemic circulation.56 These include bio-inspired strategies such 
as functionalizing nanomedicines with “self” peptides, or using leucocytes or red blood cells 
membranes to coat their surface (also illustrated in Figure 5). 
 
Figure 5: The surface of nanomedicines can be modified in many ways in order to increase their circulation time. 
PEGylation reduces serum adsorption on their surface, therefore reducing recognition by the mononuclear phagocytic 
system. Additional strategies such as the addition of ‘self’ peptides, or coating with leucocyte or red-blood cells 
membranes can also reduce clearance by the immune system. Reproduced from: Principles of nanoparticle design for 
overcoming biological barriers to drug delivery. Nature Biotechnology (2015).47 
4 Targeting strategies of nanomedicines  
As mentioned, nanomedicines have – among others - the great advantage of using energy-
dependent processes to be internalized by cells, thus avoiding an indiscriminate diffusion 
through the plasma membrane.57 This can facilitate the selective targeting of specific cell 
types. However, the targeted delivery of nanomedicines and, more in general, of any kind 
of drugs to specific tissues and organs, still remains a great challenge in drug delivery.58–60 
Passive and active targeting strategies can be used to improve the delivery of 
nanomedicines, in particular for what concerns delivery to tumours (Figure 6).9,61,62 In the 
following sections I will present these and other strategies currently investigated to improve 
the delivery of nanomedicines to their targets.
4.1 Passive targeting: the EPR effect   
Nanomedicine success in cancer therapy has been linked to the capacity of nano-sized 
objects to exploit the so-called EPR effect (Enhanced Permeability and Retention).64,65 The 
EPR effect is the higher permeability of (some) tumour vessels and the poor clearance of 
drugs from the tumor tissue, which leads to their higher retention. Inflammation or pro-
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angiogenic signals can activate the rapid formation of blood vessels in tumors, resulting 
often in large intercellular gaps between endothelial cells (Figure 6 and 7).  
 
Figure 6: Active and passive targeting strategies in tumour targeting. Nanomedicines can extravasate in the tumour tissue 
trough leaky vasculature (passive targeting) or they can be functionalized in order to target tumour cells (active targeting). 
Reproduced from: Impact of albumin based approaches in nanomedicine: Imaging, targeting and drug delivery. Advances 
in Colloid and Interface Science (2017).63 
Those leaky vessels can provide a greater access to extravascular targets compared to the 
normal vasculature. For example, while the endothelium of normal breast or pancreatic 
tissue has a pore size around 5 nm, the endothelium of a breast or pancreatic tumour may 
be up to around 50-60 nm. In a brain tumour, intercellular gaps in the endothelium can be 
around 7 nm versus less than 1 nm for normal brain tissue.7 Other tumour types, such as 
LS174T colon carcinomas, can have endothelial gaps as large as 400–600 nm.66 At the same 
time, as mentioned, tumours can also show enhanced retention due to lymphatic 
dysfunction and poor clearance. Indeed nano-sized drug delivery systems can extravasate 
and accumulate in the tumour tissue by passing through their larger endothelial pores. Once 
in the tissue, stimuli-responsive nanomedicines can be designed to achieve a controlled 
release of their content in the tumour environment (often associated with higher 
temperature and lower pH and oxygen levels), providing an additional strategy for targeted 
delivery.67 Next to active and passive targeting and nanomedicines responsive to 
endogenous stimuli, other new targeting strategies are focusing on the development of 
nanoparticles that can release the therapeutic agents in response to an external stimulus 
(for example light, ultrasound, heat, electric or magnetic fields).8,10  
Overall,  the EPR effect can be exploited for passive tumour targeting of nanomedicines and 
this can be combined to other targeting approaches, such as active targeting and the use of 
stimuli responsive materials.8 However, while the efficacy of passive targeting has been 
proved in several tumour models in vivo, its clinical relevance and efficacy in humans is still 
debated.68,69 This is due to the great tumour heterogeneity among not only different 
species, but also among individual patients, who –even for a same tumour type or within 
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the same tumour – may be characterized by very different EPR levels.12  In order to address 
this heterogeneity, and select patients who could benefit of passively targeted 
nanomedicines, more recent strategies are focusing on the development of tools to predict 
the extent of the EPR effect in individuals for a more personalized terapy,12,70 as well as on 
therapies that can enhance drug penetration in tumours, when the EPR effect is limited.11 
 
Figure 7: The tumour endothelium can be more permeable to nanomedicines than normal endothelium. Reproduced 
from: Nanoparticulate delivery systems for antiviral drugs. Antiviral Chemistry and Chemotherapy (2010).71 
 
4.2 Active targeting 
In addition to the EPR effect, as mentioned above, nano-sized drug delivery systems can use 
active targeting strategies in order to increase their target specificity (also in Figure 6). For 
example, drugs can be engineered by adding functional groups that can recognize specific 
cell types to enhance their delivery to the targeted tissue. This specific recognition can also 
increase the drug retention in the tissue, therefore increasing its therapeutic effect and 
reducing toxicity in other (non-targeted) locations. Several antibodies and few immune-
drug conjugates have arrived on the market, with many more undergoing clinical trials, 
demonstrating overall that active targeting approaches hold great promises.12 However 
actively targeted nanomedicines seem to be still far from the clinic: although there are 
several in vitro studies using targeted drug carriers, just few examples so far reached the 
clinical trials.72–74 Up to now, some studies have suggested that no significant difference in 
tumour accumulation can be observed for active and passive targeted nanomedicines in 
pre-clinical models.62,75,76 However, the efficacy of targeted nanomedicines is rarely 
compared with their untargeted counterpart during clinical trials, making it difficult to draw 
conclusions.12 Further studies are necessary to unravel why active targeting strategies seem 
to have still a modest success. On the one hand, the complexity of studying tissue properties 
and organization in different diseases, in particular in clinical contexts, represents an 
obstacle for the improvement of nanomedicine design for active targeting. On the other 
hand, it is difficult to predict the fate of nanomedicines once administered. For example, 
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protein adsorption and corona formation represent a great variable for the prediction of 
nanomedicine behaviour. Several studies in vitro have proved that the serum biomolecules 
forming the corona can mask, at least in part, targeting ligands.77,78 Moreover the presence 
of a biomolecular corona substantially decreases the overall uptake of nanomedicines in 
vitro, and this effect is higher when approaching in vivo serum concentrations,79 
substantially reducing the efficacy of the delivery.  
Because of these reasons, as mentioned, the biomolecular corona has been initially 
considered as an obstacle to targeted delivery. PEGylation and other similar strategies have 
been used to reduce the amount of bound proteins on the nanoparticle surface (Figure 5). 
Alternative strategies are instead focusing on exploiting the biomolecular corona for 
targeted drug delivery.30,41,42,45 In fact, several in vitro studies have demonstrated that 
different corona components can specifically recognize cellular receptors.19,30,41,42 This 
recognition can potentially be exploited for improving targeted delivery of 
nanomedicines.43,44 As discussed in the previous Section, the biomolecular corona 
composition is affected by the physico-chemical characteristics of 
nanomedicines.5,12,13,23,34–36 Thus, nanocarrier design could be tailored to achieve 
interaction with specific plasma proteins and form a corona to target specific cell receptors: 
in this way, controlling the corona composition can provide a new strategy to direct 
nanomedicines towards specific targets. While the idea of exploiting the biomolecular 
corona for targeting purposes is appealing, in practice the control of the corona composition 
has not been achieved yet. More studies in this direction are needed to further elucidate 
how the corona is formed and how to control it for similar purposes.  
A part from grafting targeting groups onto the surface of nanomedicines, some degree of 
targeting can be achieved also by simply tuning nanoparticle design.5,23,80–82 In fact, even 
without any particular functionalization on their surface, nanomedicines can be designed 
to exploit the cellular endocytic machinery.17 Since particles with different characteristics 
like size, charge or material, seem to be internalized by different cellular routes and seem 
to have a preference for certain cell types,5,23,80–82 we could in principle exploit these 
characteristics for improving targeted delivery. However, a clear picture of how 
nanoparticle design affects the route of internalization or the specificity for a particular cell 
type is still missing and understanding how nanomedicines enter cells still remain a great 
challenge. Size, charge, shape,83 hydrophobicity,84 rigidity,85 roughness86 and surface 
functionalization52,87 of nanomaterials are all parameters that in principle can be tuned in 
order to select the pathway of internalization of nanomedicines or to direct them towards 
a specific tissue.  
In order to illustrate the complexity of understanding how nanomedicines enter cells, here 
I will present some examples of how size and charge can influence cellular uptake. A more 
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comprehensive review on cellular uptake mechanisms and endocytosis is given later in 
Chapter 2.  
4.2.1 Endocytosis of nanomedicines 
As mentioned above, a fundamental parameter that seems to affect the pathway of 
internalization of nanomedicines is their size. It is generally accepted that the uptake 
efficiency of nanomaterials decreases with increasing particle size,88–90 probably because of 
the extensive membrane rearrangements needed for internalization of larger objects. 
However, there is less agreement on the pathways cells use for the uptake and how these 
change with nanoparticle size.88,89,91,92 For example in one study using cancer murine cells, 
nanoparticles of 500 nm were shown to enter preferentially through a cholesterol-
dependent mechanism, while 50 nm by clathrin-mediated endocytosis and microtubules.88 
In another study using HEK293 cells, spherical polystyrene nanoparticles of 100 nm were 
internalized through actin-dependent processes, 200 nm by clathrin mediated endocytosis 
(CME) and bigger particles up to 500 nm by microtubules.91 The comparison of these two 
studies, selected just as an example among several others, already highlights the difficulties 
in establishing a general rule for size-dependent uptake. Also, the assumption that a 
particular cellular pathway has a preference for particles of a specific size range is not always 
correct. For example, it was believed that particles larger than 200 nm could not be 
internalized by non-phagocytic cells,13 while later it was discovered that even cubic 
nanoparticles of 3 μm could be internalized by HeLa cells.81 Another similar example is that 
clathrin-mediated endocytosis is believed to be involved in the internalization of objects 
with a size smaller than 120 nm, since it was thought that the geometry and 3D structure of 
clathrin couldn’t  allow the formation of a larger clathrin pit. On the contrary, it has been 
shown that clathrin-mediated endocytosis can be triggered even by particles as big as 500 
nm, but in this case the pits do not close up completely (see Chapter 2 on endocytosis for 
further details).93–95 Therefore it seems that we cannot just impose a “cut-off” size for the 
internalization of nanomedicines through a specific endocytic pathway.  
Moreover, it appears that nanoparticles of a certain size may be internalized preferentially 
by specific cell types. Next to this, the same nanomedicines seem to be internalized via 
different mechanisms in different cell types. For example, it has been shown that murine 
RAW 264.7 macrophages have higher uptake efficiency for carboxylated polystyrene 
nanoparticles compared to human endothelial HCMEC or epithelial HeLa cells.96 In another 
study using carboxylated polystyrene nanoparticles of different sizes in different cell types, 
actin was required for the internalization of nanoparticles of 200 nm, but not for those of 
40 nm in 1321N1 astrocytes. Instead, in lung epithelial A549 cells, for both nanoparticle 
sizes, the uptake was not dependent on actin.97  
Unfortunately so far, only few studies have investigated in a systematic way how different 
cell types internalize nanoparticles of different size, making it still difficult to fully answer 
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this question and to conclude on the potential applicability of similar observations for 
targeting. We should add that – as mentioned - nanoparticle size also affects corona 
composition34,98 and  nanoparticle stability once in biological media, and these are all other 
important factors that should be taken into account.  
Next to size, charge is another easily-tunable parameter that can greatly influence the 
behaviour of nanoparticles in biological media99 and on cells.100 In general, as previously 
mentioned, positively charged nanoparticles seem to be internalized more efficiently than 
neutral and negative particles.81,101,102 However there are other examples showing exactly 
the opposite.103 Some studies have also shown that uptake increases with charge density 
(either positive or negative).104 As for the pathway of internalization, one study suggested 
that positively charged nanomaterials are predominantly internalized through clathrin-
mediated endocytosis, with a fraction of particles utilizing macropinocytosis, while 
negatively charged nanoparticles are more likely to use a cholesterol-dependent 
mechanism for their internalization.23,92 However, again, there are other examples that 
showed that clathrin mediated endocytosis doesn’t seem to be a relevant pathway for 
neither positive or negative nanomaterials, while cholesterol-mediated uptake is equally 
important for both.105  
We should also  stress that most of these studies were performed in a cell culture medium 
without serum proteins. This represents a further issue since – as previously mentioned - 
the charge of nanomaterials tends towards neutrality upon corona formation, once they 
are applied in a biological environment. Thus,  nanoparticles that in water possess different 
charges might end up having all a similar charge, close to neutrality, once in a biological 
media.99   
More in general, given that the biomolecular corona not only changes the charge of 
nanomaterials, but also affects their overall interactions with cells, one may wonder 
whether it is possible to extrapolate conclusions on the mechanisms of nanomedicine 
endocytosis based on studies performed in biological media very far from in vivo 
applications. In most cases, for instance, in vitro studies use serum-free media or media 
supplemented with proteins of species other than the one investigated (usually bovine 
serum is used for culturing most cells in vitro, including human cells). In light of these 
considerations, we consider essential to study - as one of the initial steps of our 
investigation - how corona formation and composition impact the mechanisms 
nanomedicines use to enter cells. This has been one of the objects of my project and is 
presented in details in Chapter 4. 
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5 Successful examples in the market 
Nanomedicines have showed to have improved targeting capabilities compared to 
conventional drugs106,107 and to reduce the side effects of conventional therapies, first, 
among others, for cancer therapy.10,12 Here I will present two successful examples of 
nanoformulations that are currently in the market, Doxil® and Abraxane®. Some other 
successful examples can be seen here.8,108  
The first liposome-based nanomedicine, Doxil® (OrthoBiotech), was approved in 1995 by 
the FDA (Food and Drug Administration) for the treatment of Kaposi’s sarcoma, ovarian 
cancer and multiple myeloma.9,69 Doxil® is a PEGylated liposome carrier of about 100 nm, 
which encapsulates the cytotoxic anticancer drug doxorubicin (Figure 8). The main 
advantage of Doxil® compared to free doxorubicin is its prolonged circulation time and 
reduced clearance by the mononuclear phagocytic system: in fact, Doxil® half-life time is 
estimated to be of 45 hours, compared to the only 2 hours of free doxorubicin. The longer 
plasma residence time has been achieved by using stable liposomes, characterized by the 
presence of phosphatidylcholine and cholesterol, with a high melting temperature (53 °C) 
and by grafting PEG on the liposome surface. Due to its prolonged circulation time and small 
size, Doxil® can use the EPR effect and accumulate in tumours (see results in Figure 8).  After 
its accumulation, doxorubicin becomes available to tumour cells by a mechanisms not yet 
understood. The current hypotheses are that Doxil® liposomes are internalized by cells and 
afterwards release doxorubicin intracellularly, or that Doxil® releases doxorubicin in the 
tumour interstitial fluid, which afterwards is taken up by the cells as a free drug.69  
Another major advantage of Doxil® is that it has shown significantly reduced cardiotoxicity 
compared with free doxorubicin, probably due to its increased specificity. In fact, free 
doxorubicin can distribute into all tissues indiscriminately and is known to accumulate in 
cardiomyocytes, where it induces strong cardiotoxicity via mitochondrial damage. 
Encapsulating the drug into a liposome reduces side-accumulation in the heart, thus 
resulting in reduced cardiotoxicity. Overall, the Doxil® formulation showed an improved 
drug delivery to tumours, allowed a lower dose to be administrated and improved the 
quality of life of patients thanks to reduced side effects.69 However, Doxil® also presented 
some unexpected side effects, such as desquamating dermatitis and shortness of breath 
due to complement activation.109 More importantly, some studies suggested that the 
overall survival of the patient is not significantly increased (see also Figure 10) after 
treatment with Doxil® compared with free doxorubicin, suggesting that the major 
improvement of the nanoformulation is the reduction of side effects.11
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Figure 8: Doxil, the first FDA-approved nanomedicine. Left:  Illustration of Doxil characteristics. Right: A comparison 
between the doxorubicin levels in tumour biopsies after administration of Doxil (DOXIL) or free doxorubicin (free DOX). 
Reproduced from: Doxorubicin encapsulated in polyethylene-glycol coated liposomes: initial clinical-pharmacokinetic 
studies in solid tumors. Reproduced from: Stealth Liposomes (1995) and Doxil - The first FDA-approved nano-drug: Lessons 
learned. Journal of Controlled Release (2012).69 
Another successful example of a FDA-approved nanoformulation is Abraxane®. Abraxane® 
is a 130 nm polymeric complex of paclitaxel bound to albumin (nabTM), used for metastatic 
or relapsed breast cancer.111 Paclitaxel is an agent that stabilises microtubules by preventing 
their depolymerisation, and therefore interferes with several processes dependent by 
microtubules like the cell cycle progression.  However paclitaxel is a highly lipophilic drug, 
thus it needs to be associated with organic agents for its clinical formulations. This has been 
shown to cause several side effects such as severe hypersensitivity reactions, neutropenia 
and prolonged peripheral neuropathy.111 The association of paclitaxel with albumin in 
Abraxane® solved these toxicity problems and provided additional benefits by taking 
advantage of the properties of albumin. In fact, albumin can bind paclitaxel as well as other 
molecules reversibly, transport them through the body and determine their subsequent 
release. Albumin has been shown to transport paclitaxel across endothelial cells and 
concentrate it in the tumour tissue. Clinical studies have shown that nab-paclitaxel is 
significantly more effective than paclitaxel in other formulations, with less toxicity, higher 
delivery in the tumour and greater antitumor activity (as illustrated in Figure 9). Moreover, 
due to the reduced side effects, the injected dose of paclitaxel can be increased, with 
positive effects on the response rate, time to disease progression and survival of patients.  
These two examples, among others, underline the great potential of nanomedicine 
formulations as drug carriers. Many other examples of approved nanoformulations show 
an overall decrease of the side effects of the encapsulated drug. However, as mentioned 
for Doxil®, just in few cases they show an improved survival of the patients (see results in 
Figure 10).7,12 
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In the following paragraphs I will describe some problems connected to nanoparticle 
delivery, which may explain this kind of observations, and possible strategies to improve 
further the efficacy of nanomedicines.  
 
 
Figure 9: Patient survival over time in patients who received nab-paclitaxel versus previous paclitaxel formulations (CrEL-
paclitaxel) in a Phase III comparative trial. Reproduced from: Expert Opinion on Pharmacotherapy(2006).111 
 
 
Figure 10: Results from Phase-III trials of FDA-approved cancer nanomedicines. Comparison with patients who received 
the free drug suggests that the nanoformulations reduce toxicity of  conventional chemotherapeutics, but only modestly 
improve the overall survival of patients. Reproduced from: Strategies for advancing cancer nanomedicine, Nature 
Materials (2013).7 
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6 Problems of drug delivery of nanomedicines and 
future perspectives 
The advantages and benefits of nanomedicine seem, from certain point of views, more 
modest than what initially thought.9,11,112 The ability to encapsulate both small hydrophilic 
and hydrophobic drugs, the long blood circulation times, the exploitation of the EPR effect 
in tumours, the high uptake rates, the ability to interact with the cellular machinery, all 
these seem to determine just a modest advantage - so far - compared to traditional 
therapies. In fact, as mentioned in the previous Section, the currently approved 
nanomedicines have shown a modest increase in the overall survival of the patients 
compared to conventional chemotherapies,10,12 although it is clear that they allow to reduce 
toxic side effects (see examples in Figure 10). This in itself can be considered a remarkable 
success, even if it is clear that there is room for further improvement. A recent debate 
pointed out the need for further optimization of nanomedicine strategies.60 By looking at 
published literature, the study highlighted that in preclinical models, on average, only a 
small percentage (claimed to be around 1%) of the injected dose of intravenously 
administered nanoparticles accumulates in tumours.62 Similar delivery problems can be 
found also for other cancer medicines such as monoclonal antibodies, in which only 1 to 10 
parts per 100,000 of intravenously administered antibodies reach their targets in vivo,6,113 
similar to clinically used liposomes.107 While it is true that just a small percentage of 
nanomaterials reaches their target, this percentage represents nevertheless an 
improvement compared to intravenously administered small molecular drugs, whose 
efficiency is estimated to be below 0.1%.106,107 Overall, improving further the targeting 
efficacy of nanomedicines could allow us to reduce the side effects in untargeted organs 
and decrease the administrated dose. Therefore it is important to understand what 
hampers an efficient delivery.  
6.1 Tissue characteristics and barriers to targeting 
As all drugs, also nanomedicines must overcome several barriers before being delivered to 
their final target: interactions with the biological environment, blood circulation and 
heterogeneous blood flow in diseased microenvironment, dense matrices, extravasation 
into and interaction with the perivascular microenvironment, penetration in the diseased 
tissue and, lastly, cellular and subcellular internalization are some of the obstacles that both 
drugs as well as nanomedicines have to overcome for their effective delivery.47 
When nanomedicines are administrated intravenously, they are distributed systemically via 
the vascular system. Therefore organs with high blood flow like liver, spleen, lungs and 
kidneys, are exposed to higher concentrations of nanoparticles, as it happens for other 
drugs. This in itself already can limit nanoparticle targeting capabilities.114 Moreover, organs 
like the liver have large fenestrations in blood vessels, that allow the extravasation of 
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injected macromolecules with a certain cut-off size (up to 150-200 nm). For this reason it is 
not surprising that a very high percentage of injected dose of nanomedicines is cleared by 
the liver. As already discussed, disease environments might as well be altered compared to 
normal tissue. For example, many tumours are characterised by higher permeability of 
vessels and poor mechanisms of clearance from the tissue(for instance due to the lack of 
lymphatic vessels), which together explain the so-called EPR effect previously described in 
Section 4.1 64,65 As mentioned there, while the EPR effect is a key strategy for passive 
targeting of tumours, its efficacy in humans is still debated.68,69 For instance it has emerged 
that not all tumours possess a clear EPR effect, and that some areas within the same tumour 
may not be well perfused, which makes them more difficult to reach and treat. In these 
cases, some studies suggested that pro-angiogenic treatments may actually allow a better 
delivery of drugs and/or nanomedicines to tumours, by re-establishing the normal 
vascularization.7,115 Other current strategies are focusing on the development of tools to 
predict the extent of the EPR effect in individuals for a more personalized terapy12,70 in order 
to pre-select patients who may benefit from passively targeted nanoformulations or from 
therapies that can enhance penetration in tumours.11  
Another problem for particle delivery is the rapid adhesion of serum biomolecules and 
opsonins on the surface of nanomedicines after administration.25–28 As mentioned earlier in 
Section 3, the formation of a corona not only causes sequestration of nanomedicines by 
macrophages and their accumulation in the liver, spleen and lymph nodes, but also can 
interfere with their targeting capabilities.77,78 Moreover the biomolecular corona 
substantially decreases the uptake of nanomedicines in vitro, and this effect is higher when 
approaching in vivo serum concentrations.79. Functionalization of nanoparticles with groups 
that prevent protein adsorption, like PEG, can reduce their opsonisation and recognition by 
the MPS (As illustrated in Figure 5 together with other bioinspired strategies to reduce 
clearance).53,54 However, there is increasing evidence that the “stealthness” conferred by 
PEGylation is hampered by unwanted adverse effects such as complement activation, which 
may result in hypersensitivity reactions and even anaphylaxis.116 PEG can also interfere with 
the binding of the targeting ligand to its corresponding cellular receptor, therefore the 
length of the PEG molecules grafted onto the surface of nanomedicines should be carefully 
controlled.54 Furthermore it has emerged that PEGylated surfaces can still adsorb proteins 
and some studies suggested that is actually the presence of certain proteins like clusterin in 
the corona of PEGylated nanomedicines to confer them the “stealth” behaviour and reduce 
their clearance by macrophages.53 
Tissue characteristics, alterations of diseased tissues, presence of the EPR effect and 
opsonisation are all aspects that should be taken into account when designing 
nanomedicines. Further studies should be carried out in order to better characterize tissue 
properties, but also the behaviour of nanomedicines in similar complex environments.  
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6.2 Cellular recognition and internalization of nanomedicines 
Another problem connected to the delivery of nanomedicines is the poor knowledge of the 
basic principles of nanoparticle-cell interactions. The capacity of nano-sized objects to 
interact with the cellular machinery represents – as mentioned earlier - a great advantage 
for nanomedicines, since it can allow to potentially regulate nanomedicine design to target 
specific cell types or pathways. Still, how the recognition between nanomaterials and cells 
is achieved and which are the molecular mechanisms leading to their uptake and processing 
are aspects not yet well understood.20–23  
In vitro studies show that the corona composition plays a crucial role in the receptor-
mediated recognition of nanomedicines.19,42,117,118 Many aspects related to the way corona-
coated nanomedicines are recognized still need to be clarified. For example, it is not known 
yet whether the interaction with the cell membrane is mediated only by corona 
biomolecules or whether bare patches of nanoparticle surface  may form as nanomedicines 
approach the cell surface. Moreover it would be interesting to understand if nanomedicines 
can be recognized by multiple receptors in the same cell type and which is the affinity for 
one receptor or another. Similarly, a nanomedicine may be recognized by multiple 
receptors at the same time (instead of individual ones), for instance by inducing their 
clustering. One cannot exclude either adhesion to cells without specific receptor 
interactions or a combination of all these different possibilities. Exploring these questions 
might help to understand better how targeting of nanomedicines works in the first place.  
As mentioned earlier, following the initial membrane adhesion and/or receptor recognition, 
nanomedicines are typically internalized by active processes. Whether and how recognition 
and internalization are connected is not known: is the receptor recognition that triggers the 
subsequent internalization (like it is described for many physiological ligands)? Or do the 
receptors mediate just the initial adhesion step and is the nanomedicine itself that triggers 
its own internalization by other ways? Are the efficacy of internalization and the mechanism 
of internalization dependent on the type of receptor recognized? 
Independently by the route of entry, in many studies it is reported that nanomedicines 
travel towards the endosomes till reaching their final localization in the cell, which in most 
cases it has been shown to be in the lysosomes.119,120 In the lysosomes, nanomedicines may 
be degraded and release their content, if biodegradable, or may accumulate and persist.17 
While this  can be very useful when the target are the lysosomes, for delivery to any other 
intracellular target, lysosomal accumulation needs to be minimized. This has led to the 
development of strategies to induce escape from the endosomal compartment. Among 
these, the so-called “proton-sponge effect” is one of the most investigated (see Figure 
11).121,122 Materials capable to induce this proton-sponge effect started to find their 
application in vivo only recently.123 
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Figure 11: Proton-sponge effect of PEI polyplexes. After uptake, PEI polyplexes act as proton sponges through protonation 
of their amine groups. Accumulation of protons together with their counter ions in the endosome stimulates entrance of 
water from the cytosol to balance the high osmotic pressure inside the endosome. Swelling of the endosome in the 
presence of PEI eventually leads to endosome bursting and release of PEI polyplexes to the cytosol. Reproduced from: 
Delivery of Macromolecules Using Arginine-Rich Cell-Penetrating Peptides: Ways to Overcome Endosomal Entrapment. 
The AAPS Journal (2009).123 
There is still a debate on whether nanomedicines can end up in compartments other than 
the lysosomes. For example, in several reports it appears that nanomedicines can be 
transcytosed in endothelial cells (Figure 12).124,125 However, the existence of a dedicated 
pathway, such as caveolae mediated endocytosis, for transcytosis of macromolecules is still 
debated in the endocytosis community (See Chapter 2 in Section 2.1 on transcytosis).  
Overall, it is clear that a better understanding of the endocytosis of nanomedicine can help 
us to find strategies to direct nanomedicines towards other non-degradative pathways, or 
to develop nanomedicines that can release their content once in the cells.  
 
Figure 12: Transcytosis of nanomedicines has been proposed to occur in endothelial cells. Reproduced from: Imaging 
approach to mechanistic study of nanoparticle interactions with the blood-brain barrier. ACS Nano (2014) 
As mentioned above, there is not yet an agreement in the scientific community about the 
pathways that nanomedicines use to be internalized by cells (see also Section 4.2.1 on the 
endocytosis of nanomedicines).21,23,24,58 Till now, a clear understanding of the endocytic 
pathways involved in nanoparticle uptake processes is still missing, in particular with 
regards to the presence of a biomolecular corona. A better characterisation of the 
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mechanisms that cells use to internalize nanomaterials can potentially help us to 
understand how to tune their final fate and localization and how to design more efficient 
nanomaterials for drug delivery.24 
Several studies report that multiple mechanisms might be triggered together (see Figure 13 
for a scheme of the major endocytic pathways).97,126 While generally the most classical 
routes, like clathrin and caveolae mediated endocytosis, are explored in these type of 
studies, it is emerging that other pathways of internalisation might be involved in the uptake 
of nanomedicines (A more detailed review on the endocytosis mechanisms in cells is given 
in Chapter 2). Recently, computer simulations and in vitro studies of nanoparticle-
membrane interactions have highlighted the possibility that the surface of nanomaterials 
can induce several changes at the plasma membrane, by determining sol-gel transitions in 
the lipid bilayer and impairing lipid lateral diffusion,127,128 but also by inducing bending of 
the plasma membrane,129,130 similar to what happens in the case of certain viruses.131 These 
changes in membrane dynamics might as well be a triggering point for the endocytosis of 
nanoparticles. This possibility will be explored more in detailed in Chapter 5. 
 
Figure 13: Endocytosis of nanomedicines can happen trough different routes. Reproduced from: Endocytosis of 
nanomedicines. Journal of Controlled Release (2010) 
6.3 In vitro models and methods to study uptake by cells 
While studying the interactions between nanomaterials and cells is extremely challenging 
to perform in vivo, in vitro studies can help to unravel the mechanisms involved in the 
endocytosis of nanomedicines. To this aim, the choice of the cell line, nanoparticle type and 
molecular techniques to characterise the uptake mechanisms is very crucial.  
Unfortunately often there are no agreements on how to perform these studies in a 
standardized way. Within the nanosafety community, dedicated to the study of potential 
hazards of nanotechnologies, several efforts have been focused on the establishment of 
standardized procedures for nanomaterial handling and for cell interaction studies in order 
to ensure quality in nanosafety testing.132–134 Some of the knowledge gained there could be 
helpful also in developing similar standards for studies aimed at characterizing how 
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nanomedicines enter cells. In fact, in a much similar way, also the study of nanomedicines 
in vitro should account for some good practices for nanoparticle handling: for example, the 
stability and potential agglomeration of nanomedicines in different media should always be 
measured, since agglomeration can strongly affect cellular responses, as well as the 
pathways of internalization. As discussed earlier in Section 3 and 4.2.1,  studies in which 
nanoparticles are incubated on cells without the presence of serum or other relevant 
biological fluids, may lead to conclusions which are not relevant for more realistic biological 
applications and in vivo outcomes.40,79 In fact, it has been recently shown in several 
examples that particular biomolecules in the corona can mediate the recognition of 
nanoparticles by specific receptors.19,42,117,118 The recognition by a certain receptor might 
direct the uptake of nanomedicines towards a mechanism or another and influence 
nanoparticle final location into cells. Currently, there are many in vitro studies in which 
nanomedicines are tested on human cell lines using culture media without serum 
supplements or containing a low percentage of foetal bovine serum. Not only the low 
percentage of serum, but also the species from which the serum originates can determine 
the formation of a corona far from the one formed in physiological conditions.79 To which 
extent the corona composition affects the uptake mechanisms by which nanomedicines are 
internalized is still to be clarified and has been part of this work (This will be presented in 
Chapter 4). 
Next to this consideration on the corona, also the cell type investigated and its cellular 
organization are important factors to be considered in the study of the uptake mechanisms 
of nanomedicines.  For example, not all pathways are active in all cell types: as an example 
of this, HepG2 cells have no endogenous caveolin-1, so they are unable to uptake 
nanoparticles by caveolae mediated endocytosis.135 Furthermore, typical cells used in the 
study of endocytic mechanisms are usually immortalized or cancer cell lines, which are 
easily transfectable and easy to culture, such as HEK293 or HeLa cells. However, these cells 
can behave quite differently from primary cells or cells isolated directly from tissues of 
patients. While on the one hand the use of primary cells can be recommended, on the other 
hand it can be an obstacle for a detailed study of cell pathways. In fact, many primary cells 
are more difficult to transfect and their cellular organization or interaction with other cell 
types might be required for their proper differentiation. Moreover, even the same cell type 
growth in different conditions, such as at different degree of cell density or differentiated 
into a cell barrier, might express different pathways and, consecutively, process the same 
nanoparticles in different ways. In Chapter 6 we will show as an example how the cellular 
organization of endothelial cells into a cell barrier influences the uptake of nanoparticles. 
Further difficulties in the study of the uptake mechanisms of nanomaterials arise from the 
fact that endocytosis represents a complex cellular process, with many molecules, feedback 
loops and signalling cascade elements involved. The endocytosis field is still very active and 
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constantly updating (In Chapter 2 we tried to summarise the latest findings in the 
endocytosis field and to illustrate the complexity of the different endocytic pathways). 
Many processes and molecular details of these pathways are still unknown. For instance, in 
recent years much attention has been given to non-canonical pathways of endocytosis, 
which often are more difficult to observe and study, but which might as well constitute 
possible routes of internalization also for nanomedicines. In light of this complexity, the 
tendency within the nanomedicine field of classifying the pathways of internalization of 
drug carriers as merely clathrin-dependent or caveolae-dependent is for sure an 
oversimplification. Furthermore, many nanomedicine uptake studies unfortunately are 
based on observations that later have been revised and corrected in the endocytosis field, 
but  not yet within the nanomedicine community. These are examples of challenges that 
interdisciplinary fields such as nanomedicine needs to face. In this context, a closer 
connection with the cell biology and endocytosis communities would be desirable.58 
The difficulties in studying the endocytic mechanisms involved in the uptake of 
nanomedicines are also connected to the fact that several techniques can be used to 
characterize uptake, but none of them, alone, can or should be considered conclusive.23 
Typical experiments are carried out by altering cellular pathways, through the use of knock 
out genes, RNA interference, chemical inhibitors or overexpression of molecules implicated 
in a specific pathway. However, it is well established that the alteration of a cellular 
mechanism might as well lead to the alteration of another mechanism or pathway 
component . For example, the overexpression of CAV1-GFP leads to the creation of 
artefacts, such as the observation of a specialized endosomal compartment for caveolae, 
the “caveosome” (see Chapter 2 for more details).136 Therefore, when performing such 
studies, it is important to have appropriate controls to verify the effect of the selected 
treatment on the pathway of interest and exclude potential artefacts of this kind. For 
example, we can use fluorescently labelled low density lipoprotein (LDL) and transferrin (TF) 
as markers for clathrin-mediated endocytosis, dextran as a fluid phase marker for 
phagocytosis and for the CLEE/GEEC pathway and LacCer for cholesterol-dependent uptake 
. Cholera toxin and SV40, previously used as markers of caveolae-mediated endocytosis,137 
have been actually found to enter cells using preferentially other routes and therefore 
shouldn’t be used anymore as markers for this pathway.138,139  Many other pathways, in 
particular the newest discovered, do not have specific markers, therefore their 
characterization and study in the context of nanomedicine uptake can be further 
challenging. The fact that the endocytic pathways are strongly interconnected and some 
components take part in multiple mechanisms poses an ulterior obstacle. For example, 
cytochalasin D, an inhibitor of actin polimerization,140 has been often used to test the 
involvement of macropinocytosis and phagocytosis in the uptake of nanomaterials. 
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However, actin has been shown to be important also for other mechanisms, including 
clathrin-mediated endocytosis and caveolae-mediated endocytosis.141  
As mentioned, several techniques can be used to studying the endocytic mechanisms of 
nanomedicines, each one with its advantages and drawbacks. Among those, RNA 
interference (RNAi) has the advantage of being very specific for a single protein or even a 
single isoform. However, the complete depletion of the protein of interest after RNAi 
requires at least 48-96 hours and during this time cells can adapt, for example by 
upregulating other proteins of the same family or other pathways. Moreover RNAi does not 
guarantee that a protein can totally be depleted from the cell, and in some cases the partial 
reduction of a protein is not enough to fully inhibit its function. So far, many studies on the 
uptake of nanomedicines make use of transport inhibitors, whose action on cells is instead 
very fast. However, some of these inhibitors lack specificity, they might interfere with 
multiple pathways and can cause cellular toxicity.142,143 A more extended discussion on 
chemical inhibitors of endocytosis and the limits connected to their use can be found in 
Chapter 3, where we have studied in detail how to optimize their use and how to interpret 
the results obtained in the context of nanomedicine uptake. Opposite to these approaches 
to block uptake pathways, other strategies can be found in which proteins are instead 
overexpressed, in order to eventually detect an increase in nanoparticle uptake.19 However, 
also this method might lead to artefacts, since the overexpression might induce the 
activation of a pathway that would be otherwise not active at all in physiological contexts.  
Furthermore, some proteins act as heterodimers or in concert with other molecular 
partners and therefore their overexpression might not produce any detectable effect if not 
combined with the overexpression of those partners as well. Overexpression is often used 
to allow the visualization of fluorescently tagged molecules by microscopy, however, as in 
the aforementioned case of GFP tagged CAV1, this might lead to additional artefacts. Recent 
advances in cellular imaging and gene editing can overcome some of these issues. The use 
of stable transfected cell lines might be a good solution when the total depletion of a protein 
is required to shut down a pathway, but also for expressing labelled proteins at physiological 
levels (like with CRISPR/CAS9).  
Further challenges can arise when trying to characterize the uptake mechanisms in specific 
cell types or cell models. In fact, as mentioned earlier, the use of RNA interference or the 
expression of non-functional mutants or labelled proteins may not be possible in cells that 
are difficult to transfect such as most primary cells. Similarly, some of these methods might 
not be suitable for specific cell models, for instance when cells are developed into cellular 
barriers. In fact, these methods can compromise their cellular organization. As an example 
of this, in Chapter 6 we show that several of the common transport inhibitors used to 
characterize uptake mechanisms do not allow to preserve barrier integrity in the chosen 
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endothelial cell barrier model. This is just another example  of the challenges in 
characterizing nanomedicine uptake. 
Overall, it is clear that none of the different methods aforementioned, alone, can provide a 
full picture of the mechanisms that nano-sized objects use to interact with cells. All the 
techniques described show different advantages and pitfalls. The combination of different 
techniques and the application of proper controls could help us to gain a better knowledge 
on the endocytic processes involved in the uptake of nanomedicines. We believe that the 
knowledge gained will help the future development of more effective nanomedicines, thus 
will improve further this promising technology. 
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Aim of the thesis 
Nano-sized materials are promising drug carriers, because of their ability to exploit cellular 
mechanisms to enter cells and their improved biodistribution compared to conventional 
drugs.1–6  While several nanomedicines are already present in the clinic, it is recognized that 
a better understanding of the processes by which these drug delivery systems interact with 
cells could contribute to advance further their success in the field.7–9   
Within this context, the aim of this thesis is to gain a better understanding of how nano-
sized materials are recognized by cells and of the endocytic mechanisms that are involved 
in their uptake.  
The characterization of the uptake mechanisms of nanomedicines is known to be 
particularly complex, as illustrated by the many studies which have already explored this 
issue, often reaching only contradictory or partial conclusions. In fact, there is still not a 
consensus on which cellular mechanisms drive the internalization of nanomedicines. 
Further difficulties in the study of the uptake mechanisms of nanomaterials arise from the 
fact that endocytosis represents a complex cellular process per se, with many molecules, 
feedback loops and signalling cascades involved. The endocytosis field is in continuous 
evolution, and many processes and molecular details are still unknown. In order to give a 
wider perspective on the endocytic mechanisms involved in the uptake of nanomedicines, 
in Chapter 2 I will present a detailed overview of the latest literature in the endocytosis 
field, illustrating how nanomedicine uptake studies should take into account these recent 
findings. 
Most classic approaches for the study of the uptake of nanomedicines are based on 
alterations of the pathways of endocytosis. For instance, pharmacological inhibitors, RNA 
interference (RNAi) or other similar approaches are used to transiently block or knock down 
the expression of key endocytosis players, thus determining their involvement in 
nanomedicine uptake. Each of these strategies presents a series of advantages and limits, 
as I have extensively illustrated in Chapter 1.10,11 Therefore in my project I have used a 
combination of methods, including chemical inhibitors of endocytosis and RNAi directed 
towards specific endocytic targets for characterizing the mechanisms cells use to of 
internalize of nanomaterials. In Chapter 3 I illustrate the challenges associated with the use 
of pharmacological inhibitors, using a panel of six compounds of this type, commonly 
applied in similar studies. I also show additional limits of these inhibitors when they are 
used for nanomedicine uptake studies. Finally, I propose a selection of proper controls for 
testing their efficacy and illustrate how to interpret the results obtained with them.  
With these premises, in the following chapters (Chapter 4-6) I proceed with investigating 
the mechanisms of recognition and uptake of nano-sized materials by cells, with a special 
 P a g e  | 36 
 
attention to the effect of the environment in which nanomaterials are dispersed. More in 
detail, in Chapter 4 I investigate how the pathways of uptake of nano-sized materials are 
affected by the biological milieu in which they are applied and by the nature of biomolecules 
adsorbed on their surface.  The results show that the same nanomaterials can enter cells 
via different pathways when coated with different coronas.  
The corona composition can also affect the initial recognition of nanomedicines at the 
plasma membrane. In fact, several studies have highlighted that the corona biomolecules 
adsorbed on the surface of nanomaterials can engage with specific cell receptors.12–15 For 
example, it has been shown that the corona of silica nanoparticles interacts with the low-
density lipoprotein receptor (LDLR) and that this interaction mediates nanoparticle 
internalization.12 Thus, in Chapter 5 I show that recognition between the LDLR and the 
corona of silica nanoparticles is present only when the corona is formed in physiological 
concentrations of serum. Afterwards I investigate whether the interaction with this 
receptor is followed by nanoparticle uptake via clathrin mediated endocytosis, since this is 
the pathway by which the LDLR is normally internalized. Since this seem not to be the case 
in our model system, I then use a combination of methods to try to characterize the 
pathways involved. In particular I focus not only on the study of the more classical 
mechanisms of endocytosis (as already done in Chapters 3 and 4), but also on a panel of 
endocytic targets rarely investigated in the context of nanomedicine uptake. In fact, in 
recent years much focus in the endocytosis field has been given to clathrin-independent 
pathways, as well as mechanisms which involve the generation and recognition of 
membrane curvature. These pathways and mechanisms are more difficult to observe and 
study. Nevertheless, they may be relevant routes of internalization of nanomedicines, 
especially considering the unique properties of nano-sized materials, which do constitute a 
unique endocytic cargo. In fact, in vitro studies of nanoparticle-membrane interactions have 
highlighted that nanomaterials can induce several changes when interacting with a 
membrane, for example by inducing its deformation and bending.16,17 Several endocytic 
mechanisms utilize, among their regulators, a class of proteins specialized to recognize and 
induce membrane curvature, containing domains with curved topologies (BAR domains).18–
20 Thus, in Chapter 5 I also explore the possibility that nanomedicines can induce membrane 
bending and trigger their internalization by the recognition and induction of membrane 
curvature mediated by BAR-domain proteins.  
Overall, in all the chapters described, I use HeLa cells as a standard model cell line for the 
investigation of the uptake mechanisms of nanomedicines. However, in vivo nano-sized 
carriers are exposed to different type of cells, whose behaviour might differ from classical 
immortalized cell lines such as HeLa cells. Among these, endothelial cells constitute one of 
the very first barriers that nanomedicines need to overcome in order to reach the targeted 
organ, following administration into the blood stream.21,22 Organized cell layers expressing 
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tight junction proteins may constitute in vitro models that better reflect the barriers 
nanomedicines encounter in vivo, in comparison to sub-confluent and confluent cells which 
are often applied for nanoparticle cell behaviour studies.6,7,11,23 Importantly, when cells are 
organised into similar barriers, they may process nanoparticles in different ways than cells 
grown to different degrees of cell density, as used in most in vitro studies. Therefore in 
Chapter 6, after an extensive optimization of the conditions to grow an endothelial cell 
barrier (HUVEC) in vitro, I address this question and focus on the effect of cellular 
organization into a barrier in the uptake of nanoparticles.  
In summary, the aim of this thesis is to unravel the endocytic mechanisms involved in the 
uptake of nano-sized drug carriers, with a special attention to the effects of the biological 
environment that nanoparticles encounter, the mechanism to generate membrane 
curvature for nanoparticle uptake, and eventual effects of cellular organization.  
While in Chapter 2 I present an extensive review of literature on the last discoveries in the 
endocytosis field, in Chapter 3 I show the advantages and limits of using pharmacological 
inhibitors as a tool in the characterization of endocytic pathways of nanomedicines. Then, I 
investigate the impact of the biological milieu in the mechanisms of uptake of 
nanomaterials (Chapter 4) and in Chapter 5 I explore more in detail the pathways of 
internalization of nanoparticles interacting via their corona with the LDL receptor (LDLR). 
Here, I focus for the first time on the molecular players involved in membrane curvature 
generation and recognition. Finally, in Chapter 6 I investigate the impact of the organization 
of endothelial cells (HUVEC) into a cell barrier on nanoparticle uptake. Thus, in Chapter 7, I 
summarize the content of this thesis and I draw the conclusions of my work.  
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Endocytosis is an essential cellular process which allows the communication of cells with 
their environment and regulates the uptake and distribution of macromolecules, as well as 
cell motility, cell division and membrane homeostasis.1–3 If the plasma membrane (PM) 
represents the barrier that defines the cellular limits and that confers a cell its identity, 
endocytosis is the active process that selects what can cross that barrier, allowing the 
exchange of nutrients and the communication of cells with their surroundings.  
Indeed, cells developed several mechanisms of endocytosis in order to select and sort the 
cargo to the correct intracellular destination.1,4 These mechanisms differs among them for 
size, receptor binding and nature of the cargos that have to be internalized. However, they 
also share a series of common features, due to the fact that, in any case, the cargo needs 
first to be recognized at the PM, then the PM must bend and form a vesicle, and finally the 
vesicle needs to be physically separated from the PM and internalized. These common 
features are: 
o A precise lipid composition of the cell membrane at the site of endocytosis (like the 
presence of sphingolipids or cholesterol) 
o Cargo recognition at the PM (receptor-mediated or not) and capture (into coated 
vesicles or specific carriers)  
o Membrane bending, which occurs trough different mechanisms, among which trough 
the insertion of hydrophobic protein motifs in the membrane (arf1, Epsin), local 
recruitment of membrane-bending domains (BARs, SNXs) or scaffolding by proteins 
(clathrin). 
o Scission of the endocytic vesicle, which can be guided by actin, dynamin and/or BAR 
proteins trough scission-mediated friction.5,6 
One may suppose that nano-sized carriers follow this same steps for their internalization. 
However, just few of these features has been explored so far in relation to the uptake of 
nano-sized materials. Some of the questions the nanomedicine field needs to address 
within this context and that constitute the basis for the work presented here are: how 
nano-sized carriers are recognized by this complex cellular machinery and whether they 
use these pre-existing pathways; how the pathways involved vary depending on 
nanomaterial properties (size, charge etc) or cellular properties; and whether nano-sized 
object are able to trigger their internalization via novel mechanisms, due to their unique 
properties.  
Scientists have struggled to unravel the molecular dynamics that drive endocytosis, which 
in many cases are still far from being clearly elucidated. In some cases the molecular players 
involved in different endocytic mechanisms are not mutually exclusive, which means that a 
strict classification is not always possible with our present knowledge. So far, the most 
common ways of classifying endocytosis are based on: 
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o The volume engulfed: there are big-scale (phagocytosis, macropinocytosis) or small-
scale internalization processes. Sometimes these two categories share the same cellular 
machinery;7,8 
o The involvement of dynamin for membrane scission;9 
o The involvement of GTPases that modulate actin remodelling (RhoA, Cdc42, ARF6);9 
o The type of cargo (receptors, MHCs, etc).10  
An example of classification of endocytosis mechanisms is given in Figure 1. 
  
Figure 1: Schematic representation of the most commonly described mechanisms of endocytosis. Red circles represent 
dynamin, whereas red lines represent actin filaments. Reproduced from(2014).8 
The classification and description of the endocytic mechanisms reported in this thesis can 
seem simplistic and far from illustrating the real complexity of endocytosis, but it can be 
useful for our investigation of the endocytosis of nanomedicines. Here I will focus mainly on 
the uptake routes of endogenous cargoes and will exclude from this thesis a detailed 
description of their intracellular sorting. Beside describing the main pathways of 
endocytosis (clathrin dependent and independent), I will dedicate a separate section to the 
mechanisms involved in the initial membrane deformation. In the last paragraph, I will 
discuss instead the endocytosis of special cargoes such as toxins and viruses, which might 
give us some insights on how cells can handle exogenous materials. Finally, after this 
background information, I will briefly discuss the strategies  used in this project to 
characterize how nanomedicines enter cells (choice of targets for RNA interference, choice 
of inhibitors and other methods). 
 
1 Clathrin-mediated Endocytosis (CME) 
One of the first endocytic mechanisms discovered11 and the most studied in detail so far is 
Clathrin-Mediated Endocytosis (CME).12,13 Briefly, CME internalizes receptors and receptor-
bound cargoes through a series of well-defined and highly regulated steps that require 
receptor binding, formation of a clathrin-coated pit (CCP) mediated by the assembly of 
several clathrin subunits, and a scission event (a scheme summarizing these different steps 
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is given in Figure 2). The assembly and pinch off from the PM of a CCP require 50–150 
seconds.14  
After an initial ligand-receptor recognition, Eps15 and FCHo proteins, which are associated 
to the PM in highly density phosphatidylinositol 4,5-bisphosphate (PIP2) sites, trigger the 
initial membrane bending.15,16  A series of adaptors, specific for the cargo that has to be 
internalized, recruits AP2, the main actor in clathrin assembly. At this stage, many 
membrane-binding macromolecules, such as epsins (EPN1, EPN2) and AP180, act both as 
cargo adaptors and membrane binding/bending effectors,13 thanks to the presence of 
ANTH, ENTH and BAR domains (for a more thorough description see Section 3 on curvature 
generation). At this stage, clathrin light and heavy chains (CLTA, CLTB, CLTC) are recruited 
to the cargo site and form the characteristic triskelia, which surround the forming vesicle.12 
Another series of membrane bending proteins characterized by the presence of a BAR 
domain, such as amphiphysin (BIN1, BIN2, AMPH2), endophilin17 (SH3GL1, SH3GL2, 
SH3GL3) and sorting nexin 9 (SNX9)18, recognizes and promotes the curvature of the 
forming vesicle, meanwhile recruiting the GTP-binding protein dynamin (DNM1, DNM2, 
DNM3)5,19,20 at the vesicle neck. The hydrolysis of GTP by dynamin allows the vesicle scission 
from the PM and its subsequent sorting to different cellular compartments or its recycling 
back to the PM. During the fission step, some of the previously mentioned components, 
such as BAR domain proteins and other adaptors, associate to actin, a cytoskeleton 
component which constitutes the pulling force that finalizes the vesicle budding and 
subsequent transport.21 While it is accepted that actin is not an essential player in canonical 
CME,22 its role in vesicle elongation starts to become essential when larger cargoes are 
involved.23 In fact, it is generally thought that CME needs specific size requirements for its 
cargo in order to occur, limited by the curvature of the triskelia. However, it has been shown 
that enlarged coated pits, called coated plaques, can also be formed in order to adapt to 
cargoes of bigger size, up to 500 nanometers.12,24,25 This is what happens in the uptake of 
some viruses, which enter cells through CME, and in these cases actin has a major role. 
Moreover, several studies indicate cholesterol as another important player in CME. Its 
depletion with compounds such as methyl-β-cyclodextrin impairs the formation of the CCP 
and leads to the accumulation of clathrin microdomains associated to the PM.26 
Several receptors enter cells using CME. Among these, the transferrin receptor (TFR) and 
the low density lipoprotein receptor (LDLR) represent classic examples. Both of these 
receptors are internalized upon ligand binding and their uptake is mainly driven by CME. 
Therefore their ligands are commonly used in the endocytosis field as probes for testing the 
efficient inhibition  or downregulation of molecules involved in CME. 
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Figure 2: Clathrin Mediated endocytosis and its main regulators. a) The proposed steps of clathrin-coated vesicle 
formation: Nucleation, cargo selection, coat assembly, uncoating (see text for details) b) The clathrin network and the 
interactions among clathrin regulators. Adapted from: Molecular mechanism and physiological functions of clathrin-
mediated endocytosis. Nature Reviews Molecular Cell Biology (2011).13 
1.1 TFR  
The transferrin receptor (TFR1) is a ubiquitously expressed transmembrane glycoprotein 
which mediates the internalization of iron-bound transferrin (TF) via CME. After the initial 
binding and internalization, the iron is released and the TF/TFR1 complex returns to the cell 
membrane, where TF is recycled back to the bloodstream, available to recapture iron. 
Depending on the cell type, this cycle can be completed in 5–20 min.27 TF can be internalized 
also by a low-affinity mechanisms dependent by TFR2, which is present just in some cell 
types and is predominant just when high concentrations of TF are present in the 
environment.28,29 It has been shown that CME inhibition through the expression of a 
dominant negative dynamin mutant can cause a failure of recycling of the TFR to the PM.30 
1.2 LDLR 
The low density lipoprotein (LDL) is one of the main lipoproteins which transport lipids in 
the blood. Its internalization is mediated through the CME pathway by the LDL receptor 
(LDLR). The LDLR family consists of 10 members in mammals, and each one of them can 
induce different signal transduction.31 After its internalization, the LDL is degraded in the 
lysosomes, while the LDLR is typically recycled back to the PM.  In some cell types the LDLR 
is ubiquitinated, internalized trough CIE (clathrin-independent endocytosis) and 
degraded.32 In other cases the LDLR has been reported to be internalized also through 
caveolae.33  
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2 Clathrin-independent endocytosis (CIE) 
There are many cargos that are internalized without the presence of clathrin. Even though 
they have several differences among them, all these pathways are classified as clathrin-
independent endocytosis (CIE).4,9,34,35 In fact, CIE can be dependent on membrane domains 
rich in cholesterol and sphingolipids, also called lipid rafts36 or can be independent on 
them.26 CIE can be receptor-mediated, like in the case of the IL-2 receptor, or receptor-
independent, like macropinocytosis. However, a common feature of all these pathways 
appears to be the involvement of actin in the internalization. Actin assembly plays a role in 
membrane remodelling events, such as protrusion during macropinocytosis,37 invagination 
during caveolin-dependent endocytosis38 and vesicle fission,39 but is not distinctive for CIE, 
since it seems to be involved also in CME, as described above.21,22 CIE can also be driven by 
toxins that binds to the outer PM leaflet and induce membrane invaginations (see Section 
4.2 on toxins). 
2.1 Caveolae-Mediated Endocytosis 
Caveolae are relatively stable 50-80 nm cup-shaped invaginations of the PM. As other types 
of lipid rafts, they are ordered microdomains enriched in sphingolipids and cholesterol.38,40–
43 Caveolae stability is due to the presence of actin filaments and caveolae shape is achieved 
by the presence of a coating characterized by integral membrane proteins called caveolins 
(Cav1-4), which associate with cytosolic proteins called cavins (cavin1-4) .44,45 Caveolar 
budding is regulated by local actin polymerization, EDH2 and Pacsin246–48 and seems to be 
both receptor dependent and independent.  EHD2 is an ATPase localized at the caveolae 
neck and is a negative regulator of budding.47 On the one hand, EHD2 binds to actin-binding 
proteins such as filamin A,49 which regulates the anchoring of the vesicles to the PM, and 
on the other hand, EHD2 interacts with Pacsin2.48,50 Pacsin2 is another key regulator of 
caveolar formation and consists of a BAR-domain that recognizes and induces membrane 
curvature. It can bind dynamin,50 Cav1 and actin.51 Also the GTPase dynamin, localized to 
the neck of caveolae, appears to be involved in caveolae regulation and scission.52 
Moreover, caveolins and cavins inhibit the CLIC pathway (see later Section 2.4) by regulating 
the local availability and activity of the main CLIC regulator, Cdc42.42 
The role of caveolae in endocytosis has been long debated. The majority of the evidences 
reporting a role of caveolae in endocytosis comes from studies performed perturbing 
cholesterol (upon filipin, nystatin or methyl beta cyclodextrin treatment), which can 
interfere with other CIE pathways.53 More in general, cholesterol perturbation can also 
affect the lipid organization of the PM and the diffusion and availability of transmembrane 
proteins and receptors, therefore their internalization.54 From these studies it has been 
reported that caveolae can regulate the uptake of the LDLR,33 albumin,55 tyrosine kinases, 
Rho GTPases56 and lipoproteins.57 Also SV40 and cholera toxins were claimed to enter 
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preferentially using caveolae-dependent endocytosis and for a long time they were used as 
markers for this pathway. In these studies, SV40 was shown to be internalized in Cav1 
positive structures, in a actin and dynamin dependent manner.38 Instead it seems that SV40 
virus is actually internalized much more efficiently by a caveolin-independent mechanism 
and that is able to induce caveolae budding.58 Also Cholera toxin was reported to be 
localized into caveolae-positive structures, however it has been later shown that it can use 
other mechanisms as well to enter cells.59–61 
More recent reports claims that caveolae, under normal non-stimulating conditions, are 
stable structures at the plasma membrane that are not involved in endocytosis to any 
significant degree.62,63  It appears, in fact, that in many cell types only about 2% of caveolae 
bud from the plasma membrane per minute41 and that these caveolae displays a “kiss-and-
run” behaviour which involves a transient budding and fusion of caveolae with life-times of 
2–5 seconds.52,64 These studies claim that a fraction of caveolae actually undergoes 
endocytosis, but only when stimulated by a ligand.41,64 Budding caveolae eventually end up 
in the early endosome.52,64 Previous reports identified a specialized endosomal 
compartment containing Cav1, the so-called “caveosome,” which later has been explained 
as an artefact of the overexpression of GFP-tagged caveolin.65  
It has also been suggested that caveolae might be involved in transcytosis in endothelial 
cells.66 In particular, since endothelial cells are very flat (around 100-200 nm), the caveolae 
can detach from the apical PM and rapidly fuse with the basal membrane or directly fuse 
without being completely detached, forming transendothelial pores.67 However how such 
channels can form without altering the cell viability is still debated in the field.68 Also the 
fact that albumin is claimed to be transported through this pathway doesn’t find support in 
the literature.43  
Caveolin has many non-endocytic functions such as NO signalling, and calcium signalling, 
cholesterol transport and homeostasis in adipocytes, but can also be a way to regulate PM 
composition. Caveolae are also considered regulators of membrane tension.69 In fact, in 
response to membrane stretch, caveolae can open up and determine the release of 
inhibited receptors localized in caveolae nanodomains, which can start a signalling cascade.  
2.2 Flotillins 
Flotillins are lipid rafts microdomains which contain 2 integral membrane proteins 
topologically similar to caveolae, called flotillin 1 and flotillin 2. The oligomerization of 
flotillins determines the formation of membrane invaginations with a morphology similar 
to that of caveolae. Oligomerization is fundamental, since the absence of one flotillin leads 
to the reduction of the protein level of the other.70 The role of flotillins in cellular uptake is 
still debated.71,72 While some suggest that flotillins define their own endocytic pathway,73 
others suggest that they might be indirectly involved in endocytosis.74 Flotillins seem to be 
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involved in the uptake of the GPI-AP CD59, which is also a CLIC cargo (see Section 2.4), and 
of Cholera toxin B subunit (CtxB).70,73 Several other cargo molecules, such as cationic 
molecules, polyplexes and proteoglycans75 as well as the Niemann-Pick C1-like 1 protein 
(NPC1L1)76 have been suggested to use a pathway which is flotillin dependent. However 
further studies are still necessary to define flotillin uptake as an independent endocytic 
mechanism. The role of dynamin in flotillin-mediated uptake is also controversial: some 
studies suggest that dynamin may be involved in this mechanism of endocytosis,73 whereas 
others demonstrated the opposite.71 Moreover, flotillins might act as molecular scaffolds 
for signalling purposes or for sensing membrane alterations in cholesterol lipid composition 
or in membrane tension. Flotillins have also been implicated in actin cytoskeleton regulation 
and have been suggested to bind to actin.77 
2.3 ARF6 related pathways 
The ADP-ribosylation factor 6 (ARF6) is a GTP-binding protein involved in many cellular 
functions, among which the trafficking of nutrients, immune receptors (MHC Class I, CD1a), 
and GPI-APs.8,10,78 ARF6 mediates the cholesterol-dependent internalization of these 
molecules into PIP2-enriched tubular structures, which are distinct from endosomes 
containing clathrin cargoes.79 After internalization, ARF6 is shut down to decrease PIP2 
levels, allowing fusion with Rab5-positive endosomes.80  The role of ARF6 in endocytosis is 
still not clear: it seems that ARF6 is not directly involved in the internalization process, but 
just in the cargo recycling step, since ARF6 inhibition does not perturb endocytosis, but 
blocks the process of cargo recycling to the PM.79 However, in certain cell types, ARF6 
regulates clathrin-dependent endocytosis.81 For example, it has been shown to determine 
the recruitment of clathrin in HeLa cells and to interact with AP2.82,83 Moreover ARF6, 
together with actin, is involved in ruffle formation and appears to regulate 
macropinocytosis, cell adhesion and migration.78,84  
2.4 CLIC/GEEC 
The CLIC/GEEC pathway is a constitutive pathway mediated by CLICs (Clathrin Independent 
Carriers), tubular structures which form at the PM and mature in early endocytic 
compartments enriched in Glycosylphosphotidylinositol-Anchored Proteins (GPI-APs) 
called GEECs (GPI-AP Enriched Endocytic Compartments).85 GPI-APs are membrane proteins 
bound to the outer leaflet of the PM and were one of the first cargo proteins to be identified 
as markers of this pathway,85,86 even if specific GPI-APs might enter also through different 
routes such as caveolae, ARF6 and flotillin -dependent pathways. GPI-APs are taken up 
slowly, with a half-time in the order of minutes to hours.86  Moreover, the CLIC/GEEC 
pathway can internalize materials that do not have specific cellular receptors such as VacA 
toxin and bacterial exotoxins, but also membrane glycosphingolipids,60 cell-surface 
glycoprotein CD44, some integrins and extracellular fluids. Unlike macropinocytosis, which 
also constitutes a major route for fluid-phase markers uptake, the CLIC/GEEC pathway is a 
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constitutive process, and is not inhibited by amiloride. In many cell types the CLIC/GEEC 
pathway is also responsible for the rapid recycling of the membrane and is reported to be 
involved in cell migration.87 
The CLIC/GEEC pathway is the main CIE route that builds carriers according to the glycolipid-
lectin or GL-Lect hypothesis (Figure 3).4,88,89 In this model, the binding of secreted lectins 
(such as galectin-3) or pathogenic factors, like toxins (botulinus, tetanus, cholera or Shiga) 
or viruses (SV40), can induce the extracellular clustering of glycosphingolipids (such as Gb3 
or GM1) and glycosylated proteins (CD44 and b1 integrin) into nanodomains that can bend 
the membrane.89 Afterwards, glycolipid crowding can induce membrane bending (see also 
later Section 3 on curvature generation). In fact, the extracellular clustering of glycolipids 
into nanodomains by cholera or Shiga toxins as well as galectin-3 is sufficient to induce 
inward membrane bending in giant unilamellar vesicles (GUVs) resembling plasma 
membrane composition. After lipid clustering and membrane bending, the cargo can be 
internalized trough different pathways, among which the CLIC/GEEC for galectin-3 and 
other lectins, and the so called Fast Endophilin-Mediated Endocytosis (FEME) for toxins 
bounded to glycosphingolipids (See next Section on FEME). Once internalized, about half of 
the CLICs are recycled back to the PM and the remaining material matures into GEECs, a 
morphologically distinct endosome which is highly acidic and which is suggested to begin 
the sorting of the cargo to different destinations.85,87 Afterwards, GEECs fuse with early 
endosomes (positive in Rab5 and EEA1).  
The uptake of GPI-APs and fluid phase markers mediated by CLIC/GEEC depends on the Rho 
family GTPase Cdc42 and the actin polymerization machinery, but not clathrin, dynamin2, 
Rac1 and RhoA.53,85 Moreover endocytosis via this pathway is also affected by alterations in 
cholesterol53 and sphingolipids90 levels, as well as perturbation of the GPI-AP clustering.91 
Membrane tension and bilayer fluidity have an important role in CLIC formation, consistent 
with its drastic reduction upon cell stretching, cell confluency, or cholesterol lowering.53 The 
CLIC/GEEC pathway seems to be more or less prevalent in different cell types. For example, 
while the internalization of GPI-APs in CHO cells depends on Cdc42,85 in HeLa cells it appears 
to be Cdc42 independent.79 Also the BAR domain protein with GTPase-activating activity 
GRAF1  plays a role in CLIC/GEEC endocytosis, marking and controlling CLICs formation. In 
fact, GRAF1, which associates to the PM through binding to phosphatidylinositol 4,5-
bisphosphate (PIP2), colocalizes with Cdc42 into CLICs and regulates Cdc42 activity.92 The 
role of GRAF1 in the CLIC/GEEC pathway however is still controversial: in fact, while 
dynamin seems not to be involved in CLIC formation,85 it can bind to GRAF1 and it is involved 
in the processing of tubes containing GRAF1.60,92 Another BAR-domain protein, SNX9, which 
is also linked to CME, seems to have a role in the CLIC/GEEC pathway, through its interaction 
with the actin machinery and PIP2.18,93 
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Figure 3: The Glycolipid-Lectin (GL-Lect) Hypothesis. Left: The CLIC/GEEC pathway. Galectin-3 binds and clusters the 
extracellular domains of glycosylated receptors (e.g., CD44). This clustered glycosylated receptors or GPI-anchored 
proteins induce membrane bending into the cytosol. CLIC formation is then supported by Cdc42/N-WASP-induced actin 
polymerization and GRAF1 binding. Local Cdc42 inactivation is mediated by GRAF1. Right: The uptake of Shiga and cholera 
toxins. Toxins biund and cluster glycosphingolipids (e.g., Gb3 or GM1)at the PM. Clustered glycosphingolipids induce 
membrane bending into the cytosol. Endophilin scaffolding induces membrane friction, and together with actin 
polymerization and/or dynamin activity, endophilin mediates the scission of CLICs and toxin-containing carriers. 
Reproduced from: Mechanisms of Carrier Formation during Clathrin-Independent Endocytosis. Trends in Cell Biology 
(2017).4 
2.5 FEME (Fast Endophilin-Mediated Endocytosis) 
In 2015 MacMahon and colleagues proposed a novel “fast-acting” pathway mediated by 
the BAR-domain protein endophilin and dependent on actin polymerization and dynamin 
activity, but independent of AP2 and clathrin (a scheme illustrating this mechanism is given 
in Figure 4).94 This pathway mediates the uptake of several receptors, among which the 
GPCRs α2a- and β1-adrenergic receptors, dopaminergic D3 and D4 receptors, RTKs, EGFR 
and HGFR, which are directly or indirectly bound to endophilin. Also native IL-2 receptors, 
comprising α, β and γ chains, dimerize upon IL-2 binding and seem to enter T cells through 
this pathway.  
Internalization mediated by FEME occurs in pre-existing membrane patches, characterized 
by the presence of PI(3,4)P2, bound to lamellipodin, that recruits endophilin at the PM. 
These patches continuously assemble and disassemble every 5–10 seconds in the absence 
of receptor activation. Upon ligand binding, endophilin bridges the membrane (through its 
BAR domain), cytosolic effectors and cargoes (through its SH3 domain) and eventually 
induces membrane bending and tubulation (See Section 3 for details on BAR domains). It is 
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likely that membrane scission occurs via the recruitment of dynamin and the actin 
cytoskeleton, combined with a friction-driven scission mediated by the BAR domain of 
endophilin.6,95 Interestingly, this pathway is activated also upon Cdc42 inhibition. 
Endophilin acts in concert with actin and dynamin for the scission event of Shiga and cholera 
toxins, two CIE cargoes, by a mechanisms reminiscent of that of FEME (Figure 3, right and 
Figure 4) .95 How endophilin and the cytoskeleton machinery can distinguish between 
membrane protrusions induced by toxins and other protrusions of similar diameter is still 
debated.  
 
Figure 4: Fast endophilin-mediated endocytosis (FEME) occurs upon the local pre-enrichment of endophilin by the 
PI(3,4)P2- binding protein lamellipodin (Lpd).  Upon activation, receptors are captured by FEME in a process mediated by 
endophilin oligomerization and adaptor recruitment. The synergistic action of actin polymerization, dynamin activity, and 
BAR domain scaffolding-induced membrane friction mediates the scission of FEME carriers. Adapted from: Mechanisms 
of Carrier Formation during Clathrin-Independent Endocytosis. Trends in Cell Biology (2017). 4 
2.6 RhoA mediated IL-2 receptor uptake  
Interleukin 2 receptor (IL-2R) internalization is linked to cell proliferation and immune 
response. IL-2R is known to be internalized through FEME upon IL-2 binding (see Section 
above). However, in non-immune cells, isolated IL-2Rβ or γc chains cannot bind IL-2, but are 
constitutively internalized through a pathway that is RhoA, cholesterol, actin and dynamin 
dependent (illustrated in Figure 5).96 IL-2R associates with lipid rafts membrane domains.36 
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Upon binding of an antibody against IL-2R, IL-2R dimerizes and activates a signal cascade in 
which RhoA and Rac1 (and its downstream targets WAVE and Pak1/2) are activated.97 This 
promotes the interaction of cortactin, a partner of actin and dynamin, with WASP and the 
formation of actin protrusions, thus forming endocytic pits.98 
RhoA-mediated uptake shares many regulatory components with macropinocytosis (Rac1, 
WAVE, WASP), but unlike the latter, it mediates the formation of small vesicles.  Moreover, 
actin recruitment and dynamin involvement resemble FEME uptake, but the mechanisms 
of vesicle formation and sorting remain different.  
 
Figure 5: Initiation of interleukin 2 receptor b (IL-2Rb) uptake is triggered by binding to anti-IL-2R antibodies. Antibody-
induced IL-2Rb clustering stimulates actin polymerization and membrane protrusions. Also Rac1 stimulates actin 
polymerization. N-WASP, cortactin, and dynamin then mediates IL-2Rb endocytic pit closure and detachment from the cell 
surface. Also in this case, the coordination among actin polymerization, dynamin activity, and membrane bending 
mediates the scission of IL-2 carriers. Adapted from: Mechanisms of Carrier Formation during Clathrin-Independent 
Endocytosis. Trends in Cell Biology (2017).4 
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2.7 Macropinocytosis 
Macropinocytosis mediates the non-selective uptake of extracellular fluids and solutes 
through the formation of morphologically distinct membrane ruffles and protrusions (Figure 
6). The engulfment of large amounts of extracellular fluids generates large endocytic 
vacuoles called macropinosomes. Uptake of surface proteins and receptors located on the 
PM in close proximity to membrane ruffles might occur concomitantly to fluid uptake. 
However there is no selection mechanism for the uptake of those membrane proteins, since 
macropinocytosis is not cargo specific. Macropinocytosis is activated by specific signals 
mediated by growth factor, chemokine, or Toll-like receptors and is the major pathway for 
antigen capture in macrophages. Some viruses, bacteria, integrin substrates and apoptotic 
cell remnants containing phosphatidylserine can also trigger macropinocytosis. Moreover, 
this pathway is often exploited by pathogens.  
Macropinocytosis starts with the GTPase Ras, which activates PI3K which generates 
PtdIns(3,4,5)P3 at the PM. This allows the recruitment at the PM and the activation of the 
Rho-GTPases Rac1 and Cdc42 together with the actin nucleation cascade (WAVE, WASP and 
Arp2/3), which is responsible for ruffle formation.99 All these steps are essential in 
macropinocytosis, since they promote actin polymerization, together with the electrostatic 
interaction between the phosphoinositides, Rho family GTPases (Rac1 and Cdc42) and actin 
promoting factors. In fact, the accumulation of cytosolic hydrogen ions (H+) neutralizes the 
negative charges of the inner PM leaflet and is an efficient way to block macropinocytosis 
with compounds such as EIPA (5-(N-Ethyl-N-isopropyl)amiloride). Also ARF6 has been 
reported to be a regulator of macropinocytosis at the PM.78,84 Macropinocytosis is also 
regulated by a Rab5 effector, Rabankyrin-5 (ANKFY1), which localizes into macropinosomes 
of epithelial cells and fibroblasts.100 In particular its function is restricted to the apical side 
of polarised epithelial cells. Recently also the BAR protein sorting nexin 9 (SNX9) has been 
implicated in macropinocytosis,93,101 since it localizes to actin-rich structures associated 
with the uptake of fluid-phase markers and can activate both Cdc42 and WASP. Moreover, 
it has been shown that macropinocytosis requires cholesterol in some cell lines, like A431.102 
Macropinosome scission is mediated by CtBP1 (C-terminal-binding protein 1) and/or 
dynamin.4  
As mentioned, macropinocytosis shares the same regulatory components of IL-2R uptake 
(see corresponding section) and is also reminiscent of phagocytosis, since it involves the 
formation of big endocytic structures that require a complex actin rearrangement. Many 
inhibitors that block macropinocytosis also inhibit FEME and IL-2R uptake,4,94 even though 
the latter two produce smaller endocytic vesicles and function upon specific cargo capture. 
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Figure 6: Macropinocytosis and its regulators. Sustained and/or elevated receptor signalling determines the recruitment 
and activation of Cdc42-N-WASP and Rac1-WAVE complexes, thereby promoting actin polymerization and membrane 
ruffling. Receptors and transmembrane proteins in close proximity to the ruffles are indiscriminately internalized. Soluble 
material (amino acids and soluble proteins) and fluid are captured inside the forming macropinosomes. Adapted from: 
Mechanisms of Carrier Formation during Clathrin-Independent Endocytosis. Trends in Cell Biology (2017).4 
2.8 Phagocytosis 
Phagocytosis is the receptor-mediated engulfment of large particles (> 0.5 μm) by cells, 
which requires big membrane rearrangements and therefore the involvement of the 
cytoskeleton. While professional phagocytes such as macrophages use phagocytosis for the 
immune responses to pathogens, other cells such as fibroblasts, epithelial and endothelial 
cells use phagocytosis for ingesting apoptotic bodies of other cells. It is also required for 
cellular remodelling and homeostasis. Phagocytosis is activated by the engagement of 
foreign bodies, opsonized particles, complement components or lectins on the surface of 
opsonized pathogens or apoptotic cells.  
Receptor activation generates a cascade of events that involves lipid synthesis (PI(4,5)P2, 
PI(3,4,5)P3 and PI(3)P)103 and the activation of Rho GTPases such as Cdc42 and Rac1,104–106 
which promotes actin polymerization (through Arp2/3, WAVE and WASP signalling) and 
membrane remodeling.103,107 Also the GTP-binding protein ARF6 is activated during 
phagocytosis and promotes membrane delivery to the nascent phagosome.108 Actin 
disassembly is also essential for the final steps of the engulfment and this is mediated by a 
decrease of PI(4,5)P2 levels at the plasma membrane.109 Another Rho GTPase, RhoA, seems 
to regulate complement receptor-induced phagocytosis106 and appears to be involved in 
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the modulation of the rate of engulfment by this mechanism.110 While phagocytosis shares 
many regulators with other endocytic mechanisms, its particular morphology and activation 
make this pathway easily distinguishable from the others. 
3 Membrane Curvature and BAR proteins 
So far, we proposed a classification of the endocytic mechanisms based on their main 
regulators. These pathways are regulated by different molecular players and interactions, 
but overall, as mentioned earlier, they share some common features for the endocytic event 
to occur, like the need for a precise lipid composition, a cargo selection mechanism, 
membrane rearrangements and a scission mechanism. In this section I will focus on the 
regulation of membrane dynamics during endocytosis, which requires specific signalling to 
induce PM reshaping during the endocytic event. In particular, the bending of the PM can 
be regulated by (Figure 7):34,111,112 
a. changes in the membrane lipid composition; 
b. clustering of membrane proteins; 
c. mechanical forces generated by the actin cytoskeleton; 
d. coat proteins or adaptor proteins that act as scaffolds; 
e. helix insertions into the lipid leaflet; 
f. proteins containing BAR domains that sense and induce curvature.  
All these mechanisms can induce membrane curvature and rearrangement and, in vivo, they 
often act in synergy. 
 
Figure 7: Mechanisms of membrane deformation. The phospholipid bilayer can be deformed into positive or negative 
membrane curvature via different mechanisms (as illustrated in panels a-e). See text for details. Reproduced from: 
Membrane curvature and mechanisms of dynamic cell membrane remodelling. Nature (2005). 113 
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Biological membranes are constituted of several types of lipids, like phospholipids, 
glycolipids and cholesterol, which all have intrinsic shapes depending on the length and 
saturation of their acyl chains and the size of their head groups. Clustering of lipids with 
similar shape, by itself, can determine the spontaneous curvature of the membrane.112 
While certain lipids have a cylindrical shape and can form a flat monolayer, like in the case 
of phosphatidylcholine and phosphatidylserine, lipids with large headgroups such as in 
phosphatidylinositol phosphates (PtdIns) instead can form membranes with positive 
curvature (outwards). For example, in many endocytic processes the presence of 
phosphatidylinositol 4,5-bisphosphate (PIP2) at the vesicle initiation site is essential.114 
Moreover their lipid headgroups are easily modifiable and therefore can constitute a useful 
modulator for the recruitment of peripheral membrane proteins to the PM.  It has been 
shown that lipid clustering of lipids with a similar shape might also occur after the 
association of bacterial toxins (cholera toxin B or Shiga toxin B) to the PM, according to the 
GL-Lect hypothesis (see CLIC/GEEC pathway and Figure 3 and 8).115,116 
 
Figure 8 Pathogens can exploit the induction of negative curvature at the plasma membrane. In the case of toxins that 
specifically bind to glycosphingolipids, it has been suggested that negative curvature might be produced by the cone shape 
geometry of protein–lipid complexes, possibly accompanied by compaction of the lipid head groups. Adapted from: 
Bending "on the rocks"-A cocktail of biophysical modules to build endocytic pathways. Cold Spring Harbor Perspectives in 
Biology (2014).111 
Coat proteins such as clathrin, caveolin and flotillin, directly or indirectly associate to 
membranes, influencing the curvature of the PM by polymerizing around the forming 
vesicle, forming a rigid scaffold. While clathrin does not bind directly to curved membranes, 
but to adaptor proteins, caveolin and flotillins can insert into membranes and facilitate 
membrane curvature.  
Another common element that participates to membrane bending events is the actin 
cytoskeleton. Actin polymerization is often associated with the formation of PM 
invaginations, but can also guide the localization of membrane proteins and receptors.117 
As discussed previously, actin is implicated in many endocytic pathways, and is particularly 
relevant when extensive membrane rearrangement are necessary (like for the engulfment 
of big particles in phagocytosis or for the formation of membrane ruffles during 
 P a g e  | 57 
 
2 
Chapter 2.  Endocytosis mechanisms 
macropinocytosis). Also other cytoskeleton components, such as microtubules and 
molecular motors (myosin, dynein) are responsible for these membrane rearrangements.  
Proteins associated with the lipid bilayer can also generate membrane curvature. For 
example, transmembrane proteins with a conical shape, such as channels and membrane 
receptors, might cluster together, or even oligomerize upon stimulus, therefore imposing a 
bending to the PM. This is what happens for the low-density lipoprotein receptor or the 
transferrin receptor when clathrin coated pits are formed.118 Peripheral proteins inserted 
in between lipid headgroups can induce a small membrane bending, which becomes more 
pronounced when there are several insertions in close proximity with each other.  
The insertion of amphipathic helices in the lipid bilayer is a mechanism shared by several 
membrane remodelling proteins, such as AP180, epsins, endophilins and amphiphysins with 
their ANTH, ENTH and BAR domains. For example, the N-terminal homology domain (ENTH) 
of epsins can specifically bind PIP2 and bend the membrane trough the insertion of an 
amphipathic helix in the lipid layer. Studies in vitro show that epsins can spontaneously 
generate tubules in artificial membranes.119 Also a subset of proteins containing BAR 
domains (called N-BARs) possess similar amphipathic helices that induce membrane 
curvature.120 
 
Figure 9: Membrane curvature sensing and generation can be induced by proteins containing BAR domains. Adapted from: 
Bending "on the rocks"-A cocktail of biophysical modules to build endocytic pathways. Cold Spring Harbor Perspectives in 
Biology (2014).111 
Another mechanism to induce membrane curvature is via BAR domain oligomerization 
(Figure 9). BAR domain proteins are a family of proteins involved in several endocytic 
pathways, such as clathrin and caveolae-mediated endocytosis, CLIC/GEEC, FEME and 
macropinocytosis. BARs are dimeric α-helix motifs and possess a curved surface that 
preferentially binds to membranes with a similar curvature (as illustrated in Figure 10). 
These domains can associate trough electrostatic interactions with negatively charged lipids 
(such as PIP2) and can induce their clustering. BAR-domains interact with the PM, the actin 
cytoskeleton and/or coat proteins which act synergistically in the membrane bending 
process.121–123 Often BAR proteins can assemble together and create scaffolds on vesicles 
and tubules in formation, which can reshape the membrane and alter its mechanical 
properties.124 BARs can have a concave structure which recognizes positive curvature, like 
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the Fes/CIP4 homology BAR domain (F-BAR)125 or a convex structure which recognizes 
negative membrane curvature, like most inverse BAR domains (I-BAR).126 Other BAR 
domains are more flat and can stabilize planar membrane sheets, like the I-BAR domain of 
Pinkbar.127 As mentioned, a subset of BAR domains called N-BARs120 are characterized by 
the presence of additional N-terminal amphipathic α-helices which probe the membrane 
for defects and insert into lipid bilayers, increasing their curvature. Then, the dimerized BAR 
domains associate to and stabilize the curved membrane. The N-BAR proteins can therefore 
sense positive membrane curvature, but also induce it (See specific Section 3.4 and 3.5 on 
N-BAR proteins).5,128  
Recently it has been proposed a model by which BAR domains can also mediate the scission 
of tubular membranes, without the involvement of dynamin. According to this model, 
known as friction-driven scission, the tube elongation causes local membrane tension until 
the membrane undergoes scission (See also Section 2.4 and 2.5).6 
 
Figure 10: BAR domains can recognize membranes with a similar curvature. BARs and F-BARs recognize positive curvature 
of different degrees, I-BARs recognize negative curvature. On the right the 3 domains are overlapped. Reproduced from: 
www.endocytosis .org 
BAR proteins often contain additional modules to assist membrane binding to lipids or to 
regulators of endocytosis, such as PH (pleckstrin homology) or PX (Phox homology) domains 
that confer lipid specificity to phosphoinositides. Many of these proteins also contain a SH3 
(Src homology 3) domain that mediates the binding with other endocytic and cytoskeletal 
proteins, such as the GTPase dynamin (mediating vesicle fission), or N-WASP (an initiator 
for actin polymerization). Therefore BAR-domain proteins can be seen as major endocytic 
regulators, since they can sense, stabilize or induce curvature, regulate actin dynamics and 
recruit endocytic regulators and adaptors (such as dynamin). 
 P a g e  | 59 
 
2 
Chapter 2.  Endocytosis mechanisms 
Given the central roles of BAR proteins in endocytosis, in this work - for the first time - I 
have investigated more in detail their involvement in the uptake of nano-sized objects 
(Chapter 5). 
In the next paragraphs I will describe with additional details the main characteristics of a 
series of BAR domain proteins involved in CME (such as FCHo, FBP17, endophilin, 
amphiphysin, SNX9) and CIE, like Pacsin2 (caveolae-mediated), SNX9 and GRAF1 
(CLIC/GEEC), endophilin (FEME) and again SNX9 (macropinocytosis). These BAR proteins 
were included in my investigation (Chapter 5).  
3.1 F-BAR proteins  
FCHo 1/2 are ubiquitous proteins part of the F-BAR domain family and are involved in the 
recognition of the initial membrane curvature that generates the clathrin-coated pits.15 
FCHo binds to PIP2 of curved PM and afterwards recruits Eps15 and subsequently the AP2 
adaptor complex.15 
Another F-BAR domain is FBP17 which is instead recruited at later stages of CME and forms 
a ring-like structure that surrounds the forming vesicle.125 FBP17 also contains a SH3 
domain, which mediates the recruitment of dynamin, and can also contribute to the 
recruitment of the actin machinery.129 FBP17 is involved in the clathrin mediated uptake of 
transferrin, but is also involved in the CIE of cholera toxin subunit B (CTxB) and epidermal 
growth factor (EGF).130 
Pacsins (or syndapins) are F-BAR domain proteins which also contain a SH3 domain that 
mediates the binding to dynamin and to the actin-nucleating complex.51 Pacsin2 is 
expressed ubiquitously and it has been shown to mediate caveolae membrane tubulation 
and to recruit dynamin-2 for caveolae fission.48,50 Consistent with this, Pacsin2 induces 
membrane tubules of about 50 nm, smaller than those induced by other F-BAR domains, 
and in the same range of caveolae invaginations (50-100nm).125 Caveolin-1 interacts directly 
with and activates the F-BAR domain of Pacsin2, allowing membrane tubulation. 
3.2 The PX-BAR protein SNX9  
Sorting nexins are a family of proteins constituted by a PX domain that recognizes 
phosphatidylinositol lipids,131 a LC domain which can bind to clathrin adaptors, a SH3 
domain and a BAR domain at the C-terminal. The PX and BAR domains form a functional 
unit (the PX–BAR module) that mediates membrane curvature sensing and deformation.132  
The BAR domain of this proteins also mediates the homodimerization between SNX family 
members,93 which is promoted by the presence of PIP2 at the PM.  
SNX9 can promote by itself membrane tubulation in vitro,132 but in vivo it is likely to act as 
a curvature sensor, recruiting dynamin and the actin cytoskeleton which then induce 
bending. 93,133 SNX9 has been prevalently associated to CME at late stage of clathrin coated 
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pits formation,18 but it has a role also in CIE. In fact, SNX9 is critical for macropinocytosis, 
since it localizes to actin-rich structures implicated in fluid-phase uptake and can activate 
both Cdc42 and WASP.93 Moreover, SNX9 seems to have a role in the CLIC/GEEC pathway, 
since it interacts with the actin machinery and PIP2, colocalizes with tubular membranes 
containing GPI-APs or CD44 and is a positive regulator of Cdc42.18,93 It can also compensate 
for GRAF1 depletion to restore CLIC/GEEC uptake.134 
3.3 The PH-BAR protein GRAF1  
GRAF1 is a marker for CLIC/GEEC endocytosis, since it is localized in tubular and punctate 
structures associated to this pathway. It interacts with Cdc42, stimulating its GTPase 
activity, and mediates the uptake of fluid-phase markers, CTxB and GPI-APs92,135. GRAF1 
acts more as a sensor of curvature than a bending protein, recruiting other remodelling 
proteins at the PM.135 GRAF1 contains a BAR domain, which senses membrane curvature, a 
PH domain (pleckstrin homology), which recruits GRAF1 at the PM through PIP2 binding, a 
SH3 domain (Src homology 3) for interaction with dynamin, and a GAP domain, which has 
GAP (GTPase activating) activity towards Rho family GTPases.92,135 The BAR and PH domains 
(PH-BAR) work together for PIP2 binding and curvature sensing.92 Moreover the PH-BAR 
domain can interact and inhibit the GAP domain.136 When this autoinhibition is removed, 
the GAP domain activates preferentially Cdc42, but also RhoA and Rac1.137 GRAF1 can 
regulate actin remodelling through an indirect regulation of RhoA and Cdc42 activity.53 
Moreover, although CLIC/GEEC is dynamin-independent,85 GRAF1 can recruit and interact 
with dynamin.92  
3.4 The endophilins N-BAR proteins  
Endophilins are a family of N-BAR domain proteins comprising endophilin A1 and A3 
(SH3GL2 and SH3GL3, respectively), mainly brain-specific and localized at the presynaptic 
membrane, and endophilin A2 (SH3GL1), which is ubiquitously expressed. In this thesis I will 
mainly focus on the latter, since expressed in all tissues. Endophilin structure is 
characterized by a C-terminal SH3 domain, which binds to dynamin-1 and synaptojanin in 
the brain, a N-terminal BAR domain, which includes an amphipathic α-helix called H0, 
essential for membrane bending, and an additional α-helix that protrudes from the concave 
structure of the BAR domain, called Helix 1 (H1).128 
Endophilin is implicated in the formation of clathrin coated pits,17,21 however it seems not 
fundamental for this process since its inhibition doesn’t lead to CME impairment.19 
Recently, endophilin has been proposed to be a marker for FEME (Fast-acting mediated 
endocytosis).94 In particular, endophilin acts in concert with actin and dynamin for the 
scission event of Shiga and cholera toxins, two CIE endocytic cargoes.95  
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3.5 The amphiphysins N-BAR proteins  
Most of the knowledge about amphiphysins comes from tubulation experiments in vitro 
that showed that amphiphisin-1 can tubulate artificial membranes on its own.138 
Amphiphysins are nucleocytoplasmic proteins expressed in all tissues and with several 
cellular functions, among witch as regulators of endocytosis and membrane trafficking and 
recycling. In mammalians there are 2 isoforms, amphiphysin 1 (or AMPH1) and amphiphysin 
2 (also named bridging integrator-1 or BIN1), which can form homo and heterodimers 
(Figure 11). A distinct BAR domain protein, called BIN2, has been shown to hetero-dimerize 
with BIN1, but its function in endocytosis is still not clear.139 Amphiphysins contain an N-
terminal α-helix for membrane bending and recognition and an N-terminal SH3 domain 
which mediates the binding with dynamin with low affinity.140  
 
Figure 11: BAR family of adapter proteins. SH3, Src homology 3 domain; MBD, Myc binding domain; CLAP, clathrin-AP2 
binding region. Adapted from: - Reviews on Cancer (2009).148 
In the brain, amphiphysin 1 can interact with actin effectors and in testis cells it can regulate 
actin polymerization during phagocytosis.141 Amphiphysin 2 (BIN1) has many splicing 
variants in different tissues. For example, the variant enriched in the brain contains a CLAP 
domain for clathrin and AP2 binding and can interact with dynamin, synaptojanin and 
endophilin to form clathrin coated pits.138,142 Other variants, such as isoform 8 of 
amphiphysin 2, function in muscle T-tubule formation and are connected to several 
myopathies.143,144 They function by clustering of PIP2 and recruitment of dynamin at the 
PM.145 Ubiquitous variants, like isoform 9 and 10, lack the CLAP domain and are not involved 
in CME, but in the formation of tubules and in membrane recycling.146 In fact, 
downregulation of BIN1 in HeLa cells does not decrease the uptake of transferrin, a CME 
marker, but instead increases its uptake due to defects in receptor recycling. These 
ubiquitous isoforms are also involved in tubulation of organelles through the binding of 
microtubules. In fact, in HeLa cells their capacity to induce tubule formation is blocked by 
the perturbation of microtubules by nocodazole.147  
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Overall, the BAR family of adapter proteins contain many different molecules with distinct 
features and clearly a central role in multiple pathways of endocytosis, where they 
contribute to mechanisms to sense and induce membrane curvature. 
Their role in CIE is being explored in more details in the last years, while their involvement 
in the uptake of nanomedicines has not been investigated as yet.  This has been part of this 
thesis and is presented in Chapter 5. 
 
4 Viruses and Toxin uptake 
Some of the knowledge obtained so far on the endocytic mechanisms derives from the 
study of viruses and bacterial and plant toxins. As pathogens, virus and toxins on one hand 
can exploit physiological pre-existing routes and on the other they can induce and trigger 
signalling that affects their internalization, features that nano-sized cargoes may as well 
share.149,150 Their endocytosis might not be representative of a physiological pathway, 
therefore caution has to be taken when studying their uptake.  
In this paragraph I will focus on the entry routes of the most studied viruses and toxins and 
potential parallels with nanomedicine behaviour. 
4.1 Toxins 
Cholera toxin (CTx), produced by the bacterium Vibrio cholera consists of five binding 
subunits (CTxB) and a single A-chain. CTxB can bind specifically to the glycosphingolipid GM1 
in the outer leaflet of the plasma membrane and, as mentioned above, induces membrane 
bending as described in the GL-lect hypothesis (see also Section 2.4, Figure 3 and Figure 8). 
CTxB can be internalized by several mechanisms. For example, it was observed to be 
localized into caveolae-positive structures, therefore it has been widely used as a marker 
for caveolae mediated endocytosis since then.151 However, more recently it has been shown 
to be internalized by other mechanisms, among which also by CME.59–61 In Caco-2 and HeLa 
cells, CTxB is internalized in a clathrin and caveolae independent manner, and the 
mechanism has been found to be partially dependent on actin.59 In other cases CTxB uptake 
has been shown to be independent of cholesterol.152 Moreover also flotillins seem to be 
involved in the uptake of CTxB.70,73 It seems that endophilin acts in concert with actin and 
dynamin for the scission event of cholera toxins, in a mechanism which resembles FEME.95  
FBP17 is also involved in the CIE mediated uptake of cholera toxin subunit B (CTxB).130 
Shiga toxin from Shigella dysenteriae is composed of a catalytic A-subunit and a B-subunit 
(STxB), which binds to the glycosphingolipids receptor globotriaosylceramide (Gb3).153 It 
has been proposed that STxB can induce clustering of Gb3 receptors and generate 
membrane bending in a clathrin-independent manner, as described in the GL-lect 
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hypothesis.154 Also in this case, the toxin has been reported to be internalized through 
multiple mechanisms: STxB can enter through CME155,156 and it has been shown to 
upregulate its own CME uptake.157 In energy-depleted cells, STxB induces tubulation of the 
plasma membrane, which does not depend on CME but on dynamin.116  Endophilin acts in 
concert with actin and dynamin for the final scission event, in a mechanism which resembles 
FEME95. 
4.2 Viruses 
Virus entry is generally mediated by cellular receptors. Some receptors mediate just the 
adhesion of viruses to the plasma membrane, while others have additional roles in signalling 
and endocytosis. It appears, however, that the majority of viral receptors are not directly 
involved in the uptake of physiological ligands. Furthermore, the receptor used by viruses 
for their uptake defines the entry mechanism and which tissue can be infected.158  
Interestingly, viruses can use more than one type of receptor and therefore, can exploit 
multiple endocytic mechanisms at the same time. For example, herpes simplex virus uses 
different pathways in different cell types. Viruses can also induce receptor clustering for 
their entry. The clustering can generate signalling platforms at the PM membrane and this 
in itself can induce the endocytic event (as described in Section 3 and Figure 7).159 
Another interesting observation is that serum components can mediate the interaction of 
viruses and cells. In fact, once in biological fluids, viruses are covered by antibodies and 
opsonins and it has emerged that these molecules can promote their entry.160,161 This is very 
similar to what happens in vivo to man-made nanoparticles, which – as mentioned earlier - 
adsorb on their surface serum biomolecules which form a layer called corona (as discussed 
in details in Chapter 1).162,163 It will be very interesting to investigate whether viruses share 
a corona with similar properties to that of nanomedicines. 
Overall, viruses are particularly interesting for this dissertation because – as previously 
mentioned - they can be considered as “natural” nanoparticles. In fact, their size range, 
which is between 20 and 200 nm, till a maximum of 2 μm, allows us to classify them as such. 
Furthermore, as illustrated above and in previous Sections, they seem to share many 
features with man-made nano-sized objects in the way they interact and are processed by 
cells. More in general, the study of the mechanisms of virus recognition and internalization 
can help us to better understand the endocytic mechanisms involved in the uptake of man-
made nanoparticles or to suggest viral-inspired strategies for improving drug delivery. 
Moreover this knowledge can allow designing strategies to exploit viruses for drug 
delivery.159 In fact, since decades several studies use inactivated viral particles or particles 
resembling the design of viral capsids to exploit virus endocytic routes for targeting 
purposes.164,165  Indeed, viral nano-carriers are one of the major classes of drug carriers 
investigated, especially in the field of gene delivery.165  
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5. Final remarks: how endocytosis has been studied 
in this thesis 
Several of the mechanisms of endocytosis described so far have been implicated in the 
internalization of nanomedicines.2,166,167 Many studies have focused their investigation on 
the most classical pathway of endocytosis, such as clathrin-mediated, caveolae-mediated 
and macropinocytosis.168–172 However, here we showed that endocytosis includes many 
more pathways which are constantly being updated and revised. Many of the pathways 
described in this Chapter have not being investigated in detail in the nanomedicine field so 
far. Furthermore, as discussed in Chapter 1, endocytosis requires multiple molecular 
processes and regulators, which, in most cases, are strictly interconnected among them, 
making their characterization particular challenging. 
Within this context, in this thesis, in Chapter 4 I focus on the involvement of most classical 
pathways of endocytosis in nanoparticle uptake, investigating the role of CME, cholesterol, 
macropinocytosis, dynamin, microtubules and actin in the uptake of 50 nm silica 
nanoparticles, with a special focus on the effect of the biological environment and corona 
formation. This investigation is carried out using classic transport inhibitors such as 
chlorpromazine hydrochloride, methyl-β-cyclodextrin, 5-(N-Ethyl-N-isopropyl)amiloride 
(EIPA), dynasore, nocodazole and cytochalasin D, whose mechanisms of action are 
described in detail in Chapter 3. In Chapter 5 I attempt to define which mechanisms are 
involved in the uptake of nanomaterials by selecting a panel of targets for RNAi implicated 
in several endocytic processes and combining this investigation with transport inhibitors 
and other techniques. I start by examining the involvement of CME in the uptake of 
nanomaterials by using RNAi to shut down the expression of a series of molecules involved 
in this pathway, such as CLTC, DNM2, ARF6, Epn1, Fcho2, Endophilins, SNX9, Amphiphisin2 
(BIN1). This is combined to the use of chemical compounds to block CME, deplete 
cholesterol and block actin polymerization, as well as overexpress the C-terminal of AP180, 
which inhibits clathrin-coated pit maturation. Next, I investigate the potential involvement 
of all other pathways described as follows: caveolae-mediated endocytosis (using siRNA 
against CAV1 and Pacsin2, cholesterol depletion, DNM2 inhibition, and by blocking actin 
polymerization), Flotillin-mediated endocytosis (siRNA against Flot1), CLIC/GEEC (siRNA 
against Cdc42, Graf1, SNX9, cholesterol depletion and by blocking actin polymerization), 
ARF6-mediated pathway (siRNA for ARF6 and cholesterol depletion), FEME (siRNA against 
endophilins, by blocking actin polymerization, and DNM2 inhibition), RhoA-mediated 
endocytosis (siRNA again RhoA, Rac1, DNM2, cholesterol depletion, and by blocking actin 
polymerization), macropinocytosis (siRNA against Rac1, Cdc42, ARF6, Ankfy1, SNX9, 
blocking actin polymerization, and by cholesterol depletion), and phagocytosis (siRNA for 
Cdc42, Rac1, ARF6, RhoA, blocking actin polymerization, cholesterol depletion). 
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Finally, I study more in depth the role of curvature generation in the endocytosis of 
nanomedicines by investigating for the first time the role of a panel of BAR proteins in 
nanoparticle uptake using RNAi against GRAF1, endophilins (SH3GL1, 2 and 3), 
amphiphysin2 (BIN1), Pacsin2, Ist1 and Fcho2. 
Finally in Chapter 6 I show the limits of RNAi and chemical inhibitors in the characterization 
of nanoparticle uptake mechanisms in endothelial cell barriers made of primary HUVEC 
cells. Primary cells can in fact show very low transfection efficiency, thus limiting the use of 
strategies such as RNAi or the expression of mutants and fluorescent proteins. Furthermore, 
I show that barrier integrity is compromised by many of the common chemical inhibitors, 
thus limiting their potential application. This poses further challenges in the 
characterization of uptake mechanisms in this type of cell models and suggests that other 
methods need to be applied in these cases. 
For all of the work presented, it is important to keep in mind that, as discussed in detail in 
this Chapter, many of the molecular players investigated are involved in multiple pathways 
(For example Cdc42, which is the main regulator of the CLIC/GEEC pathway, has also being 
involved in macropinocytosis and phagocytosis). Therefore caution should be taken in 
interpreting the results obtained, taking into account the many similarities shared by 
multiple pathways. This is presented and discussed in more details in each of the Chapters 
presented. 
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Abstract 
Understanding how cells process nano-sized materials 
could contribute to further improve their success for 
nanomedicine and drug delivery applications. Many 
nanomedicine uptake studies use pharmacological 
inhibitors to characterize the pathways involved. 
However, these compounds can have toxic effects on 
cells: stringent controls are necessary to verify their 
efficacy and exclude their toxicity. The results generated 
need to be interpreted with care. Moreover, 
nanomedicine uptake studies should be performed in 
the presence of serum, which complicate the use of 
pharmacological inhibitors. We illustrate these concepts 
with a panel of six common pharmacological inhibitors 
and a model nanoparticle-cell system. Careful controls 
of drug efficacy and toxicity are included and different 
limits and challenges presented, including unique nano-
related complications when they are applied to the 
question of nanomedicine uptake. Overall this study 
illustrates some of the challenges that this 
interdisciplinary field needs to face for its further 
improvement. 
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Background 
Nano-sized drug carriers are used to improve targeted delivery of drugs to their site of 
action.1–3 Several products are now on the market and extensive research is still ongoing in 
order to further advance the development of successful nanomedicines. Recent debates 
within the field have highlighted that a better understanding of the mechanisms by which 
these materials are processed at cellular level is one of the factors that could enable such 
improvements.4–6 
Cells use different processes to internalize extracellular materials such as proteins, large 
molecules and natural nano-sized materials, such as for instance lipid nanoparticles (HDL, 
LDL etc.). These are all active processes that require energy consumption by the cell. Several 
mechanisms of endocytosis have been identified and extensive reviews are available to try 
to classify and summarize the key aspects of each of these different pathways.7–10 However, 
the field is still very active and still constantly updating. It is generally recognized that 
nanomedicines typically enter cells by active processes. Unless specifically engineered to do 
so,11 these objects are in fact too large to simply diffuse inside cells, therefore cells need to 
spend energy for their internalization.12,13 However, the details of the molecular machinery 
involved and the pathways utilized are in many cases still unclear, as well as very challenging 
to characterize.  
Several studies have tried to determine how the mechanism of uptake changes with 
nanoparticle type as a function of their size, charge, shape and other nanoparticle 
parameter. For instance Reijman et al. and Chitrani et al. have tried to investigate the effect 
of size and shape on nanoparticle uptake mechanisms;12,13 dos Santos et al. have done 
similar efforts to try to characterize the uptake of particles of different sizes and how these 
change in a panel of different cell lines;14 Arvizo et al have tried to demonstrate the 
correlation between uptake and surface charge of gold nanoparticles.15 More recently it has 
emerged that not only nanomaterial properties such as size, shape and charge, but even 
the medium in which the nanomedicines are dispersed and the resulting corona of 
molecules adsorbing on their surface can affect the details of the mechanisms they use to 
enter cells.16,17 
The fact that the field of endocytosis is still so active in itself in investigating how cells 
internalize extracellular cargoes further complicates this challenge. A close connection 
between the nanomedicine field and the cell biology community is highly auspicabile4,6 to 
avoid discrepancies between the latest findings in endocytosis and the ongoing studies on 
nanomedicine characterization. This is only one of the examples on the complexity that 
interdisciplinary fields, such as nanomedicine, need to face. 
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Overall, several methods are available to study transport in cells. Most classic approaches 
are based on methods to block a certain portal of entry and - in this way - determine its 
involvement in the uptake of the material of interest. These include for instance the use of 
pharmacological inhibitors and RNA interference or other approaches to knock down or 
transiently block the expression of key proteins involved in endocytosis. However, when 
attempting to block transport, cells can adapt by over-activating alternative mechanisms 
normally less relevant, or by overcompensating for the blocked function or protein.18 This 
makes interpretation on the role of certain pathways in the unperturbed cells 
complicated.19 
Next to these methods, imaging based approaches can be used to try to characterize the 
pathways involved by directly visualizing uptake and determine whether the material of 
interest is associated to key endocytic structures or proteins during internalization. This can 
be done by immunostaining or for instance by using cells expressing fluorescently labelled 
proteins of interest.20 Even though similar imaging-based approaches do have the 
advantage of trying to characterize endocytic pathways without perturbing it, the analysis 
needed to demonstrate that a certain structure or protein is involved is not always 
straightforward. Moreover, it has been shown that also overexpression of fluorescent 
proteins can alter physiological processes.21 More recent technologies such as CRISPR/CAS9 
may be used to avoid such limits. 
When attempting to block transport, strategies such as RNA interference, knock down or 
CRISPR/CAS9 technology can be used to reduce or block the expression of key proteins 
involved in the different pathways. These methods are relatively specific, however 
interfering with the expression of one single protein does not necessarily imply that the 
pathway is fully blocked. Thus, careful controls need to be performed to verify not only the 
blocked or reduced expression of the target of interest, but also the effect on the pathway 
under study.19,22 Furthermore, as mentioned above, cells have time to adapt to the induced 
perturbation, since silencing - for instance - requires at least 3-5 days before the protein of 
interest is reduced.  
Perhaps the most classical method used to block transport involves the use of 
pharmacological inhibitors. Most studies on the uptake of nanomedicines indeed make use 
of this kind of compounds to try to determine how nanomedicines enter cells.12,14 
Pharmacological inhibitors have been developed and used extensively since many decades 
as a tool to block or interfere with determined transport pathways. Advancement in drug 
design has allowed improving their properties and selecting compounds with higher 
specificity and superior efficacy through the years.23 Compared to other methods that block 
transport, pharmacological inhibitors are usually preferred because of their fast action, thus 
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limiting the possibility for cells to adapt to the perturbation they induce, and because they 
are seemingly easy to use.  
However, it is also well known that pharmacological inhibitors possess limits associated with 
both their specificity and toxic side effects. For instance, Vercauteren et al. have shown in 
details how pharmacological inhibitors can have very different toxicity and efficacy 
depending on the cell line in which they are used;22 similar results have been observed also 
in other works and when comparing the results obtained with inhibitors and RNA 
interference to downregulate the expression of key proteins involved in endocytosis.24 
Within this context, in this work we have selected a panel consisting of six pharmacological 
inhibitors and used them to illustrate the challenges associated to their use, while trying to 
characterize the uptake of one model nanoparticle-cell system.  
We use this example to discuss limits related on the mechanism of action of the selected 
compounds and interference, in many cases, with multiple mechanisms of uptake; we also 
show how the results generated with these compounds can be confused by their toxicity, 
and how this - if overlooked - can lead to wrong conclusions. Next to this, we illustrate the 
need of control markers to verify and demonstrate the efficacy of these inhibitors in the 
cells and conditions tested, and we discuss challenges associated with the selection and 
availability of such controls. Finally, we also show specific limits when these compounds are 
used for nanomedicine uptake studies, in particular due to the interference of proteins in 
the cell culture medium on their action. 
Results and discussion 
The selected panel of pharmacological inhibitors and their 
mechanisms of action  
In order to illustrate limits and challenges associated to the use of pharmacological 
inhibitors to study uptake of nanomedicines, the following compounds have been selected: 
o Chlorpromazine and EIPA (5-(N-ethyl-N- isopropylamiloride), typically used as inhibitors of 
(respectively) clathrin mediated endocytosis and macropinocytosis. These are good examples of 
compounds which should have effect on one specific pathway, but with a relatively complex 
mechanism of action. 
o Methyl beta cyclodextrin to determine the effect of cholesterol depletion on nanoparticle uptake 
o Nocodazole to determine the role of microtubules 
o Cytochalasin D to determine the role of actin 
o The dynamin inhibitor dynasore to determine the role of dynamin. 
As opposed to the first two, these latter compounds have relatively specific mechanism, but 
they block components which are involved in multiple mechanisms of endocytosis, thus 
alone do not allow to identify a specific pathway. 
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Chlorpromazine (CP) is a good example of a compound used to block one specific pathway, 
that is - in this case - clathrin mediated endocytosis (CME).22,26 CP is a cationic amphiphilic 
drug which inhibits the function of AP2, one of the key adaptor proteins in CME. This results 
in the formation of clathrin lattices onto endosome, instead of clathrin-coated pits on the 
cell membrane. CP is also known to block receptor recycling by trapping receptors inside 
the endosomes.26 Thus the mechanism of action is complex to describe and this compound 
interferes with CME at multiple levels.  
Similarly, amiloride and its derivative EIPA are often used as specific inhibitors of 
macropinocytosis: these compounds are actually inhibitors of the Na+/H+ exchanger pump 
in the plasma membrane. It is proposed that they block macropinocytosis as a consequence 
of their interference with the pH of the cytosol close to the cell membrane27,28 where 
macropinosomes form. The resulting acidification then blocks Rac1 and Cdc42 signalling 
which is essential for macropinocytosis (note however that Cdc42 signalling is essential also 
for the so called Cdc42 dependent mechanism of clathrin independent endocytosis (CIE), 
also referred to as CLIC-GEEC pathway). 
The other selected pharmacological inhibitors instead have a more direct mechanism of 
action in blocking a key component of endocytosis, but – as mentioned - they do not allow 
direct identification of the pathway involved, since such components are essential for 
different ones. More in detail, cytochalasin D is a mycotoxin that blocks actin polymerization 
by binding to the barbed end of F-actin.29 Thus CytD can be used to rule out the role of actin 
in the uptake process under study. However, actin is known to be involved in several 
pathways. This means that caution should be taken into interpreting CytD as an inhibitor of 
- for instance - macropinocytosis30, since also CME31 and other CIE mechanisms32 depend 
on actin.  
Similarly, nocodazole is a compound that binds to tubulin, blocking microtubule 
polymerization33. This compound can be used to rule out the role of microtubules. However, 
microtubules are essential components for CME,34 macropinocytosis and possibly other 
mechanisms.35,36 More importantly microtubules also control the intracellular trafficking of 
vesicles after internalization.37 
Dynasore is a commonly used dynamin inhibitor.38,39 Although its specificity is sometimes 
still questioned,40 dynasore is generally used to inhibit dynamin, a key protein for vesicle 
fission. The presence of multiple dynamin isoforms with different expression levels in 
different tissues can complicate the outcomes of experiments using this and other similar 
dynamin inhibitors, since inhibition of an isoform may be compensated by the presence of 
the other isoforms. Triple knock out cells have been generated to try to overcome these 
limits. 41 Furthermore, multiple pathways do depend on dynamin activity (indeed Pagano et 
al. 32 classify endocytic pathways into dynamin dependent and dynamin independent, thus 
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illustrating the key role of this protein in uptake). Thus, also in this example, having 
established that a certain uptake mechanism depends on dynamin does not allow alone to 
identify the pathway involved.  
Finally, methyl-β-cyclodextrin is a common agent for cholesterol depletion. MβCD and other 
compounds such as filipin, nystatin etc. can be used to interfere with the cholesterol in the 
cell membrane. In general, it is important to keep in mind that cholesterol depletion can be 
a very disruptive treatment for cells. It has consequences not only for caveolae mediated 
endocytosis, as often implied, but for almost every endocytic mechanism, also strongly 
depending on the concentration used and cells tested (the effects of these different 
compounds and the role of cholesterol in multiple uptake pathways have been extensively 
reviewed by Sandvig et al.).19 
Clearly, none of these latter four compounds alone allows determining the pathway 
involved in the uptake of the material of interest since, as explained above, they affect 
components of the transport and cell machinery which are involved in multiple 
mechanisms. 
Selection and availability of control markers to test and 
demonstrate the effect of pharmacological inhibitors 
A first essential requirement when using pharmacological inhibitors is to test and verify 
their efficacy in the conditions used with appropriate control markers. A good control 
should be a protein or other cargo which is known to enter cells via a determined pathway. 
Thus, one can use such controls to test whether in the cell type under study and conditions 
tested, a certain pathway is effectively blocked. 
In many cases protocols are applied based on information found in literature, but 
unfortunately often without prior verification on the drug efficacy using similar controls. As 
mentioned earlier, several studies have highlighted instead how different cell types can 
have different sensitivities to the action of these compounds.22 In other words, one cannot 
simply apply a protocol as found in literature: preliminary tests are needed to determine 
the drug concentration which is effective in the particular cell type of interest. For this study, 
HeLa epithelial ovarian cancer cells were selected as a model cell line commonly used to 
characterize cellular transport.12,42,43 These cells are often used also within the 
nanomedicine community when characterizing nanocarrier uptake and behaviour in 
cells.12,14 
Other parameters that can affect the efficacy of these compounds, are: the length of the 
pre-incubation with the inhibitor prior to the exposure to the tested compound or 
nanomedicine; the overall exposure time to the drug; the medium in which the drug and 
tested nanoparticle or compound are dispersed (serum free or complete cell culture 
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medium supplemented with serum proteins); the cell number (cell density) and cell passage 
number. For instance, higher cell numbers may require higher concentrations of the drug 
for it to be effective and are typically associated with lower toxicities. Similarly, cells at 
higher passage number can become less sensitive to the compounds. These factors are all 
rather common for any drug tested, not only pharmacological inhibitors of transport 
pathways. Nevertheless, it is important to stress their effect on drug efficacy and overall the 
need of careful and appropriate controls which should take them all under consideration. 
In order to be able to test and optimize all these parameters, as mentioned above an 
appropriate control marker, known to enter cells via a specific endocytic pathway should 
be selected. As easy as this may sound, for several of the mechanisms of endocytosis 
described in literature such stringent controls may be missing or are constantly debated. 
This is again a reflection of the fact that – as mentioned earlier - endocytosis is still a very 
active field of research and the classification and characterization of endocytic pathways 
and cargoes specifically assigned to a given pathway is constantly being updated and 
revised.  
In the case of CME, the selection of appropriate markers may seem easy, as it is generally 
recognized that cargoes such as for instance transferrin (TF) or low density lipoprotein (LDL) 
are internalized by cells via this pathway.44,45 
However other complications may arise. For instance, we tested the uptake of labelled 
transferrin in HeLa cells in the presence of chlorpromazine (Supplementary Figure S1). For 
short incubation times, the exposure to CP leads to a strong reduction of transferrin uptake, 
suggesting inhibition of CME. However, after 1h of exposure this reduction is fully lost and 
transferrin uptake levels are comparable to those observed in control cells not exposed to 
CP. This could be due to the cells adapting quickly to the effect of CP and compensating it 
in some way. However, a 60 minute pre-exposure to the drug leads to a strong reduction of 
transferrin uptake, ruling out this interpretation. Still, also in this case, after 60 minutes 
exposure to transferrin in the presence of CP, the effect of CP is lost. Interestingly, no such 
loss of inhibition is observed in the same cells using CP in the exact same conditions but 
with LDL as a control marker (also in Supplementary Figure S1). A possible interpretation is 
that after longer exposure times, transferrin (and not LDL) adheres out of the cell 
membrane, even if uptake is blocked and this pollutes the flow cytometry measurements. 
Alternatively, cells exposed to transferrin in the presence of CP may adapt and use 
alternative routes for its uptake. Further studies are required to understand this 
phenomenon, which here we include solely to illustrate the complexity of outcomes that 
one may observe, even when setting up control experiments with these inhibitors. This 
example also shows that performing experiments over time may add important information 
in comparison to a simpler snapshot at a given exposure time, though the effect of the 
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inhibitors over time may also change due to the cells adapting to the treatment, or other 
pathways being activated to compensate for the inhibition.  
As a further example, Supplementary Figure S1 also shows controls for cells exposed to 
dynasore. As previously mentioned, dynamin is involved in several uptake pathways 
including CME, thus we expect the uptake of LDL and TF to be both reduced in the presence 
of this compound. Again, in the conditions tested we found that TF uptake is only partially 
reduced while LDL uptake is strongly inhibited over time. Overall, this shows that even when 
appropriate markers are available and are used as controls on the effect of the inhibitors 
on a given pathway, ulterior factors may complicate the results and make the selection of 
appropriate protocols challenging.  
The selection of appropriate cargoes to test the efficacy of the inhibitors on pathways other 
than CME is more complicated.  
Molecules such as cholera toxin B or SV40 are typically used as cargoes for caveolae 
mediated endocytosis. However it has been shown that - for instance - cholera toxin seems 
to be able to enter different cells independently of caveolae and via different mechanisms, 
including both CME and CIE.46,47 Even more importantly, the actual role of caveolae in 
endocytosis is strongly debated within the endocytosis community.48,49 It has been shown 
in fact that in many cell types caveolae do not even pinch off from the plasma membrane, 
rather have a role in maintaining cell shape and controlling membrane tension.50 In these 
cases, just a fraction of caveolae is mobile and can undergo endocytosis, mainly if activated 
by a ligand.51 Another ongoing debate is related to the capacity of this pathway to promote 
transcytosis in endothelial cells,52,53 an observation that has been confuted in other works.54 
This all has been beautifully summarized by Iversen et al.19 Again, this is another example 
highlighting how the endocytosis field in itself is still extremely active, and the drug delivery 
community needs to strongly connect with it to be able to interpret their findings in light of 
the latest developments.  
Molecules such as LacCer, a glycosphingolipid that resides preferably in lipid rafts, are often 
used to verify the efficacy of cholesterol depletion protocols. LacCer uptake is in fact known 
to be dependent on cholesterol.22,55 Thus LacCer has been used here to test the efficacy of 
cholesterol depletion via methyl-β-cyclodextrin (MBCD). 
Finally, even more challenging is the selection of markers and specific cargoes to test the 
effect of pharmacological inhibitors on the so-called CIE pathways or to be able to 
differentiate them. Reviews on endocytosis are constantly updating the list of cargoes 
involved in certain CIE pathways, and similarly the community is still debating on their 
existence, inter-connections and characteristics.9,32,56,57 
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When using compounds such as cytochalasin D and nocodazole, imaging of actin and 
microtubules, respectively, can be used to easily assess the efficacy of the protocol applied 
in altering these structures. Again, it is important to keep in mind that given the different 
sensitivity of different cell types to these drugs, some optimization of protocols is always 
required and similar controls are necessary to demonstrate the effect of the drug in the 
conditions applied and specific cell type tested. 
Optimization of protocols for the use of the pharmacological 
inhibitors 
In order to determine the conditions for using the panel of inhibitors on HeLa cells, different 
doses of the various compounds were tested and their effect on the uptake of control 
cargoes (when available) measured, together with the effect on the uptake of 50 nm silica 
nanoparticles as a model nanoparticle. We also included a measurement of the cell viability 
via MTT assay, and light microscopy imaging of the cells in order to get an overview on the 
impact of the inhibitor tested on the cellular morphology and eventual toxicity. 
Silica nanoparticles of 50 nm were chosen as a common model nanoparticle used in many 
cell-nanoparticle studies and with size comparable to many drug carriers currently under 
investigation for drug delivery. These particles constitute an optimal model thanks to their 
well-known stability and formation of homogenous dispersions, even in the cell culture 
medium supplemented with serum that is used to maintain cells.58,59 The size distribution 
and zeta potential in relevant media and over time is included in Supplementary Figure S2 
and Table S1. We stress that also for studies focused on the mechanisms of uptake of 
nanoparticles and other drug carriers it is crucial to include this information (unfortunately 
often missing): dispersion in cell culture medium can lead to agglomeration, as also 
sometimes incubation in such media over time in the conditions applied for cell experiments 
(37 C and 5% CO2). Presence of agglomeration over time could affect strongly the pathways 
involved in uptake.  
Another key factor that has been nowadays recognized to control and dictate the biological 
behaviour of nano-sized object is the corona that forms once they are exposed to biological 
environments, due to adsorption of biomolecules on their surface.60,61 It has emerged in 
fact that cells recognize these molecules and the uptake and intracellular fate can strongly 
be affected by this layer.16,62,63 While the specific effects of the corona on the mechanisms 
cells use to internalize nanocarriers is emerging only recently and still needs to be fully 
elucidated, it is clear that studying these pathways in the complete absence of any form of 
corona, such as in serum free media, may have totally different outcomes than in real 
applications. Bare nanoparticle surfaces can strongly adhere on cells, sometimes even 
leading to cell membrane damage and consecutively presence of particles free in the 
cytosol, and ultimately cell death.59 Even when similar strong effects may be not present, it 
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is clear that we will have to elucidate how this layer affects the mechanisms of uptake and 
more importantly, consider what is the “correct corona” to use when studying uptake for a 
given application and nanocarrier investigated. While here – to begin with - we limit to 
exclude artificial serum free conditions and we consider a simple situation for nanoparticles 
dispersed in 10% FBS (clearly not a relevant corona for application in humans), this crucial 
aspect is object of further ongoing studies. 
We also stress that we have taken particular care in performing these inhibition and uptake 
experiments as a function of time. Time resolved experiments in fact provide more 
complete information on the kinetic of the process and are of particular importance when 
studying internalization of larger objects such as nanocarriers, as opposed to (much smaller) 
proteins. Uptake kinetics are in fact typically slower. Furthermore, shorter exposure times 
can be affected by particle adhesion to the outer cell membrane, which may confuse the 
results.64 Even if longer exposure times may lead to cells adapting to the effect of the drug 
or multiple pathways being activated, eventual effects of this kind (which are also 
interesting to capture) can be monitored by using the appropriate controls over time in the 
same conditions, as indeed we show below.  
Figure 1 shows the results obtained for cells exposed to chlorpromazine at different 
concentrations. This drug, as previously mentioned, is often used as inhibitor of CME and 
provides a very interesting example on possible complications in using pharmacological 
inhibitors, in relation to their toxicity. 
For the lower CP concentration tested, the inhibition of the control marker LDL was already 
extremely strong, suggesting that these conditions are efficient in blocking the pathway 
(Figure 1A). However only a minor effect could be observed on nanoparticle uptake, but this 
was much stronger at higher CP concentrations (Figure 1B). Thus, based on the results 
obtained at higher CP concentrations, including the LDL controls, one could conclude that 
these nanoparticles do enter cells by CME. However, cell viability measurements clearly 
indicated that the higher CP concentration tested induced a very strong toxicity on cells, 
which is also confirmed by imaging. Thus, the observed reduction in nanoparticle uptake is 
most likely a simple consequence of the very strong toxicity of the compound on cells, 
rather than a proof of uptake by CME. This is particularly clear when comparing the results 
for the control LDL which is efficiently blocked at much lower CP drug concentrations, where 
no effect is observed on nanoparticle uptake. 
It is important also to note that while nanoparticles were added to cells in the presence of 
proteins to allow corona formation, controls with labelled markers such as transferrin or 
LDL were done in absence of serum. This is a standard praxis to avoid competition with the 
unlabelled transferrin and LDL which are present in the serum. However, it is also well 
known that drug efficacy can be limited by protein adsorption and only the fraction of free 
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drug is active. Thus, as an ulterior control, in order to exclude that CP efficacy was reduced 
in presence of serum, uptake of labelled LDL was also performed in medium supplemented 
with serum. The results clearly showed that CP efficacy was not affected by the presence of 
proteins (Supplementary Figure S3), thus excluding - in this case - that the absence of effect 
of CP on nanoparticle uptake was due to loss of efficacy when serum is present.
Figure 1. Uptake in cells exposed to chlorpromazine to block clathrin mediated endocytosis. HeLa cells were exposed to 0, 
10 or 20 μg/ml chlorpromazine (CP). A) Uptake by flow cytometry of 2 µg/ml Dil-LDL in sfMEM, used as a control of drug 
efficacy (upper panel: average median fluorescence intensities; lower panel: same data normalized for uptake in control 
cells without CP); B) Uptake by flow cytometry of 100 μg/ml  red silica nanoparticles in cMEM (upper panel: average 
median fluorescence intensities; lower panel: same data normalized for uptake in control cells without CP); C) Viability 
measured by MTT test (left panel) and light microscopy images (right panel) of HeLa cells exposed for 4h to CP in sfMEM 
or cMEM (scale bar: 200 μm). The viability data are normalized by results obtained in control cells without CP. Positive 
control (Ctrl +) performed as described in the Methods. Flow cytometry data represent the average and standard deviation 
over 3 replicates of the median fluorescence intensity of at least 20000 cells except where indicated (X:  average of 2500 
cells acquired; Y: average of 13000 cells acquired). 
Figure 2 shows a similar study performed on cells exposed to the macropinocytosis inhibitor 
EIPA. In this case labelled dextran is used as a control fluid phase marker to determine the 
appropriate EIPA concentration to use on cells. It is interesting to mention that the so-called 
fluid phase marker dextran typically used as a control, as here, is also in itself a small 
nanoparticle (10 kDa dextran has a diameter of around 6 nm).65 While the lower 
concentrations tested showed only a partial dose-dependent reduction of dextran uptake 
(Supplementary Figure S4), at 100 µM a strong reduction of dextran uptake was obtained, 
which was not further improved when using higher EIPA concentrations (Figure 2A). In the 
case of the nanoparticles, instead, as observed for CP, 100 µM gave only a minor uptake 
reduction, but the effect was stronger for higher EIPA concentrations (Figure 2B). Cell 
viability measurements and microscopy clarified also in this case that in these conditions 
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the observed reduction in nanoparticle uptake was most likely only a side effect of the 
strong toxicity on cells (Figure 2C).  
 Figure 2. Uptake in cells exposed to EIPA to inhibit macropinocytosis. HeLa cells were exposed to 0, 100, 150 or 200 μM 
5-(N-Ethyl-N-isopropyl)amiloride (EIPA). A) Uptake by flow cytometry of 250 µg/ml 10kDa TRITC Dextran in cMEM, used 
as a control of drug efficacy (upper panel: average median fluorescence intensities; lower panel: same data normalized 
for uptake in control cells without EIPA); B) Uptake by flow cytometry of 100 μg/ml red silica nanoparticles in cMEM (upper 
panel: average median fluorescence intensities; lower panel: same data normalized for uptake in control cells without 
EIPA); C) Viability measured by MTT test (upper panel) and light microscopy images (lower panel) of HeLa exposed for 4h 
to EIPA in cMEM (scale bar: 200 μm). Flow cytometry data represent the average and standard deviation over 3 replicates 
of the median fluorescence intensity of at least 20000 cells except where indicated (X = not enough cells (less than 500); 
Y= average of 700 cells measured; Z= average of 8000 cells measured). 
Another interesting observation was that when using non-toxic EIPA concentrations (50-
100 µM), the reduction of nanoparticle uptake seemed stronger for the latest times tested. 
This may indicate that macropinocytosis is at least partially involved in the uptake of these 
nanoparticles at the longer exposure times. Similar reslts have been reported in other 
works.66 Particle size measurements showed good stability of the dispersions for up to 24 
hours (Supplementary Figure S2), excluding the possibility that such an effect may be 
connected to particle agglomeration over time and activation of mechanisms commonly 
associated with the uptake of larger objects. Further studies are required to elucidate these 
results and fully clarify whether macropinocytosis is involved in the uptake of these 
nanoparticles.  
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Figure 3. Uptake in cells exposed to dynasore to inhibit dynamin. HeLa cells were exposed to 25, 50, 100 or 200 μg/ml 
dynasore. A) Uptake by flow cytometry of 2 µg/ml Dil-LDL in sfMEM, in control cells (Ctrl) and cells exposed to 25 μg/ml 
dynasore (Dynasore); B) Uptake of 100 μg/ml red silica nanoparticles in cMEM, in control cells (Ctrl) and cells exposed to 
25 μg/ml dynasore; C) Viability measured by MTT test of HeLa cells exposed for 4 h to different doses of dynasore in cMEM. 
The viability data are normalized by results obtained in control cells without dynamin. Positive control (Ctrl +) performed 
as described in the Methods; D) Uptake by flow cytometry of 2 µg/ml Dil-LDL in cells exposed to different concentrations 
of dynasore in sfMEM and cMEM; E) Uptake by flow cytometry of 100 μg/ml red silica nanoparticles in cMEM in cells 
exposed to different concentrations of dynasore; F) light microscopy images of cells exposed for 4 h to different doses of 
dynasore in cMEM (scale bar: 100 μm). Flow cytometry data represent the average and standard deviation over 3 
replicates of the median fluorescence intensity of at least 20000 cells except where indicated (X = not enough cells (less 
than 500). Y=average of 4000 cells. Z= average of 10000 cells). In D and E data are normalized by the uptake in control cells 
without dynamin. 
Figure 3 shows the optimization of protocols for the use of dynasore to inhibit dynamin. 
With this compound, we could observe a very good inhibition of the uptake of LDL at 
concentrations not associated with a decrease in cell viability (Figure 3A and 3C). In these 
conditions, we found that the uptake of silica nanoparticles was not affected by this 
compound (Figure 3B). However, we also found that when LDL was used in presence of 
serum, dynasore efficacy was partially lost. Increasing the drug concentration only partially 
reduced LDL uptake in serum, but still with almost no effect on nanoparticle uptake. 
Furthermore, at these higher concentrations strong toxicity was observed (Figure 3C). 
Overall this is an interesting example of a unique nano-specific challenge when using 
pharmacological inhibitors to study nanocarrier uptake: given the need to include some 
biological fluids to allow corona formation, some of these compounds – unfortunately - may 
become fully ineffective. Other methods need to be used to try to determine – in this 
example – the role of dynamin in uptake, or different inhibitors not affected by the presence 
of biological fluids need to be selected. 
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Figure 4 shows similar results for methyl beta cyclodextrin. Cholesterol depletion was 
extremely effective in blocking uptake of LacCer, here used as a control marker (Figure 4A), 
while only a minor effect was observed on the uptake of the silica nanoparticles (Figure 4B). 
However as for dynasore, when experiments with the control marker LacCer were done in 
the presence of serum (Figure 4A, lower panel), the efficacy of MBCD was lost, and 
increasing drug concentration, also in this csae, only led to strong cell death (Figure 4C) 
without any sign of improved efficacy. Thus, other compounds not sensistive to the 
presence of proteins should be selected when studying the role of cholesterol on 
nanocarrier uptake into cells. 
Figure 4. Uptake in cells exposed to methyl-β-cyclodextrin to deplete cell membrane cholesterol. HeLa cells were 
exposed to 0, 2,5, 5 or 10 mg/ml methyl-β-cyclodextrin (MBCD). A) Uptake by flow cytometry of 1 µg/ml LacCer in sfMEM 
in control cells (Ctrl) and cells exposed to 2,5 mg/ml MBCD (MBCD); B) Uptake of 100 μg/ml red silica nanoparticles in 
cMEM in control cells (Ctrl) and cells exposed to 2,5 mg/ml MBCD (MBCD); C) Viability measured by MTT test (upper panel) 
of HeLa exposed for 4h to different doses of MBCD in cMEM. The viability data are normalized by results obtained in 
control cells without MBCD. Positive control (Ctrl +) performed as described in the Methods; D) Uptake by flow cytometry 
of 1 µg/ml LacCer in cells exposed to different concentrations of MBCD in sfMEM and cMEM; E) Uptake by flow cytometry 
of 100 μg/ml red silica nanoparticles in cMEM in cells exposed to different concentrations of MBCD; F) light microscopy 
images of cells exposed for 4 h to different doses of MBCD in cMEM (scale bar: 100 μm). Flow cytometry data represent 
the average and standard deviation over 3 replicates of the median fluorescence intensity of at least 20000 cells except 
where indicated (X = not enough cells (less than 500), Y: average of 5000 cells counted). In D and E data are normalized by 
the uptake in control cells without MBCD. 
Figure 5 shows the results obtained with cytochalasin D, with additional optimization in 
Supplementary Figure S5: concentrations were tuned to achieve disruption of actin 
filaments, as clearly visible by immunostaining, but also with simple light microscopy, from 
the strong alteration of cell morphology (Figure 5A and Supplementary Figure S5A). It is 
important to confirm that this was not associated with decreased viability, as indicated by 
MTT measurements at all concentrations tested (Figure 5C and Supplementary Figure S5B). 
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Interestingly, actin disruption clearly affected the uptake of the nanoparticles, suggesting a 
role for actin in the internalization mechanism (Figure 5B). 
 
Figure 5. Uptake in cells exposed to cytochalasin D for actin depolymerization. HeLa cells were exposed to different 
concentrations of Cytochalasin D (CytoD). A) Fluorescence (scale bar: 50 μm) and light microscopy images (scale bar: 150 
μm) of HeLa cells exposed for different times to 2,5 μg/ml CytoD, used as a control of drug efficacy; green: actin staining 
by TRITC-Phalloidin, and blue: DAPI stained nuclei.  B) Uptake by flow cytometry of 100 μg/ml red silica nanoparticles in 
cMEM in control cells (Ctrl) and cells exposed to 2,5 μg/ml CytoD; C) Viability by MTT test of HeLa cells exposed for 4 h to 
different doses of CytoD in cMEM. The viability data are normalized by results obtained in control cells without CytoD. 
Positive control (ctrl +) performed as described in the Methods. Flow cytometry data represent the average and standard 
deviation over 3 replicates of the median fluorescence intensity of at least 20000 cells.  
Finally, Figure 6 shows the results obtained with nocodazole to disrupt microtubules (see 
also Supplementary Figure S6 for further controls). Microtubule disruption led to reduction 
in nanoparticle uptake (Figure 6B), suggesting that the cell cytoskeleton is involved in the 
mechanism of internalization or that altering the intracellular trafficking machinery has an 
effect on the uptake levels. 
Figure 6. Uptake in cells exposed to nocodazole to disrupt microtubules. HeLa cells were exposed to different 
concentrations of nocodazole. A) Fluorescence (scale bar: 50 μm) and light microscopy images (scale bar: 150 μm) of  HeLa 
cells exposed for different times to 5 μM nocodazole, used as a control of drug efficacy; red: α-Tubulin staining and blue: 
DAPI stained nuclei. B) Uptake by flow cytometry of 100 μg/ml red silica nanoparticles in cMEM in control cells (Ctrl) and 
cells exposed to 5 μM nocodazole; C) Viability by MTT test of HeLa cells exposed for 4 h to different doses of nocodazole 
in cMEM. The viability data are normalized by results obtained in control cells without nocodazole. Positive control (Ctrl 
+) performed as described in the Methods. Flow cytometry data represent the average and standard deviation over 3 
replicates of the median fluorescence intensity of at least 20000 cells.  
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Summary 
In summary, optimization of the protocols used with the selected panel of pharmacological 
inhibitors allowed to define conditions in which controls showed good efficacy of the drug 
tested without strong effects on cell viability. However, it is important to add that even with 
the optimized protocols, reproducibility with these compounds can be challenging. 
Supplementary Figure S7 shows results for independent replicates to illustrate this and 
Figure 7 shows the average uptake levels obtained across all samples for the same exposure 
times in independent experiments in cells exposed to the different compounds, after 
normalization for the uptake levels in control cells.  The observed variability is probably 
connected to the toxicity intrinsically associated with the activity of these compounds, 
aimed at blocking a vital function of cells such as transport, even when conditions are 
optimized. By reproducing multiple times the experiments with the optimized conditions, 
we could also clearly see that for drugs where only minor effects were observed on 
nanoparticle uptake, like chlorpromazine, these were easily lost when averaging over 
multiple replicates. Instead, where the inhibitory effect was more substantial, as expected, 
it was easier to reproduce it in independent replicates. This overall suggests the need to set 
relatively high thresholds on the efficacy of inhibition.  
Looking at the results of Figure 7, and using high thresholds on the inhibitory effect (the red 
line in the Figure is set for 40% inhibition in comparison to untreated cells), we could 
conclude that with compounds like chlorpromazine higher variability was observed and its 
effect on uptake is questionable. At the same time a clear effect was observed with 
cytochalasin D and nocodazole, and for the longer exposure times also with EIPA. As an 
ulterior complication unique to the use of these compounds for nanomedicine uptake 
studies, we have also found that for some inhibitors, efficacy was reduced or fully lost in 
the presence of serum, likely due to protein adsorption. We stress again that for 
nanoparticles and other nanomedicines, the presence of a biological fluid to allow corona 
formation is an essential prerequisite: in real applications, in fact, cells will always encounter 
these materials covered by biological molecules, and the presence or absence of this layer 
fully change the behaviour on cells. 
A last challenge is that to summarise similar results and attempt to conclude on the pathway 
involved in the uptake of these nanoparticles. While our aim in this work is mainly to 
illustrate the complexity of this question and challenges associated to the use of 
pharmacological inhibitors, rather than answering on how this selected model nanoparticle 
enters cells, we include some considerations on the possible interpretation of these results. 
The results obtained with chlorpromazine seem to exclude CME. Interestingly, instead, 
other works in literature consider CME as one of the main pathway involved in the uptake 
of nanoparticles smaller than 100 nm,12 because of their size and the size of clathrin coated 
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pits. Other studies however have already contradicted these findings.67,68 It will be 
important to fully elucidate whether one can extrapolate on pathways of nanocarrier 
uptake solely based on their size, which – based also on these results - seems rather unlikely. 
Unfortunately, with the selected panel we could not conclude on the role of cholesterol and 
dynamin, which both help to classify uptake mechanisms. The results obtained with 
cytochalasin D point towards an actin driven mechanism, and those with EIPA would suggest 
that macropinocytosis may be involved at the longer exposure times, with a clear role also 
for microtubules, as illustrated with nocodazole. Further studies using compounds not 
sensitive to the presence of proteins and combining multiple methods (such as RNA 
interference or imaging live cells expressing fluorescently labelled proteins of interest, just 
to mention few examples) are required to conclude on the mechanisms of uptake in this 
particular example. 
Figure 7. Overview of uptake inhibition results in HeLa cells. Uptake by flow cytometry in HeLa cells exposed to 100 µg/ml 
red silica nanoparticles in cMEM in the presence of 10 µg/ml chlorpromazine, 100µM 5-(N-Ethyl-N-isopropyl)amiloride 
(EIPA), 5 µM nocodazole or 2.5 µg/ml cytochalasin D for the indicated times. Data represents the averaged mean and 
standard deviation of three independent experiments, each normalized by the results in control cells exposed to the same 
nanoparticles without inhibitors (% ctrl).  
 
Conclusions 
Answering the question on the mechanisms nano-sized drug carriers use to enter cells is an 
essential step for the drug delivery community, that can help optimizing the design of truly 
successful nanomedicines and targeted drugs. 
At the same time, the field of endocytosis is still highly active in defining and characterizing 
the different mechanisms cells use to internalize proteins, biomolecules and other cargoes. 
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This poses considerable challenges in highly interdisciplinary fields such as that of 
nanomedicine, and points toward the need of a closer connection with the endocytosis 
community.  
Within this context, pharmacological inhibitors are useful tools in cell biology to study 
transport pathways, often used in nanomedicine uptake studies due to their apparently 
ease of use. However, we have showed here that these need to be handled with extreme 
attention. Stringent controls are required to optimize conditions for the cells used for the 
study, demonstrate their effect using appropriate control markers (where available), and 
exclude strong toxicity, which in some cases can be easily misinterpreted with efficient 
inhibition. 
Even when conditions are optimized, multiple independent replicate experiments are 
needed to try to conclude on the effect of these compounds and results can be highly 
variable: time resolved experiments with high threshold on the inhibitory effect may be 
useful to try to conclude on the results obtained. Furthermore, the need to include corona 
effects when studying nanomedicine uptake means that it will be important to consider 
what is the “appropriate corona” for a given nanomedicine and application (for instance 
using bovine serum on human cells is likely not relevant, as also using serum for inhaled 
nanomedicines). This is a further aspect for the field to evaluate and address. 
Overall, while it is true that pharmacological inhibitors, such as those used here, allow 
simple screening on the role of certain components (actin, microtubules, cell membrane 
cholesterol etc.) or pathways on the uptake of nanocarriers, it is important to keep in mind 
the difficulty that remains in determining the pathway involved solely based on the results 
obtained with this kind of compounds. The combination with other methods (each 
presenting advantages and limits) is probably the best approach to try to fully characterize 
the pathways involved and answer this central question for the field. 
 
Methods 
Cell culture  
HeLa cells (ATCC® CCL-2TM, Manassas, VA, USA) were grown in a complete cell culture 
medium (cMEM) composed by MEM (GibcoTM Thermofisher Scientific, Landsmeer, 
Netherlands) supplemented with 10% v/v Fetal Bovine Serum (FBS, GibcoTM Thermofisher 
Scientific) under standard conditions (37 °C, 5% CO2). Cells were defrosted and cultured 
following company instructions and were not kept in culture for more than 20 passages.  
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Nanoparticle characterization 
Plain fluorescently labelled silica nanoparticles (SiO2 NPs) of 50 nm diameter with an 
excitation and emission wavelength of, respectively, 569 and 585 nm were purchased from 
Kisker Biotech (Steinfurt, Germany). NP hydrodynamic diameter and ζ-potential were 
measured by Dynamic Light Scattering (DLS) using a Malvern Zetasizer Nano ZS (Malvern 
Instruments Ltd., Worcestershire, UK) with disposable capillary cells (Malvern). In order to 
assess NPs stability, 100 μg/ml NPs were dispersed in 1ml of dH2O, PBS, cMEM or MEM 
supplemented with 4 mg/ml Human Serum (Pooled human serum from TCS BioSciences Ltd 
Botolph Claydon, UK) and measured immediately at 20˚C or after 24 h at 37°C, 5% CO2. Size 
measurements were averaged results from 5 runs of at least 3 measurements. 
Studies with pharmacological inhibitors of endocytosis 
In order to assess the role of different endocytic pathways on the uptake of 50nm SiO2 NPs, 
HeLa cells were treated with inhibitors of endocytosis prior to and during NPs addition. An 
extensive optimization of the inhibitors exposure conditions has been performed and is 
described in Results and discussion. Drug toxicity on cells has been measured via an MTT 
assay (see below for details). Briefly, 50000 cells/well were seeded in a 24-well plate 
(Greiner Bio-One BV, A. Alphen on den Rijn, Netherlands) 24h prior to the experiments. 
Then, HeLa cells were pre-incubated for 10 or 20 minutes (in the case of Nocodazole) in 
cMEM with the different inhibitors at the following concentrations: 5-(N-Ethyl-N-
isopropyl)amiloride (EIPA) 100 µM, chlorpromazine hydrochloride (CP) 10 µg/ml, methyl-β-
cyclodextrin (MβCD) 2.5 mg/ml, dynasore 25 μg/ml (all from Sigma-Aldrich St. Luis, USA), 
nocodazole 5 µM (Biovision, California, USA), cytochalasin D 2.5 µg/ml (Thermofisher 
Scientific) After the pre-incubation, 50 nm SiO2 NPs were dispersed in cMEM or MEM 
supplemented with 4 mg/ml Human Serum and incubated on cells with or without the drug. 
The efficacy of the drugs was assessed by measuring the uptake of fluorescently labelled 
markers of endocytosis or by immunohistochemistry. 2 µg/ml of fluorescently labelled Low 
Density Lipoprotein (Dil-LDL, (Thermofisher Scientific) was dispersed in MEM with or 
without 10% FBS and used as a marker for Clathrin-Mediated Endocytosis. 15 µg/ml of 
fluorescently labelled human transferrin (TF, Thermofisher Scientific) was dispersed in 
serum free MEM and also used as a marker for Clathrin-Mediated Endocytosis. 1 µg/ml of 
BODIPY® FL C5-Lactosylceramide/BSA complex (LacCer; Thermofisher Scientific) was 
dispersed in MEM with or without 10% FBS and used as a marker for caveolae mediated 
and lipid raft dependent endocytosis. 250 µg/ml TRITC Dextran of 10 kDa (Thermofisher 
Scientific) was dispersed in cMEM and used as a marker for macropinocytosis. Samples were 
collected and prepared for flow cytometry as described below. Alternatively, the efficacy of 
cytochalasin D and nocodazole on, respectively, actin or microtubule disruption was 
assessed by immunohistochemistry as described below. 
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MTT assay 
HeLa cells viability after treatment with different concentrations of inhibitors has been 
assessed via MTT assay. Briefly, 50000 cells/well were seeded in a 24-well plate 24h prior 
to the experiments and afterwards incubated with the different inhibitors in MEM or cMEM 
as described above for about 4 hours. As a positive control, HeLa cells were incubated with 
50 µg/ml amino modified 50 nm polystyrene NPs (Bang Laboratories, Sanbio BV, Uden, 
Netherlands), in serum free MEM. These NPs are known to induce strong cell death, 
especially when exposed to cells in absence of serum, due to their positive charge.25 After 
the incubation period, HeLa were washed with cMEM and were incubated in 500 µl of 0.5 
mg/ml MTT solution (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma-
Aldrich) dissolved in cMEM. After formation of a precipitate (about 2h), cells were incubated 
under continuous agitation with 250 µl of DMSO in order to dissolve the MTT precipitate. 
After 15 minutes, 200 µl of solution were transferred in a 96-well plate (Greiner) and 
absorbance at 550 nm measured using an UV-plate reader (Molecular Devices LLC., 
Sunnyvale CA, USA). 
Flow cytometry analysis 
Cell fluorescence intensity due to uptake of 50 nm SiO2 NPs, LacCer, Dextran or LDL was 
measured by flow cytometry. After different exposure times, HeLa were washed once with 
cMEM and twice with PBS in order to remove the excess of fluorescent NPs and markers 
outside the cells. Subsequently HeLa were collected using 0.05% trypsin–EDTA, centrifuged 
and resuspended in PBS for the measurement. Cell fluorescence was recorded using a 
Cytoflex Flow Cytometer (Beckman Coulter, Woerden, the Netherlands) with a 488 nm 
laser. Data were analyzed using Flowjo data analysis software (Flowjo, LLC). Double scatter 
forward and side scattering plots were used to set gates in order to exclude cell debris and 
cell doublets and select intact cells. A total of at least 20000 cells were acquired per sample 
and each sample was performed in triplicate. The results are expressed as the averaged 
median cell fluorescence intensity and standard deviation over the 3 replicates. 
Immunohistochemistry  
For immunohistochemistry, cells were plated on glass coverslips inserted in 24-well plates 
and experiments were performed as described previously. The efficacy of nocodazole on 
microtubules depolymerization was assessed by incubating HeLa cells for 1h with a mouse 
primary antibody against human α-Tubulin (Merck Millipore, Netherlands) followed by 1h 
incubation with a secondary antibody Alexa Fluor®488 goat anti-mouse (Thermofisher 
Scientific). Efficacy of cytochalasin D on actin disruption was assessed by incubating samples 
with TRITC-Phalloidin (Sigma-Aldrich), which selectively stains F-actin. After each step of 
antibody incubation, cells were washed 3 times with PBS. Nuclei were stained by incubating 
cells for 5 minutes with 0.2 μg/ml DAPI (4',6-diamidino-2-phenylindole). Afterwards, slides 
were mounted with Mowiol 4-88 mounting medium (EMD Chemical, Inc, CA, USA). Image 
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acquisition was performed using a Leica TCS SP8 fluorescent confocal microscope (Leica 
Microsystems, Wetzlar, Germany) with a 405nm laser for DAPI excitation, a 488 nm laser 
for Alexa Fluor®488, and a 552 nm laser of TRITC. Images were processed using ImageJ 
software (http://www.fiji.sc).  
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Supplementary Information 
 
Figure S1. Uptake of low density lipoprotein and transferrin as controls of chlorpromazine and dynasore efficacy. HeLa 
cells were exposed to 3 μg/ml fluorescently labelled transferrin (TF) in sfMEM (left panels) or 2 μg/ml Dil low density 
lipoprotein (LDL) in sfMEM (right panels) in the presence of 10 μg/ml chlorpromazine (CP)(upper panels) or to 26 μg/ml 
dynasore (Dyn) (lower panels) Uptake results in control cells not exposed to CP are also included (Ctrl). In A, results in cells 
pre-incubated for 10 or 30 min to the inhibitors are shown, showing that increasing pre-incubation time did not change 
the outcomes. Overall the results show that the effect of CP on TF uptake was lost at longer exposure time (A, upper panel) 
while this was not the case for LDL (B, upper panel). In the presence of Dyn instead only a partial reduction of TF uptake 
was observed (A, lower panel), while LDL uptake was strongly inhibited for the full time of the experiment (B, lower panel). 
While the TF results indicate only partial inhibition with both drugs, LDL results confirm drug efficacy in the conditions 
tested. The results are discussed in more details in main text. 
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Water 20 59±1 0.25±0.03 -25±1 
sfMEM 20 44±1 0.09±0.03 -17±3 
cMEM 20 Xxx Xxx -7±1 
TableS1. z-average hydrodynamic diameter (diameter, d, nm), and polydispersity index (PDI) extracted by cumulant 
analysis of DLS data and zeta potential of 50 nm red silica nanoparticles in different media. 100 µg/ml nanoparticles in 
water, PBS or cMEM (10% FBS) were measured immediately after dispersion at 20˚C. The size distribution results for the 
dispersions in cMEM are shown in Figure S2. 
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Figure S2. Size distribution by intensity (diameter, d, nm) (A, C and D) and zeta potential (B) of 50nm red silica nanoparticle 
dispersions in different media. Nanoparticles were dispersed in water, PBS or cMEM (10%FBS) at 20˚C and measured 
immediately or (for dispersion in cMEM) after 1 and 24h incubation at 37˚C, 5% CO2 as for experiments with cells. The size 
distribution in cMEM shows a second peak around 5-10 nm due to the presence of free proteins in solution. Red, blue and 
green distributions represent three different size measurements of the same samples.  The results confirmed that good 
dispersions were obtained in all media and remained stable also in cMEM for up to 24 h in the conditions used for cell 
experiments. 
  
 P a g e  | 102 
 
Figure S3. Optimization of chlorpromazine concentrations. A) Uptake by flow cytometry of 1 mg/ml Dil-LDL in sfMEM or 
cMEM in cells exposed to 0, 10 and 20 μg/ml CP; B) same data for results in cMEM, normalized for uptake in control cells 
without CP; C) Light microscopy images of HeLa exposed for 4h to different concentrations of CP in cMEM (scale bar: 200 
μm). Flow cytometry data represent the average and standard deviation over 3 replicates of the median fluorescence 
intensity of at least 20000 cells, except where indicated (X= average of 15000 cells). The results suggested that good 
inhibition was obtained already at 10 μg/ml CP and the efficacy of CP was maintained even when added to cells in the 
presence of proteins in cMEM.  
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Figure S4. EIPA optimization. HeLa cells were exposed to 0, 50, 75 or 100 μM 5-(N-Ethyl-N-isopropyl)amiloride (EIPA). A) 
Uptake by flow cytometry of 250µg/ml 10kDa TRITC Dextran in cMEM, used as a control of drug efficacy; B) Uptake by 
flow cytometry of 100 μg/ml red silica nanoparticles in cMEM; (upper panel: average median fluorescence intensities; 
lower panel: same data normalized for uptake in control cells without EIPA) C) Viability by MTT test (upper panel) or light 
microscopy images (lower panel) of HeLa cells exposed for 4h to EIPA in cMEM (scale bar: 200 μm). The viability data are 
normalized by results obtained in control cells without CP. Positive control (Ctrl +) performed as described in the Methods. 
Flow cytometry data represent the average and standard deviation over 3 replicates of the median fluorescence intensity 
of at least 20000 cells. The results showed increasing efficacy of EIPA at increasing concentrations up to 100 μM and MTT 
suggested no major effects on viability, even at the highest concentration tested. Thus 100 μM EIPA was selected for 
following tests with nanoparticles. 
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Figure S5. Optimization of cytochalasin D concentrations. HeLa cells were exposed to 0 (Ctrl), 1, 2,5 or 5 μg/ml Cytochalasin 
D (CytoD). A) Fluorescence (scale bar: 50 μm) and light microscopy images (scale bar: 150 μm) of HeLa cells exposed for 
different times to different concentrations of CytoD; Red: actin staining with TRITC-Phalloidin. Blue: DAPI stained nuclei. 
B) Uptake by flow cytometry of 100 μg/ml red silica nanoparticles in cMEM in HeLa cells exposed to different 
concentrations of CytoD. Flow cytometry data represent the average and standard deviation over 3 replicates of the 
median fluorescence intensity of at least 20000 cells, normalized by results obtained in control cells without CytoD (0). 
The results confirmed good efficacy of the drug at all concentrations tested (A), with similar efficacy on silica uptake (B). 
2,5 μg/ml Cytochalasin D was selected for following studies with nanoparticles. 
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Figure S6. Optimization of nocodazole concentrations. HeLa cells were exposed to 0, 5, 10 or 20 μM nocodazole. A) 
Fluorescence (scale bar: 50 μm) and light microscopy images (scale bar: 150 μm) of HeLa cells exposed for different times 
to different concentrations of nocodazole; Green: α-Tubulin staining. Blue: DAPI stained nuclei. B) Uptake by flow 
cytometry of 100 μg/ml red silica nanoparticles in cMEM in cells exposed for different times to different concentrations 
of nocodazole. Flow cytometry data represent the average and standard deviation over 3 replicates of the median 
fluorescence intensity of at least 20000 cells. The results confirmed good efficacy of the drug at all concentrations tested 
(A), with similar efficacy on silica uptake (B). Thus, 5 μM nocodazole was selected for following studies with nanoparticles. 
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Figure S7. Summary of results from independent experiment replicates. HeLa cells were exposed to 100 µg/ml red silica 
nanoparticles in cMEM in the presence of 10 µg/ml chlorpromazine (CP), 100µM 5-(N-Ethyl-N-isopropyl)amiloride (EIPA), 
5 µM nocodazole or 2.5 µg/ml cytochalasin D (CytoD) for the indicated times. Each experiment was repeated multiple 
times (from 3 to 6 times as it is possible to see in each panel), and for each exposure time 3 replicates were performed in 
each experiment. Data represents the average and standard deviation over 3 replicates of the median fluorescence 
intensity, each normalized by the results in control cells without drug. The figure allows to compare results of independent 
experiment replicates and shows that for some drugs such as CP, lower effects on silica uptake and – due to this - higher 
variability is observed, while other compounds such as nocodazole and cytoD have stronger effects on particle uptake with 
higher reproducibility across independent experiments. The same data after averaging over the independent experiment 
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Abstract 
Nano-sized objects, such as nanoparticles and other 
drug carriers used in nanomedicine, once in contact with 
biological environments are modified by adsorption of 
environmental biomolecules on their surface. The 
presence of this corona strongly affects the following 
interactions at cell and organism level. It has also been 
shown that specific corona proteins can be recognized 
by cell receptors. However, the effect of corona 
composition on the following mechanisms of 
internalization by cells has not yet been investigated. 
This is of particular importance when considering that 
the same nanoparticles can form different coronas, for 
instance when exposed to different amount of serum. 
Thus, in this work, silica nanoparticles were chosen as a 
model representative nano-sized material, and their 
corona when exposed to different serum content was 
characterized. In particular we focused on the corona 
formed at low serum content, comparable to standard 
cell culture medium used for in vitro testing, and higher 
serum content, more closely resembling in vivo serum 
concentration in blood. The results confirmed that 
serum content affects corona composition. Thus, uptake 
efficiency in HeLa cells of the different corona complexes 
was compared and the mechanisms of uptake 
characterized using a panel of transport inhibitors. The 
results clearly showed that the same inhibitors had 
different effects in reducing uptake of the corona-
nanoparticle complexes formed at low and high serum 
content. This suggests that the same nanoparticles are 
internalized by cells via different mechanisms when they 
are coated by different coronas. 
Keywords: biomolecule corona, 
nanoparticle, uptake mechanisms, 
transport inhibitors, silica 
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Background 
Nano-sized materials are widely investigated for their potential use as drug delivery systems 
thanks to their ability to interact with the cellular components in novel ways and the 
possibility to engineer them for multiple functionalities.1–3 Several examples are already in 
the clinic, however it is recognized that a better understanding of the processes by which 
nano-sized objects are distributed in the body and internalized and trafficked by cells could 
contribute to advance further the success of nanomedicine.4–6 Factors such as the impact 
of the biological surrounding, how nano-sized materials are recognized  and subsequently 
processed by cells are still debated in the scientific community.  
In recent years particular interest has been drawn on the influence of the environment in 
which these nanomaterials are applied on the subsequent outcomes at organism and 
cellular level. Once in contact with a biological environment, nano-sized objects 
immediately interact with the surrounding biomolecules, which can adsorb on the 
nanoparticle surface, leading to the formation of a biomolecular corona.7. Some of the 
biomolecules in this layer associate to the nanoparticle surface almost irreversibly, affecting 
de facto the following behaviour. For instance, it has been shown that the formation of 
corona can affect nanomaterial biodistribution, macrophage sequestration, immune system 
activation, cellular recognition and nanomaterial final fate.8–10 The formation of a 
biomolecular corona can - in some cases - also affect the specificity of targeted drugs, by 
masking targeting ligands grafted onto the nano-carrier.11,12 Polymers such as PEG are 
usually grafted on the nanoparticle surface to partially reduce protein binding and 
subsequent macrophage sequestration.13–15 However, it has been demonstrated that 
corona is formed also on PEGylated surfaces, and more recently it has been proposed that 
it is actually the detailed composition of the PEG-corona and the presence of specific 
proteins such as clusterin to confer the so-called stealth effect of PEGylated surfaces.7,16,17  
At the same time, researchers have also tried to exploit the biomolecular corona as a novel 
targeting strategy to direct nanoparticles towards specific cellular routes.18–20 
So far, corona formation and its composition have been widely investigated.21–24 It is clear 
that different nanoparticles properties such as size, charge and shape, can influence the 
corona composition, and this can lead to different cellular responses to nanomaterials.25–27 
Moreover, the nature of the biological fluid in which nanoparticles are dispersed, such as 
foetal bovine serum, human serum or plasma, also determines the corona composition.28 
Another important aspect is that the corona composition can change even in the same fluid, 
when the ratio between nanoparticle and fluid concentration is varied. For instance it has 
been shown that the corona formed at low serum content, similar to what used in standard 
cell culture medium for in vitro studies, can be very different from the corona formed at 
higher protein content, more closely resembling in vivo conditions.29 Several studies have 
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also highlighted that corona proteins can engage with specific cell receptors.9,20,30,31 This all 
together points to the question on the potential impact of the corona on the mechanism of 
nanoparticle uptake into cells, especially given the capacity of cell receptors to recognize 
this layer. Recent works have shown that indeed the presence of corona has an impact on 
the mechanisms cells use to internalize nano-sized materials.32,33 However, no information 
is available so far on potential influence of corona composition on this aspect. This is 
particular important in relation to translation to in vivo conditions, considering that in vitro 
testing and uptake studies are currently performed using either artificial serum free 
conditions or (bovine) serum concentrations far from the actual serum composition in the 
blood.  
Within this context, the aim of this work was to determine whether and to what extent the 
corona composition might influence the mechanisms involved in the uptake of nano-sized 
materials. In particular we focused on comparing the mechanisms of uptake for corona 
formed in standard in vitro serum concentrations, as commonly used for cell culture 
medium and a higher serum concentration more closely resembling in vivo serum content 
in blood. 50nm silica nanoparticles (SiO2 NPs) were used as a representative model system 
to characterize the corona composition in the two conditions. Then, the effect of serum 
content on uptake efficiency was investigated using HeLa cells as a model cell line routinely 
applied for similar studies. Finally, the mechanisms of uptake were characterized by using 
common chemical inhibitors of endocytosis, in order to determine eventual differences due 
to corona composition.  
Results and discussion 
Characterization of the corona-nanoparticle complexes 
50 nm silica nanoparticles were chosen as a model system to investigate the effect of corona 
composition on the mechanisms of uptake by cells. These particles were selected as a well 
characterized model, known to form stable dispersions also in cell medium supplemented 
with proteins. Extensive information on their corona properties and interactions with cells 
is already available.21,29,34–36 Furthermore, simple centrifugation can be used to separate the 
corona coated nanoparticles from the unbound serum biomolecules, making isolation of 
hard corona complexes relatively easy (see Methods and Supplementary Table S1 for 
details).  
As mentioned above, rather than studying the effect of the presence or the absence of a 
corona on the mechanisms of uptake into cells, the aim of this work was to determine 
eventual differences when the same nanoparticles were dispersed in low or high serum 
amounts, comparable –respectively - to standard in vitro conditions (with cell culture 
medium usually supplemented with 10 % FBS, roughly corresponding to 4-6 mg/ml 
proteins) and higher serum content, more closely resembling in vivo protein concentration 
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in blood (50-60 mg/ml). It is in fact known that these particles form very different coronas 
when exposed to serum at different concentrations,29 thus it is important to consider 
eventual effects on the mechanisms used to enter cells. To this aim, pooled human serum 
was used (rather than standard foetal bovine serum) as a more representative species of 
origin when testing uptake mechanisms on human cells. 
The nanoparticle dispersions in the cell media (MEM) supplemented with the different 
amount of serum were then characterized by Dynamic Light Scattering (Supplementary 
Figure S1). The same was done after isolation of the hard corona complexes formed at low 
and high serum amounts (low and high serum corona, LC and HC, respectively). The results 
confirmed the formation of stable dispersions in all the different conditions and for the 
dispersion with proteins left in solution (in situ). Some agglomeration was detected when 
serum was left in solution, possibly due to some protein agglomerates. However, overall, 
DLS analysis by number suggested in all cases the presence of a relatively homogenous 
distribution, with a hydrodynamic diameter compatible with particles covered by proteins 
absorbed on their surface (around 70-90 nm).  
As expected, SDS-PAGE confirmed that the dispersion in different serum concentrations led 
the adsorption of different amounts and types of proteins on the surface of the NPs (Figure 
1), with lower amount of corona proteins recovered at low serum concentrations. More in 
details, some of the bands identified (indicated by the arrows, for instance, at around 70 
and 25 kDa) were exclusively present in one sample or the other.  
 
 
Figure 1. Identification of the corona proteins on 50 nm SiO2 nanoparticles dispersed in different serum content. SDS-
PAGE gel image of the proteins recovered on corona-NPs complexes formed in 12 mg/ml (lane 1 and 2) or 62 mg/ml (lane 
3 and 4) human serum and isolated after 30 min (lane 2 and 4) or 1h (lane 1 and 3) centrifugation, as described in Materials 
and Methods. Corona-NP complexes were washed and centrifuged for a total of 4 times, after which the same amounts 
of nanoparticles (30 μg/ml) were loaded in a 10% polyacrylamide gel. The gel shows that different bands were present in 
the corona formed in low and high serum content. M: molecular weight ladder. 
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LC-MS was used to characterize further the corona composition (Table 1 and full results in 
Supplementary Material). About 300 different proteins were identified in both samples, 
apolipoproteins being the most abundant ones, with the 20 most abundant ones alone 
contributing to roughly 40% of the total proteins recovered. As also observed in the gel, 
although most of the proteins were present in both coronas, the relative abundance of 
some of them was very different between the two samples. For instance, the histidine-rich 
glycoprotein was particularly enriched in the corona formed at high serum amount as also 
apoE, while vice versa apoA1 was much higher in the low serum corona complexes. Similar 
differences may lead to different uptake efficiency and/or mechanism, as discussed later. 
 
Protein % LC % HC 
Apolipoprotein A-I  13.60 5.43 
Histidine-rich glycoprotein  4.34 7.56 
Apolipoprotein A-II  8.06 4.64 
Apolipoprotein E  3.02 2.66 
Protein SAA2-SAA4  2.50 1.57 
Apolipoprotein B-100  2.07 1.80 
Alpha-1-antitrypsin  2.87 2.31 
Serum paraoxonase/arylesterase 1  1.26 0.69 
Apolipoprotein A-IV  1.23 0.79 
Transthyretin  1.06 1.21 
Serum albumin  1.04 1.00 
Apolipoprotein L1  1.01 0.63 
Total % top 12 proteins =42 30 
Table 1: List of the most abundant proteins identified in the corona of 50 nm silica nanoparticles at different serum 
content. Corona –NP complexes were formed after dispersion in 12 mg/ml (low serum corona, LC) or 62 mg/ml (high 
serum corona, HC) of human serum and isolated with a total of 4 washing steps in PBS, as described in Materials and 
Methods. Thus, the corona proteins were identified by mass spectrometry. Data represent the relative percentage of 
proteins over total (See Methods for details). The table shows the most abundant proteins in the two samples. 
 
Nanoparticle uptake efficiency in situ and after corona 
isolation 
As a next step, the cellular uptake efficiency of silica nanoparticles in the different serum 
conditions was tested. To this aim, HeLa cells were used as a standard cell model commonly 
applied for similar uptake studies both in the endocytosis and nanomedicine fields.37–39 
HeLa cells were exposed to the nanoparticles in the presence of low and high serum content 
in situ, or after isolation of the corona-nanoparticle complexes and removal of the free 
proteins in solution (Figure 2). As already observed in literature, the uptake efficiency in the 
presence of low amount of serum was higher than for NPs incubated with high amount of 
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serum.9,11 In particular, even after several hours of incubation, the uptake in the presence 
of high concentration of proteins in situ remained very low. The lower uptake can be 
explained – at least in part - by the presence of high amount of free serum biomolecules in 
solution: since the corona biomolecules can mediate the uptake of nanoparticles through 
their recognition by specific cellular receptors,9,11,26 it is likely that the free serum proteins 
in solution might also compete for the same receptors and - in this way - reduce the uptake 
levels of the corona-nanoparticle complexes. Indeed, for both the dispersion at low and high 
serum content, the uptake was higher after removal of the free protein in solution, when 
the corona-nanoparticle complexes were isolated, this effect being more evident at 
increasing time. Given the very different uptake efficiency, and in order to focus solely on 
the effect of corona composition in different serum content on the mechanisms of uptake, 
we decided to perform our studies using isolated corona-nanoparticle complexes and 
exclude additional effects due to the interference of the free serum molecules in the 
process.  
However, it is important to note that even after removal of the excess free serum, the 
uptake efficiency was lower for the complexes formed at higher serum content. 
Quantification by fluorescence of the nanoparticles recovered after corona isolation 
(Supplementary Table S1) confirmed that this was not simply due to loss of nanoparticles in 
the isolation procedure. We discuss further on this aspect later in the manuscript. 
 
Figure 2. Uptake kinetics of red 50 nm SiO2 NPs dispersed in different amounts of human serum and respective corona-
nanoparticle complexes. HeLa cells were exposed to 100 µg/ml NPs in low or high amount of human serum in situ (with 
excess free proteins left in solution) or of the corresponding corona-NP complexes isolated from excess proteins, as 
described in the Methods. The results are the average and standard deviation over 3 replicates of the median fluorescence 
intensities obtained by flow cytometry (see Methods for details). 
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Uptake mechanisms of low and high serum corona-
nanoparticle complexes 
In order to characterize the mechanisms of uptake of the different corona-complexes, 
common pharmacological inhibitors were used. These compounds are often used to study 
transport into cells, given their fast action and apparently ease of use.39–43 However, due to 
their toxicity and their limits connected to the lack of specificity, stringent controls are 
needed in order to verify their efficacy and set up protocols specific to the cells and 
conditions applied. We previously performed an extensive study on these aspects and 
carefully optimized their use on HeLa cells, in order to demonstrate their efficacy and 
minimize their toxicity (Francia et al. 2018, unpublished results –  included in Chapter 3 in 
this thesis). The same conditions were applied for this study. There, we also found that the 
presence of serum can strongly limit the efficacy of some of these compounds. Thus, the 
use (discussed above) for this work of isolated corona-complexes added to cells in serum 
free conditions also allowed us to ensure optimal efficacy of all of the applied inhibitors.  
A panel of six different inhibitors was used. Figure 3 shows one representative example of 
the kinetic of uptake of corona-nanoparticle complexes formed using low and high amount 
of serum (central and right panels), in the presence or absence of each of the different 
inhibitors. Even though the previously optimized protocols were used, we included a control 
of the inhibitor efficacy in order to confirm drug efficacy in each individual experiment (also 
in Figure 3, left panels). These results together with other two replicates are shown in 
Supplementary Figure S2. The same data normalized by the results in cells without 
inhibitors, averaged with other two independent kinetics experiments are given in Figure 4 
as an overview of inhibition efficacy. 
Chlorpromazine hydrochloride (CP) was used as inhibitor of clathrin mediated endocytosis, 
one of the most relevant and characterized mechanisms of uptake into cells.42,44 It is 
generally believed that particles and drug carriers with sizes up to roughly 100 nm typically 
use clathrin mediated endocytosis to enter cells.39,45 Cells exposed to CP showed up to 70% 
reduction of uptake of Dil-labelled low density lipoprotein (LDL), known to enter cells via 
this mechanism46, confirming drug efficacy in the conditions applied. Interestingly, while 
the uptake of LC complexes was substantially reduced after CP incubation (from 35 to 75% 
at increasing exposure time), no reduction of uptake could be observed for the complexes 
formed at high serum content (HC). This suggests that the uptake of 50nm SiO2 NPs depends 
on clathrin mediated endocytosis only when these particles are added to cells in lower 
amounts of serum, as commonly applied in in vitro conditions. The absence of effect for 
corona complexes formed at higher serum content - on the contrary - suggests that these 
nanoparticles may use a different mechanism in conditions more closely resembling in vivo 
serum content. 
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Figure 3. Characterization of the uptake mechanisms of 50 nm silica nanoparticle corona complexes in low and high 
amount of serum.  HeLa cells were exposed to 100 µg/ml corona coated complexes formed on 50 nm SiO2 NPs in low and 
high serum amount in the presence of a panel of endocytosis inhibitors. Briefly, the corona complexes formed on 300 
µg/ml nanoparticles incubated in MEM supplemented with 12 mg/ml (low serum corona, LC, middle panels) or 62 mg/ml 
(high serum corona, HC, right panels) of human serum were isolated as described in Materials and Methods and added to 
HeLa cells at a final nanoparticle concentration of 100 µg/ml in the presence or absence of 100 µM EIPA, 10 µg/ml 
chlorpromazine, 2.5 mg/ml methyl-β-cyclodextrin (MβCD), 25 μg/ml dynasore , 2.5 µg/ml cytochalasin D or 5 µM 
nocodazole. For each inhibitor, the left panels show the corresponding control of drug efficacy, with HeLa cells exposed 
to 2 µg/ml Dil-LDL in serum free MEM as controls for chlorpromazine and dynasore, and to 1 μM LacCer in serum free 
MEM for methyl-beta-cyclodextrin, and immunostaining of actin and tubulin, for cytochalasin D and nocodazole controls, 
respectively (see Methods for details). Uptake kinetics were obtained by flow cytometry and the results are the average 
and standard deviation over 3 replicates of the median cell fluorescence intensities of cells exposed to control markers 
and corona complexes with or without the different inhibitors. In the confocal images: blue stained nuclei and red stained 
actin or tubulin (for cytochalasin D and nocodazole controls respectively). Scale bar: 100 µm. 
5-(N-Ethyl-N-isopropyl)amiloride (EIPA) was used as inhibitor of macropinocytosis.47,48 This 
mechanism involves an actin driven formation of membrane ruffles to engulf a portion of 
extracellular medium.48 Several examples in literature have suggested the involvement of 
this mechanism in the uptake of nanomedicines and nanoparticles.49,50 EIPA efficacy on 
HeLa cells in the conditions applied was confirmed  using a fluorescent fluid phase marker, 
10kDa TRITC Dextran51: its uptake was reduced of up to 80% after 5h in the presence of 
EIPA. The uptake was reduced of 50 to 80% in the presence of EIPA for the corona-
nanoparticle complexes formed in the presence of low amount of serum (LC), and roughly 
50% for the complexes at high serum content (HC). Thus, based on these results, 
macropinocytosis appears to be involved in the uptake of 50nm SiO2 NPs, with a slightly 
higher effect in the case of corona formed in low serum (LC).  
The role of cholesterol in the uptake was assessed by using methyl-β-cyclodextrin (MβCD), 
a compound which sequesters the cholesterol in the cell membrane, often used as inhibitor 
of lipid-raft mediated mechanisms. MβCD efficacy on HeLa cells was confirmed by 
measuring its effect on the uptake of a fluorescent sphingolipid, BODIPY® FL C5-
Lactosylceramide/BSA complex (LacCer)42,52 (70% of reduction of uptake after MβCD 
incubation). Also in this case, nanoparticle uptake was strongly reduced for corona formed 
at low serum content (from 20 to 70% at increasing exposure time), whereas no effect was 
observed for the complexes formed at high serum content. 
Next, dynasore53,54 was used to inhibit dynamin, a key protein for several pathways of 
endocytosis, including CME and other dynamin dependent mechanisms. Dynamin mediates 
the scission of the cell membrane for the formation of the endosome. Its efficacy on HeLa 
cells was confirmed by the strong reduction (75%) on the uptake of LDL upon dynasore 
treatment. For cells exposed to the nanoparticles, dynasore led to a reduction of up to 60% 
in the uptake of LC complexes, and only 30% for HC, in comparison to untreated samples. 
In both cases the reduction was higher at longer exposure times. 
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The role of the actin cytoskeleton and microtubules in the uptake of the 50 nm SiO2 NPs 
was studied using, respectively, Cytochalasin D and Nocodazole (Figure 3E and 3F)55,56. Actin 
has a predominant role for macropinocytosis to mediate the formation of membrane 
ruffles57. However, it is involved also in several other mechanisms, including CME58,59. The 
disruption of actin and microtubules upon treatment with the inhibitors was confirmed by 
confocal microscopy using TRITC-phalloidin or an antibody against α-tubulin (left panels). 
The effect of Cytochalasin D was comparable for LC and HC nanoparticle complexes, with 
up to roughly 40% reduction of uptake in respect to controls. On the other hand, nocodazole 
had a strong effect on the uptake of the corona complexes formed in low serum content 
(50% reduction of LC uptake at all times), while it had little or no effect for complexes 
formed in high serum (up to maximum 20% reduction of HC uptake). These results showed 
again interesting differences depending on corona composition.  
A summary of the result obtained with the different inhibitors in multiple independent 
experiments is given in Figure 4. Taken together, screening with multiple inhibitors allowed 
us to determine important differences in the mechanisms involved in the uptake of the 
corona complexes formed in different amount of serum. The results suggest that the 
composition of the corona affects not only recognition on the cell membrane, as previously 
reported, but also the following mechanism of internalization by cells. In other words, cells 
seem to use different mechanisms to internalize the same nanoparticles when dispersed in 
the presence of low serum, as used for standard in vitro testing, or higher serum content 
more closely resembling in vivo blood concentration.  
Next to this, the results also suggest an involvement of multiple mechanisms in all 
conditions. Clathrin mediated endocytosis and macropinocytosis seem involved in the 
uptake of the corona-nanoparticle complexes formed using low amount of serum (Figure 4 
– white bars), and their uptake depends also on cholesterol and microtubules. Furthermore, 
the time resolved study allowed us to gain further insights on changes over time, suggesting 
a role for actin and dynamin, mainly at shorter and longer exposure times, respectively, for 
the uptake of the LC complexes.  
Instead, in the case of corona-nanoparticle complexes formed using high amount of serum 
several differences were observed and overall all inhibitors seemed to have a minor effect 
in reducing nanoparticle uptake (Figure 4 – black bars). One reason for this can be related 
to the slower uptake kinetics for these complexes, even after corona isolation. In fact, 
uptake levels were overall extremely low in the first 2 hours of incubation and because of 
this, it may be harder to see clear effects on uptake when inhibitors are added (Figure 3, 
right panels). Unfortunately, these compounds cannot be used for much longer time, due 
to their intrinsic toxicity. We have succeeded in extending their use for up to 5 hours 
(already relatively long exposure time in comparison to many examples in literature)40,60 
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only after extensive optimization. Nevertheless, the results suggested that HC uptake 
depends in part  on dynamin, macropinocytosis, actin and microtubules, however with 
effects never stronger than a 40% uptake reduction. On the other hand, clearly clathrin 
mediated endocytosis and cholesterol didn’t appear to be involved in the uptake of these 
NPs when corona was formed at high serum content.  
Figure 4. Overview of inhibition efficacy on the uptake of 50 nm silica nanoparticle corona complexes in low and high 
amount of serum in HeLa cells exposed to a panel of inhibitors. Briefly, the corona complexes formed on 300 µg/ml 
nanoparticles incubated in MEM supplemented with 12 mg/ml (low serum corona) or 62 mg/ml (high serum corona) of 
human serum isolated as described in the Methods, were incubated on HeLa cells at a final nanoparticle concentration of 
100 µg/ml in the presence or absence of 100 µM EIPA, 10 µg/ml chlorpromazine, 2.5 mg/ml methyl-β-cyclodextrin (MβCD), 
25 μg/ml dynasore, 2.5 µg/ml cytochalasin D or 5 µM nocodazole. Data are normalized for the fluorescence intensity of 
untreated cells to show the inhibition efficacy. The results are the average and standard deviation of the median cell 
fluorescence intensities obtained in three independent experiments (with the exception of the last exposure time, 6 h, for 




So far, most studies on the mechanisms that nanomedicines - and nanoparticles in general 
- use to enter cells, have adopted either serum free conditions or dispersion in standard cell 
culture medium supplemented with low amount of (bovine) serum. Serum is added to cell 
cultures solely for the purpose of providing nutrient to cells. However, the presence of 
biological fluids such as serum has much more profound effects on the behaviour on nano-
sized objects on cells. In fact, in the presence of a biological environment nano-sized objects 
acquire a new identity due to the adsorption of molecules on their surface and corona 
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formation. Cell receptors can recognize and engage with such corona molecules, and overall 
it is known that this layer has profound effects on the resulting interactions with cells. 
It comes natural then to wonder whether not only the presence of this layer can affect the 
mechanisms nano-sized objects use to enter cells (as in some cases recently reported)32,33, 
but also its composition in different serum content. Indeed, our results suggest that the 
serum concentration affects the uptake mechanisms used by nanoparticles to enter cells: 
the same nanoparticles are processed by cells using different mechanisms in low or high 
amounts of serum, with the latter reflecting more closely the in vivo serum concentrations.  
Another interesting observation is that when the particles are coated by a corona formed 
in conditions more closely resembling in vivo conditions, their uptake is lower. Similar 
observations were already reported for experiments where the excess proteins were left in 
situ11,61. However the lower uptake is not simply due to the presence of a higher amount of 
proteins in solution, which might compete with the corona proteins for the same cellular 
receptors9, as lower uptake was observed here also after corona isolation and removal of 
free excess proteins. It is known that the presence of the corona reduces, overall, the 
adhesion to the cell membrane and therefore also the uptake efficiency.62 A work using 
protein arrays to monitor the interactions of bare and corona coated nanoparticles with 
thousands different cellular proteins has shown that at increasing serum content towards 
in vivo conditions, a decrease in unspecific interactions between corona proteins and other 
protein targets was observed, followed by an increase in new specific biological recognitions 
by corona proteins, which become stronger for corona formed at higher serum content.63 
The results obtained here could further support similar observations and overall would 
suggest that the formation of a more developed and biologically relevant corona is 
accompanied by reduced uptake in cells, an important aspect to further elucidate, and 
which may have important implications for nanomedicine applications.  
A possible explanation of the reduced uptake levels and of the different mechanisms 
involved in the uptake by cells could be related to the observed differences in the 
composition of the corona at different serum content. For instance, a study on 
macrophages64 suggested that the presence of histidine-rich glycoprotein in the corona is 
associated to decreased uptake. Thus, the higher abundance of this protein in the HC in 
comparison to LC could be one of the factors contributing to the lower uptake of the 
complexes formed at higher serum content, as also the observed differences in uptake 
mechanisms. Further studies are necessary to fully demonstrate effects connected to the 
relative abundance of this and other proteins in the two conditions, and overall specific 
effects due to the composition of the corona. Corona proteins which can hamper the uptake 
of nanomaterials could be very useful in the future design of smart nanomedicines. 
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Finally, the results also suggest that multiple mechanisms may be present at the same time, 
especially when corona is formed at lower protein content, such as in standard in vitro 
conditions. The lower serum content could lead to the presence of multiple sub-populations 
of coronas of different compositions, as sometimes hypothesized,7 and this could explain - 
at least in part - the observed co-presence of different uptake mechanisms. Other possible 
explanations may be connected to the lack of specificity of these inhibitors and intrinsic 
interconnections between multiple pathways of endocytosis. More subtle evolution of the 
dispersion or the corona composition over time could also partially explain the presence of 
multiple pathways, given the observed differences in efficacy of some of the inhibitors over 
time. For instance, it was reported that the corona can evolve during exposure to cells, due 
to absorption of cellular proteins secreted in the extracellular medium. Finally, one cannot 
fully exclude that novel pathways or mechanisms specific to nano-sized materials and not 
yet characterized may be activated by these special cargoes. This may be particularly the 
case for the more developed corona formed at higher serum content, for which all inhibitors 
seemed to be overall less effective. 
Interestingly, many studies refer to clathrin-mediated endocytosis as the major player in 
the uptake of nanomaterials for sizes up to around 100 nm.39,45 These studies are typically 
performed in serum free conditions or standard low serum cell culture medium. Indeed, our 
results also suggest a role for clathrin-mediated endocytosis for nanoparticles dispersed in 
standard low serum content. However, this was not the case when the same nanoparticles 
were dispersed in higher serum content.  
Finally, while here as a first step we just considered the corona formed at higher serum 
content to more closely resemble in vivo blood content, overall the results clearly highlight 
the importance of defining what the “correct corona” is for each nanomedicine and 
application, when investigating its efficacy and overall behaviour on cells. Even when simply 
considering nanomedicines in blood, other factors such as blood flow and the more complex 
plasma composition in vivo will surely lead to additional differences compared to what 
observed here, which should also be considered. Similar considerations should also be 
applied for nanomedicines administered via different routes, such as for installation, 
inhaled or ingested nanomedicines, for which a serum corona may not be relevant.  
 
Methods 
Cell culture  
HeLa cells (ATCC® CCL-2TM, Manassas, VA, USA) were cultured in MEM (GibcoTM 
Thermofisher Scientific, Landsmeer, Netherlands) supplemented with 10% v/v Fetal Bovine 
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Serum (FBS, GibcoTM Thermofisher Scientific) at 37 °C, 5% CO2. All experiments were 
performed with cells cultured for no longer than 20 passages after defrosting.  
Nanoparticle characterization 
Fluorescently labelled 50nm silica nanoparticles (SiO2 NPs) were purchased from Kisker 
Biotech (Steinfurt, Germany). NPs were labelled by the manufacturer during polymerization 
using a fluorescent monomer with excitation and emission of 569/585 nm respectively. NP 
stability over time was assessed by measuring the particle hydrodynamic diameter by 
Dynamic Light Scattering (DLS) and ζ-potential measurements using a Malvern Zetasizer 
Nano ZS (Malvern Instruments Ltd., Worcestershire, UK) using disposable capillary cells 
(Malvern). In summary, 100 μg/ml NPs were dispersed in 1ml of dH2O, PBS or MEM 
supplemented with 4 or 20 mg/ml pooled Human Serum (TCS BioSciences Ltd Botolph 
Claydon, UK). Size measurements were performed immediately after dispersions at 20˚C or 
after incubating the NP dispersions at 37 °C, 5% CO2 for 24 hours to mimic conditions 
applied for cell experiments. Similarly, the NP-corona complexes formed as described below 
were also characterized after isolation and dispersion in serum free MEM at the same final 
concentration as applied on cells (100 μg/ml). Size results are the average from 5 runs of at 
least 3 measurements. NP ζ-potential was measured in the same conditions.  
Nanoparticle-corona formation and characterization 
NP-corona complexes were formed and isolated in vitro before incubation on cells. Briefly, 
300 μg/ml SiO2 NP was dispersed in MEM containing roughly 62 mg/ml (high corona NPs – 
HC-NPs) or 12mg/ml (low corona NPs – LC-NPs) of pooled Human Serum (TCS BioSciences 
Ltd Botolph Claydon, UK) diluted in PBS at 37 °C under continuous shaking. Thus, the same 
ratio of NP to protein was used as for experiments in situ. After 1h of incubation the 
dispersion was centrifuged for 1h at 16000 g in order to pellet the corona coated NP 
complexes. The supernatant containing unbound serum was collected and its fluorescence 
measured at a spectrofluorometer together with that of the resuspended pellet in order to 
verify that no NPs were left in solution and all of them were recovered in the pellet. The 
pellet containing corona-NP complexes was resuspended in PBS by careful pipetting. For 
cell experiments with isolated corona-nanoparticle complexes, the complexes were further 
diluted in serum free MEM to a final concentration of 100 μg/ml and then added to cells. 
For SDS PAGE and mass spectrometry analysis, instead, the corona-NP complexes were 
washed in 1 ml of PBS and centrifuged again at 16000 g for 1 h for a total of 4 centrifugation 
in order to isolated hard corona coated nanoparticles. The final amount of NPs present in 
the pellet after 4 washing steps was quantified again as above with a spectrofluorometer. 
Afterwards, the corona-NP complexes were resuspended in gel loading buffer, boiled 5 
minutes at 95 ˚C and loaded into a 10% polyacrylamide gel for SDS-PAGE. After the 
electrophoretic run, the gel was incubated for 1h with a solution containing 0.1% w/v 
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Coomassie blue R-250 in a water:methanol:glacial acetic acid (5:4:1) solution, washed with 
milliQ water and pictures were taken using a ChemiDoc™ XRS (Biorad, USA).   
Mass spectrometry analysis 
For mass spectrometry analysis, the protein content of the recovered corona-nanoparticles 
complexes prepared as described above was quantified after 4 centrifugation and washing 
steps using a Pierce™ BCA Protein Assay Kit (Thermofisher). Corona-NP complexes were 
diluted in PBS in order to have the same protein concentration for all samples. Then samples 
were incubated with the same volume of 0.1% Rapigest (Waters Chromatography B.V., 
Etten-Leur, The Netherlands), a MS-compatible surfactant used to enhance enzymatic 
digestion of proteins. Afterwards, samples were incubated for 3h at 37 ˚C with 40 μl of a 
solution of 400 ng of sequencing grade modified trypsin (Promega Corporation, Madison, 
WI, USA) resuspended in 0.1% Rapigest, to allow protein digestion. Samples were shake 
every hour during digestion. The digestion reaction was stopped by adding 10 μl of 75% v/v 
acetonitrile and 25% of a solution of 5% v/v formic acid in water. The nanoparticles and 
digested peptides were loaded in SPE (Solid Phase Extraction) GracePure™ columns (W. R. 
Grace & Co., Columbia, MD, USA). Columns were first equilibrated by adding twice 1 ml 
0.1% v/v formic acid in acetonitrile and then twice 1 ml 0.1% v/v formic acid in water. Then 
900 μl 0.1% v/v formic acid in water were added to the samples, that were subsequently 
loaded in the columns. Samples were washed twice with 1 ml of 0.1% v/v formic acid in 
water and then eluted by adding twice 400 μl 50% v/v acetonitrile + 0.1% v/v formic acid. 
The eluted sample was spin down for 5 minutes at 16100 rcf in order to pellet down the 
remaining nanoparticles. The supernatant containing the peptides were collected and dried 
using a speed vacuum for about 2 h. Afterwards, samples were resuspended in75 μl 0.1% 
formic acid in water and 2 μl were loaded into the a Q Exactive™ Plus Hybrid Quadrupole-
Orbitrap™ Mass Spectrometer (Thermofisher) using Acclaim™ PepMap™ 100 C18 LC 
Columns (Thermofisher). Samples were analysed using the software PEAKS Studio 8.5 
(Bioinformatics Solutions Inc., Waterloo, ON, Canada). Results were adjusted by the 
molecular weight of the proteins identified and their relative abundance was calculated (% 
RAP). 
Studies with pharmacological inhibitors of endocytosis 
HeLa cells were treated with pharmacological inhibitors in order to study the pathways of 
endocytosis involved in the uptake of 50 nm SiO2 NPs. The optimization of the incubation 
conditions of the inhibitors used has been described elsewhere (Francia et al, unpublished 
results). In brief, 50000 cells/well HeLa cells were seeded in a 24-well plate one day before 
the experiments. Cells were pre-treated with the inhibitors for 10 minutes (or 20 minutes 
for Nocodazole) diluted in cMEM. The concentrations of inhibitors used in the present work 
are the following: 100 µM 5-(N-Ethyl-N-isopropyl)amiloride (EIPA), 10 µg/ml 
chlorpromazine hydrochloride (CP), 2.5 mg/ml methyl-β-cyclodextrin (MβCD), 25 μg/ml 
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dynasore (all from Sigma-Aldrich St. Luis, USA), 5 µM nocodazole (Biovision, California, USA), 
2.5 µg/ml cytochalasin D (Thermofisher Scientific). Afterwards, 100 µg/ml corona-NPs 
complexes were incubated on cells with or without the presence of the inhibitors. Drug 
efficacy on cellular pathways was assessed in parallel to each experiment by measuring the 
uptake of markers of endocytosis or by immunohistochemistry. As a control for CP and 
dynasore the uptake of 2 µg/ml fluorescently labelled low density lipoprotein (Dil-LDL, 
(Thermofisher Scientific) dispersed in serum free MEM was measured. As a control for 
MβCD, the uptake of 1 µg/ml BODIPY® FL C5-Lactosylceramide/BSA complex (LacCer; 
Thermofisher Scientific) dispersed in serum free MEM was measured. As a control for EIPA, 
the uptake of 250 µg/ml TRITC Dextran of 10 kDa (Thermofisher Scientific) dispersed in 
cMEM was used.  
Flow cytometry analysis 
HeLa cells were incubated with fluorescently labelled 50 nm SiO2 NPs, LacCer, Dextran or 
LDL and their uptake was measured by flow cytometry. After exposure, cells were washed 
with cMEM and twice with PBS to remove the excess NPs and markers. Afterwards, cells 
were detached from the plate using 0.05% trypsin–EDTA for 5 minutes, centrifuged, 
resuspended in PBS and measured immediately using a Cytoflex Flow Cytometer (Beckman 
Coulter, Woerden, the Netherlands) with a 488 nm laser. Data were analysed using Flowjo 
software (Flowjo, LLC). Dead cells and cell doublets were excluded from the plots by setting 
gates in the forward and side scattering double scatter plots. At least 20000 cells were 
acquired for each sample and each sample was repeated in triplicate. Results are expressed 
as the average of the median cell fluorescence intensity and standard deviation over the 3 
replicates. 
Immunohistochemistry  
The efficacy of cytochalasin D and nocodazole on, respectively, actin or microtubule 
disruption was assessed by immunohistochemistry. 50000 cells/well HeLa cells were seeded 
in a 24-well plate in which 13mm thickness glass coverslips were inserted. HeLa cells treated 
with nocodazole were incubated for 1 h with a mouse primary antibody against human α-
Tubulin (Merck Millipore, Netherlands) followed by 1 h incubation with a goat anti-mouse 
Alexa Fluor®488 secondary antibody (Thermofisher Scientific). Cells treated with 
cytochalasin D were incubated with TRITC-phalloidin (Sigma-Aldrich), which selectively 
stains F-actin. Cells were washed 3 times with PBS after each antibody incubation and 
subsequently incubated for 5 minutes with a PBS solution containing 1:5000 4',6-diamidino-
2-phenylindole (DAPI) for nuclear staining. Finally, glass coverslips were mounted on slides 
using Mowiol 4-88 mounting medium (EMD Chemical, Inc, CA, USA). Images were acquired 
using a Leica TCS SP8 fluorescent confocal microscope (Leica Microsystems, Wetzlar, 
Germany) with a 405 nm laser for DAPI excitation, a 488 nm laser for Alexa Fluor®488 
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secondary antibody, and a 552 nm laser for TRITC-phalloidin. ImageJ software 
(http://www.fiji.sc) was used for image processing.  
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Supernatant (1st centrifugation) 2.1% 8.0% 
Pellet (1st centrifugation) 100.9% 93.6% 
Pellet (4th centrifugation) 83.1% 91.6% 
Table S1. Nanoparticle quantification by fluorescence intensity. Corona-nanoparticle complexes were formed as described 
in Materials and Methods. After centrifugation, the nanoparticles recovered in the supernatant and in the pellet were 
quantified with a spectrofluorimeter. Data are expressed as percentage relative to the intensity of the starting NP 
dispersion prior to centrifugation. LC: Complexes formed using low amount of serum. HC: Complexes formed using high 
amount of serum. The results confirmed that centrifugation allowed to separate the nanoparticles in the pellet and even 
after 4 centrifugations more than 90% of the initial nanoparticles were recovered. This also implies that the lower uptake 
levels observed for the HC complexes in cells was not simply a consequence of particle loss in the isolation procedure (see 
Figure 2 in manuscript). 
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Figure S1. Size distribution by intensity of 50 nm SiO2 nanoparticle dispersions in different media. 300 µg/ml nanoparticles 
was incubated in MEM supplemented with 12 mg/ml (LC) or 62 mg/ml (HC) of human serum and isolated as described in 
Materials and Methods from the excess free proteins prior to characterization by Dynamic Light Scattering (DLS). 
Alternatively (lower panels), the dispersions formed by 100 µg/ml nanoparticles in MEM supplemented with 4 mg/ml (low 
serum) or 20 mg/ml (high serum) were also characterized. Size measurements are the average of 5 runs of at least 3 
measurements. The results suggested that homogenous dispersions of corona-coated nanoparticles could be obtained at 
both serum contents. A second peak indicative of few larger objects was detected in the nanoparticle dispersions in situ, 
when proteins were left in solution, possibly due to some serum aggregates. However also in these cases DLS confirmed 
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Figure S2. Normalized uptake kinetics of 50 nm silica nanoparticle corona complexes in low and high amount of serum on 
HeLa cells treated with endocytosis inhibitors. Briefly, the corona complexes formed on 300 µg/ml nanoparticles in MEM 
supplemented with 12 mg/ml (A, low serum corona) or 62 mg/ml (B, high serum corona) of human serum isolated as 
described in the Methods, were incubated on HeLa cells at a final nanoparticle concentration of 100 µg/ml in the presence 
or absence of 100 µM EIPA, 10 µg/ml chlorpromazine, 2.5 mg/ml methyl-β-cyclodextrin (MβCD), 25 μg/ml dynasore, 2.5 
µg/ml cytochalasin D or 5 µM nocodazole. Data are the average and standard deviation over 3 replicates, normalized for 
the fluorescence intensity of untreated cells. The results of three independent experiments are shown and the 
corresponding average results are given in Figure 4.  he results of independent experiments clearly show that in some of 
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Abstract 
Nano-sized objects such as drug carriers used for 
nanomedicine applications enter cells via active energy 
dependent mechanisms. Targeting can be used to 
achieve specific recognition by cell receptors, however 
also for targeted drugs the details of the endocytic 
mechanisms involved in the following internalization are 
not always clarified. Within this context in this work we 
combined different methods to characterize the 
mechanism of uptake of a model nanoparticle (50 nm 
silica) into cells, including major pathways of 
endocytosis and several other clathrin independent 
mechanisms more recently identified within the 
endocytosis field. Additionally, we have studied the 
potential involvement of a series of proteins known to 
sense and generate membrane curvature, in order to 
determine whether novel mechanisms may be involved 
in the internalization of this special type of cargo. The 
results indicated that multiple uptake mechanisms seem 
to be partially involved and that several proteins capable 
to induce membrane curvature have a clear role in the 
uptake of these nano-sized materials. 
 
Keywords: uptake mechanisms, 
membrane curvature, biomolecule 
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Chapter 5. Mechanisms of uptake and membrane 
curvature generation for cell internalization of 
nano-sized objects 
 P a g e  | 134 
 
Background, results and discussion 
Nano-sized materials are promising tools in nanomedicine to achieve controlled delivery of 
drugs to their targets, in particular for cancer treatment.1,2 While many studies tried to 
identify which of the known classical pathway of endocytosis3–8 are involved in their 
internalization – a central question that in most cases remains still very hard to answer - 
very little is known on the molecular mechanisms driving membrane bending generation 
and vesicle formation when such nano-sized cargoes engage with cells.9,10 A better 
description of the cellular machinery involved could help us to tune nanocarrier design in 
order to better control their fate inside cells for an improved targeting efficiency.11 Indeed, 
active targeting strategies can be developed by decorating the nanocarrier surface with 
ligands capable to recognize the targeted cells. However, once in contact with a biological 
environment, for example after intravenous administration, nano-sized materials adsorb on 
their surface a “corona” of biomolecules,12 which confers them a new biological identity.13 
In some cases, the corona can mask the presence of surface ligands, impairing targeting.14 
At the same time, corona proteins themselves can in some cases be recognized by specific 
cell receptors.15–18 What drives internalization after the initial cell recognition (with or 
without active targeting or corona recognition, as well as for bare nanoparticles in absence 
of a corona) is not yet known. Computer simulations and in vitro studies of nanoparticle-
membrane interactions have shown that the surface of nano-sized objects can induce 
several changes when interacting with a membrane, for instance leading to sol-gel 
transitions in the bilayer and impairing lipid lateral diffusion,19,20 but also inducing 
membrane bending9,10 in ways similar to what observed with certain viruses of comparable 
sizes.21 Membrane bending is one of the essential steps for endocytosis to occur,22–24 often 
mediated by the presence of proteins containing modules with curved structure (BAR-
domains), which can recognize and induce membrane curvature.25–27 Thus, one may wonder 
whether the observed nanoparticle-induced effects on membranes might as well be a 
triggering point for the following endocytosis.  
In this context, in order to identify the molecular players involved in nanocarrier 
internalization, we combined several complementary techniques including RNA 
interference to shut down the expression of key endocytic proteins, pharmacological 
inhibitors of uptake and expression of non-functional mutants. Following recent findings in 
the endocytosis field, together with standard pathways of endocytosis such as clathrin and 
caveolae mediated endocytosis, we also investigated the potential involvement of proteins 
participating to all the different clathrin independent pathways.28–30 50 nm silica 
nanoparticles were selected as a well-characterized model nanoparticle, with a size 
comparable to many nanocarriers used for drug delivery. In particular, we focused on this 
example since it has been recently shown that the uptake of these nanoparticles is mediated 
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by recognition of corona components by the LDL receptor (LDLR).16 It is known that the LDLR 
is internalized preferentially by clathrin mediated endocytosis,31 but in some cases clathrin 
independent mechanisms may also play a role.31,32 Moreover, clathrin mediated 
endocytosis has often been reported as one of the main mechanisms involved in the uptake 
of nanoparticles and drug carriers of similar size in in vitro studies.4,33 Thus  by studying this 
particular corona-nanoparticle complex, we aimed at investigating whether a nanocarrier 
“targeted” to a specific receptor (in this case via recognition of proteins in its corona) is 
internalized via the same mechanism as its natural ligands.  
Figure 1: Uptake of silica nanoparticles in LDLR silenced HeLa cells in different media. HeLa cell controls silenced for a 
scramble siRNA (Neg) or for the LDL receptor (LDLR) were incubated for 24 hours with 100 μg/ml 50 nm silica nanoparticles 
dispersed in human serum (HS) or human delipidised serum (HSD) at a concentration of 4 mg/ml (low) or 20 mg/ml (high) 
or – alternatively - to 100 µg/ml corona complexes formed as follows: briefly, 300 μg/ml 50 nm silica nanoparticles were 
dispersed in human serum (HS) or human delipidised serum (HSD) at a concentration of 12 mg/ml (LC) or 62 mg/ml (HC). 
The formed nanoparticle-corona complexes were then isolated as described in the Methods and resuspended to a final 
concentration of 100 μg/ml in serum free MEM for exposure to cells. Cell fluorescence intensity was then measured by 
flow cytometry. a) Data normalized by the uptake in control cells, silenced with a scramble siRNA, averaged over 3 
replicates. b) Raw cell fluorescence intensity data of results in panel a. The results are the average and standard deviation 
over 3 replicates. In all cases, both controls and LDLR silenced samples were incubated with the same dispersion of 
nanoparticles.  
First, in order to confirm recognition by the LDLR, nanoparticle dispersions were prepared 
in the presence of two different concentrations of human serum as well as in human 
delipidised serum. The delipidised serum was used as a negative control since it does not 
contain the lipid fractions and apolipoproteins which are known to interact with the LDLR.16 
Then, the nanoparticle-corona complexes were isolated from the unbound serum proteins 
in order to reduce their interference. Size distribution and zeta potential measurements 
confirmed that homogenous nanoparticle dispersions were obtained in the different 
conditions tested (See Supplementary Figure S1). Next, uptake was investigated in human 
epithelial cancer HeLa cells, used as a model cell line commonly applied in many studies 
both in the nanomedicine and endocytosis fields. In order to verify whether the different 
coronas allowed recognition by the LDLR, we then compared uptake levels in control cells 
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expressing the LDLR and LDLR-silenced HeLa cells (Figure 1, Supplementary Figure S2 for 
uptake kinetics and Supplementary Figure S3a for controls on silencing efficacy). 
Interestingly, the results show that this recognition is present only for nanoparticles 
dispersed in the presence of high concentrations of human serum, more closely resembling 
the environment nanomedicines encounter following parenteral administration.13,34 More 
in details, in the presence of higher amounts of human serum, silica uptake was reduced of 
about 70% in silenced cells compared to cells treated with a scramble siRNA, while no 
difference was observed for nanoparticles dispersed in low amount of serum nor in 
delipidised serum. A time-resolved uptake kinetics confirmed this observation and also 
showed very low uptake efficiency in the first hours, making overall the reduction of uptake 
in LDLR silenced cells more clearly visible only after 14-16 h of exposure (Supplementary 
Figure S2). We selected this longer exposure time to further characterize the following 
mechanisms of internalization. 
To this aim, RNA interference was used to shut down the expression of a panel of proteins 
involved in several endocytic pathways (Figure 2a and Supplementary Figure S3a for 
silencing efficacy). As previously mentioned the panel included major markers of clathrin 
mediated endocytosis (clathrin and dynamin 2), caveolae-mediated endocytosis (caveolin 
1) and macropinocytosis (Rac1, Ankfy1, Cdc42, ARF6), but also proteins involved in other 
clathrin independent mechanisms which have been described within the endocytosis field, 
such as those classified as flotillin-mediated (flotillin 1), CLIC/GEEC (Cdc42 and Graf1), ARF6-
mediated (ARF6), RhoA-mediated (RhoA, Rac1, and again dynamin 2). We note however 
that due to the intrinsic interconnections among cellular pathways several of these markers 
are known to participate to multiple endocytic mechanisms. 
RT-qPCR confirmed that the RNA levels of all targets after silencing was reduced in most 
cases of more than 90%, while in others to at least 60% (Supplementary Figure S3a) and WB 
of – as an example - CLTC confirmed that protein levels after silencing were not detectable 
(Supplementary Figure S3c). Given the observed role for LDLR in the uptake, RT-qPCR was 
also used to measure LDLR expression after silencing each of the targets, in order to 
determine eventual side effects on its expression, which could then affect nanoparticle 
uptake indirectly (Supplementary Figure S3d). Uptake of labelled LDL, known to enter cells 
via recognition of the LDLR and following clathrin mediated endocytosis, was also measured 
in the full panel of silenced cells to further test the effect of silencing (also in Supplementary 
Figure S3).  
Indeed, as expected, LDL uptake was strongly reduced in cell silenced for the LDLR, however 
this was not the case in cells silenced for clathrin heavy chain (CLTC), a key protein in clathrin 
mediated endocytosis. The combined study on LDLR expression in the silenced cells showed 
that in HeLa cells silenced for CLTC, LDLR was overexpressed, possibly explaining the 
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observed increase in the uptake of LDL (Supplementary Figure S3e). Compensation via other 
isoforms of CLTC may also contribute to this result. Silencing CLTC did not have an effect on 
the uptake of silica either.  
Given the results on LDL uptake in cells silenced for CLTC, in order to further rule out the 
involvement of clathrin mediated endocytosis, we performed additional studies using 
chlorpromazine (CP)35,36 and by overexpression of the C-terminal of the adaptor protein 
AP180.37 Both treatments are known to inhibit this pathway. Indeed, as expected, exposure 
to CP effectively blocked the uptake of LDL (as we show in details in Chapters 3 and 4) 
however it determined only a minor reduction (30%) of the uptake of silica nanoparticles 
(Figure 2c). Similarly, cells overexpressing the C-term-AP180 (green) were not able to 
internalize transferrin, another classic marker of clathrin mediated endocytosis, but did not 
show any decrease in the uptake of silica (Figure 2b). This suggested that even if the LDLR 
is required for the uptake of silica nanoparticles, clathrin mediated endocytosis is not the 
main pathway involved (we note that pharmacological inhibitors such as CP cannot be used 
for very long times on cells due to their intrinsic toxicity. The extensive optimization 
described in Chapter 3 allowed us to extend their use to up to 5-6 hours. Considering the 
slow uptake kinetics observed for the silica corona complexes formed at high serum 
amount, the effects of these compounds on uptake may be less evident). 
The panel of siRNA, combined with results obtained with a series of other common 
pharmacological inhibitors, indicated other players involved in the internalization. We note 
instead that for silica corona conditions for which we did not observe a role for LDLR, none 
of these targets had an effect on nanoparticle uptake (Supplementary Figure S4). For the 
complexes formed at higher serum amount, instead, a minor reduction of uptake was 
observed in cells silenced for DNM2, a key protein for CME and several CIE pathways, while 
silencing ARF6, fundamental for endocytic recycling but also involved in CME, 
macropinocytosis and marker for the so called ARF6-mediated endocytosis, resulted in 
around 50% uptake reduction (Figure 2a). We note that, similarly to what observed in cells 
silenced for CTLC, DNM2 silencing determined an upregulation of the LDLR (Supplementary 
Figure S3d) and - probably as a consequence of this - an increase in the uptake of LDL 
(Supplementary Figure S3e). Dynamin involvement in the uptake was further confirmed by 
the use of dynasore, a selective dynamin inhibitor,38,39 which reduced silica uptake of 
around 40% (Figure 2d and respective control on LDL uptake in Chapters 3 and 4). 
The depletion of CAV1, a protein involved in caveolae-mediated endocytosis, also 
determined - on average - a reduction of 50% in the uptake of silica nanoparticles, whereas 
silencing FLOT1, a marker for the flotillin-dependent pathway, determined a 40% uptake 
reduction. Surprisingly, however, cholesterol depletion by methyl beta cyclodextrin 
(MBCD)40 only slightly affected uptake levels (Figure 2e and respective controls on the 
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uptake of LacCer, a sphingolipid known to be internalized in a cholesterol-dependent 
manner35,41 in Chapters 3 and 4). Cholesterol is involved in many endocytic routes, including 
caveolae and flotillin mediated pathways. A possible explanation of this apparent 
discrepancy is that CAV1 and FLOT1 depletion indirectly affects nanoparticle internalization 
by a different mechanism, for instance by decreasing membrane plasticity, since both are 
reported to be regulators of membrane tension.42  Next to this, silencing the expression of 
Rac1, involved in RhoA-mediated endocytosis, macropinocytosis and phagocytosis, and 
ANKFY1, involved preferentially in macropinocytosis, determined a reduction of the uptake 
of about 40 %. Macropinocytosis is often reported as a mechanism involved in the 
internalization of nano-sized drug carriers and larger particles.43 To further study its 
involvement, we performed further studies using EIPA, a selective inhibitor of 
macropinocytosis and an inhibitor of Rac1 and Cdc42 signaling.44 Exposure to EIPA reduced 
the uptake of silica nanoparticles of only 20-30% after 6 hours (Figure 2f and respective 
controls on the uptake of the fluid phase marker dextran in Chapters 3 and 4). 
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Figure 2: Characterization of uptake mechanisms of silica nanoparticle-corona complexes in HeLa cells. a) HeLa cells were 
silenced for 72 hours for a panel of endocytic targets (as indicated in the labels). Thus, cells were exposed for 14 hours to 
100 µg/ml corona complexes formed as follows: briefly, 300 μg/ml 50 nm silica nanoparticles were incubated for 1 hour 
at 37 ˚ C in 60 mg/ml human serum, then centrifuged for 1 h to remove the excess unbound proteins and the corona coated 
pellet was resuspended in serum free MEM to a final concentration of 100 μg/ml for exposure to cells. The results are the 
average and standard deviation of the median cell fluorescence intensity measured by flow cytometry over 2 independent 
experiments, each with 3 replicates for each condition. The results show reduction of uptake in cells silenced for several 
of the selected targets. b) Confocal fluorescence images of HeLa transfected with a plasmid carrying a GTP tagged AP180 
whose expression blocks clathrin mediated endocytosis. After 24 h, cells were exposed for 10 minutes to 15 μg/ml labelled 
TF in serum free MEM or for 24 hours to 100 µg/ml nanoparticle-corona complexes formed as described above. Blue: DAPI 
stained nuclei; green: GFP expression of transfected cells; white: transferrin (left) or silica nanoparticles (right). Scale bar: 
50 µm. The results confirm excellent inhibition of TF uptake in the transfected cells (green) but no effects on nanoparticle 
uptake. c-h) Uptake kinetics of corona complexes in HeLa cells exposed to a panel of transport inhibitors. HeLa cells were 
exposed to 100 µg/ml silica nanoparticle-corona complexes (prepared as described above) in the presence or absence of 
10 µg/ml chlorpromazine (CP), 100 µM 5-(N-Ethyl-N-isopropyl)amiloride (EIPA), 2.5 mg/ml methyl-β-cyclodextrin (MβCD), 
25 μg/ml dynasore, 5 µM nocodazole or 2.5 µg/ml cytochalasin D (CytoD). The results are the average and standard 
deviation over 3 replicates of the median cell fluorescence intensity measured by flow cytometry.  
Finally, blocking actin and microtubule polymerization by the use of, respectively, 
cytochalasin D and nocodazole determined around a 40% reduction of the uptake of silica 
nanoparticles (Figure 2g and 2h and in Chapters 3 and 4 their efficacy was tested by 
immunostaining), suggesting an important role for actin and the cytoskeleton in the 
internalization mechanism. 
These data all together suggested - on the one hand - that despite the observed role for 
LDLR, clathrin mediated endocytosis is not involved in the uptake of these nanoparticles, 
and - on the other hand - that markers involved in multiple mechanism of CIE seem to have 
all a partial involvement in the internalization. This makes the characterization of the 
pathway of uptake not trivial. A possible explanation may be that indeed these special 
objects are internalized via multiple pathways (possibly also mediated by multiple 
receptors, next to the LDLR). Another interpretation can be connected to known limits of 
the different methods applied to study transport into cells: it is in fact known that when 
interfering with a certain entry route, cells may respond by adapting and overcompensating 
for the blockage using alternative pathways. At the same time, all controls performed (here 
included in Chapters 3 and 4) showed that the different treatments were very effective in 
blocking the uptake of control markers. Thus, the partial effects observed in the case of 
silica uptake may reflect something peculiar to the way cells internalize these nano-sized 
objects. Together with the apparent discrepancies in some of the results (for instance for 
CAV1 silencing and cholesterol depletion or for macropinocytosis), these results may also 
suggest that the uptake of this special cargo may involve a different mechanism, not directly 
classifiable under the known pathways of endocytosis.  
In order to elucidate on all this, we then tried to characterize in more details the possible 
mechanism for curvature generation involved in the uptake of nano-sized objects. As 
previously mentioned (and here discussed in detail in Chapter 2), after an initial recognition 
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or adhesion on the cell membrane, endocytosis requires the formation of a membrane 
invagination to engulf the extracellular material and allow its internalization into a vesicle. 
Membrane curvature in cells can be generated by several mechanisms, such as via 
scaffolding by proteins such as clathrin, or by elements of the cytoskeleton such as actin, 
but also via changes in lipid composition at the site of uptake, as well as clustering of 
specially shaped transmembrane proteins, or insertion of specific protein motifs in the 
bilayer (alpha helix, C2 domains, loop insertions).23,25 As mentioned earlier, several studies 
in vitro and computer simulations of nanoparticle-membrane interactions showed that the 
highly curved surface of nano-sized objects can induce several changes on lipid membrane, 
like sol-gel transition in the lipid chains and bending of the lipid bilayer.9,10,19,20 Since 
membrane bending is an essential step to allow vesicle formation in endocytosis, we 
hypothesize that similar effects induced by curved nano-sized objects may be in themselves 
a triggering point for the internalization. Specialized proteins containing BAR domains are 
known to be capable to sense and induce curvature and their role in endocytosis, including 
CIE, is being constantly updated.23–25,45 Thus, as a first step to identify potential proteins 
involved in mechanisms of membrane curvature generation for nanoparticle uptake, we 
selected a panel of proteins containing BAR domains to study their potential role in the 
process.25,26,46 The panel included a series of BAR domain proteins whose involvement in 
endocytosis has already been reported, including for classic pathways and cargoes such as 
clathrin mediated endocytosis (Fcho2, endophilins, SNX9, BIN1), caveolae mediated 
endocytosis (PACSIN2) and several other CIE (Graf1, endophilin, SNX9, IST1). 
Interestingly, the inhibition of several of the selected BAR domain proteins, among which 
BIN1, IST1, PACSIN2 and GRAF1, caused a marked reduction of silica nanoparticle uptake, 
up to 50% compared to controls (Figure 3a and Supplementary Figure S5a for respective 
controls and RT-qPCR). Silencing these targets did not induce substantial changes in the 
expression of LDLR, thus excluding that the observed reduction was due to indirect effects 
on LDLR (Supplementary Figure S6a). (We note in Supplementary Figure S6b that the uptake 
of LDL, instead, was reduced after silencing of GRAF1 and IST1, an interesting observation 
not yet reported in literature). Only in the case of Fcho2 we could observe an increase in 
LDLR expression, also accompanied by increased LDL uptake after silencing, however this 
didn’t reflect in an increase in the uptake of silica nanoparticles, which was - on the contrary 
- partially decreased. Similarly, both BIN1 and PACSIN2 silencing didn’t interfere with LDL 
uptake, but markedly decrease the uptake of silica nanoparticles, suggesting that these 
targets have indeed a special role in the uptake of these nano-sized objects.  
Additional controls were performed on BIN1 silenced cells to further confirm the results. 
BIN1 (also known as Amphiphysin2) is a N-BAR protein which is able to recognize and induce 
the bending of membranes.47,48 Together with RT-qPCR on this and all other curvature 
targets (Supplementary Figure S5), Western Blot analysis confirmed that BIN1 protein was 
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effectively depleted after silencing (also in Supplementary Figure S5). Uptake kinetics by 
flow cytometry and fluorescence imaging also confirmed a reduction in the uptake of silica 
nanoparticles after silencing its expression (Figure 3 b, c and d). Moreover, silencing of BIN1 
in other cell lines including human embryonic kidney HEK293 cells and lung epithelial A549 
cells also caused a reduction in the uptake of silica nanoparticles (Figure 3e), suggesting that 
this protein may be involved in the uptake of these particles also in other cell types. To 
better understand the role of BIN1 in the uptake of silica nanoparticles, additional studies 
were also performed in different serum concentrations and dispersion conditions (Figure 
3f). Also in this case, as already observed after LDLR silencing for the same conditions in 
Figure 1, there was an increase in nanoparticle uptake in delipidised human serum. 
Additionally, a reduction of the uptake of BIN1 could be observed also when nanoparticles 
were incubated in situ with the lower serum amount, but not when corona was isolated at 
the same concentration. Further studies are necessary in order to better characterize the 
involvement of BIN1 and each of the other identified curvature proteins in the uptake of 
silica nanoparticles, as well as to extend these results to a larger panel of BAR-domain 
proteins. 
In conclusion, in this study we investigated the endocytic mechanisms involved in the 
internalization of 50 nm silica nanoparticles in HeLa cells, with a particular focus on proteins 
responsible for the generation and recognition of membrane curvature. First, we observed 
that the already reported recognition of corona proteins on these nanoparticles by the 
LDLR16 depends on the type and concentration of serum used to form the nanoparticle-
corona complexes. More specifically, uptake was mediated by the LDLR only when the 
particles were dispersed in higher serum amounts. Thus, we used a panel of siRNA and 
pharmacological inhibitors to characterize the mechanism of internalization, and showed 
that despite LDLR involvement, clathrin-mediated endocytosis is little or only partially 
involved in the uptake of these nanoparticles, while blocking targets involved in several 
other mechanisms, among which macropinocytosis, flotillin-dependent, caveolae-
dependent endocytosis, all partially reduced silica uptake. This led us to the hypothesis that 
after the initial recognition by LDLR, this special nano-sized cargo may trigger uptake via a 
different mechanism of curvature generation. By screening for a panel of BAR domain 
proteins known to be capable to sense and induce membrane curvature, we then identified 
a series of novel molecular players, such as BIN1, PACSIN2 and IST1 which clearly play a role 
in the internalization of these nanoparticles. Further studies are needed in order to fully 
elucidate their involvement in the internalization process and to determine how similar 
observations translate to other nano-sized carriers of different size and properties.  
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Figure 3 Role of a panel of (BAR domain) curvature proteins in the uptake of silica nanoparticle corona complexes in HeLa 
cells. a) HeLa cells were silenced for 72 hours for a panel of BAR domain curvature proteins (as indicated in the labels). 
Thus, cells were exposed for 14 hours to 100 µg/ml corona complexes formed as follows: briefly, 300 μg/ml 50 nm silica 
nanoparticles were incubated for 1 hour at 37˚C in 60 mg/ml human serum, then centrifuged for 1h to remove the excess 
unbound proteins and the corona coated pellet was resuspended in serum free MEM to a final concentration of 100 μg/ml 
for exposure to cells. The results are the average and standard deviation of the median cell fluorescence intensity 
measured by flow cytometry over 2 independent experiments, each with 3 replicates for each condition. The results show 
reduction of uptake in cells silenced for several of the selected targets.  b) Confocal fluorescence images and corresponding 
intensity quantification of HeLa cells silenced for BIN1 and exposed for 14 hours to 100 µg/ml nanoparticle-corona 
complexes (white) prepared as described above. The results are the average corrected total cell fluorescence (CTCF, which 
represent the integrated density minus the cell area multiplied by the mean fluorescence of the background) of at least 4 
frames and confirm strong uptake reduction in BIN1 silenced cells. Scale bars 50 μm. Blue:  DAPI stained nuclei. c) Confocal 
fluorescence images of HeLa cells silenced for BIN1 and exposed for 14 hours to 100 µg/ml nanoparticle-corona complexes 
(red) prepared as described above Blue: DAPI stained nuclei, green: LAMP1 stained lysosomes. Scale bars 50 μm. 
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Microscopy confirmed nanoparticle uptake and accumulation in the lysosomes. d) Uptake kinetics of nanoparticle-corona 
complexes in BIN1 silenced HeLa cells (red line) or control HeLa cells silenced with a scramble siRNA (black line). The results 
are the average and standard deviation over 3 replicates of the median cell fluorescence intensity obtained by flow 
cytometry. e) Effect of BIN1 silencing in the uptake of nanoparticle-corona complexes in HeLa, HEK293 and A549 cells. The 
results are the average and standard deviation over 2 replicates of the median fluorescence intensity obtained by flow 
cytometry on HeLa, HEK293 and A549 cells silenced as described in the Methods for BIN1, normalized by the uptake in 
cells silenced with a scramble siRNA (14h hours exposure to 100 µg/ml corona complexes). f) Effect of BIN1 silencing on 
the uptake by HeLa cells of silica nanoparticles at different serum concentrations. HeLa cells silenced for BIN1 as described 
in the Methods were incubated for 24 hours with 100 μg/ml 50 nm silica nanoparticles dispersed in human serum (HS) or 
human delipidised serum (HSD) at a concentration of 4 mg/ml (low) or 20 mg/ml (high) or alternatively to 100 µg/ml 
corona complexes formed as follows: briefly, 300 μg/ml 50 nm silica nanoparticles were dispersed in human serum (HS) 
or human delipidised serum (HSD) at a concentration of 12 mg/ml (LC) or 62 mg/ml (HC). The formed nanoparticle-corona 
complexes were then isolated as described in the Methods and resuspended to a final concentration of 100 μg/ml in serum 
free MEM for exposure to cells. Cell fluorescence intensity was then measured by flow cytometry. Data are normalized by 
the uptake in control cells, silenced with a scramble siRNA, averaged over 3 replicates. Both controls and samples were 
incubated with the same dispersion of nanoparticles.  
 
Methods 
Cell culture  
HeLa cells CCL-2TM purchased from ATCC® (Manassas, VA, USA) were cultured in complete 
cell culture medium (cMEM) including MEM (GibcoTM Thermofisher Scientific, Landsmeer, 
Netherlands) supplemented with 10% v/v Foetal Bovine Serum (FBS, GibcoTM Thermofisher 
Scientific) and growth at 37 °C, 5% CO2. The cells were routinely tested for mycoplasma 
contamination and were kept in culture for up to maximum 20 passages.  
Nanoparticle characterization and corona complexes 
preparation 
Fluorescently labelled 50 nm silica nanoparticles (Kisker Biotech, Steinfurt, Germany, 
maximum excitation wavelength of 569 nm and maximum emission of 585 nm) were 
characterized by Dynamic Light Scattering (DLS) using a Malvern Zetasizer Nano ZS (Malvern 
Instruments Ltd., Worcestershire, UK). In order to isolate corona-coated nanoparticle 
complexes, 300 μg/ml NPs were dispersed in 62 or 12 mg/ml human serum (TCS BioSciences 
Ltd Botolph Claydon, UK) for 1 h at 37 °C and then centrifuged at 16100 rcf for 1h49. The 
pellet was resuspended in PBS and then diluted in serum free MEM to a final concentration 
of 100 μg/ml of nanoparticles. The hydrodynamic diameter of pristine nanoparticles 
dispersed in dH2O or PBS and nanoparticle-corona complexes were measured by DLS. Size 
measurements were averaged results from 5 runs of at least 3 measurements. 
Studies with pharmacological inhibitors of endocytosis 
The role of several endocytic mechanisms in the uptake of 50 nm SiO2 NPs was assessed by 
using inhibitors of endocytosis and previously optimized protocols to exclude toxicity. 
Briefly, HeLa cells were seeded at a concentration of 50000 cells/well in 24-well plate 
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(Greiner Bio-One BV, A. Alphen on den Rijn, Netherlands). 24 h after seeding, HeLa cells 
were pre-incubated for 10 (or 20 minutes for Nocodazole) in serum free MEM culture 
medium with the different inhibitors at the following concentrations: 5-(N-Ethyl-N-
isopropyl)amiloride (EIPA) 100 µM, chlorpromazine hydrochloride (CP) 10 µg/ml, methyl-β-
cyclodextrin (MβCD) 2.5 mg/ml, dynasore 25 μg/ml (all from Sigma-Aldrich St. Luis, USA), 
nocodazole 5 µM (Biovision, California, USA), cytochalasin D 2.5 µg/ml (Thermofisher 
Scientific). Afterwards, 100 μg/ml nanoparticle-corona complexes dispersed in serum free 
MEM were incubated on cells with or without the drug. As control of drug efficacy, we used 
fluorescently labelled markers of endocytosis or immunohistochemistry labelling. 2 µg/ml 
of fluorescently labelled Low Density Lipoprotein (Dil-LDL, Thermofisher Scientific) and 15 
µg/ml of 546 fluorescently labelled transferrin (Thermofisher Scientific) dispersed in serum 
free MEM were used as a marker for Clathrin-Mediated Endocytosis. 1 µg/ml of BODIPY® FL 
C5-Lactosylceramide/BSA complex (LacCer, Thermofisher Scientific) dispersed in serum free 
MEM was used as a marker for caveolae mediated and lipid raft dependent endocytosis. 
250 µg/ml 10KDa TRITC Dextran (Thermofisher Scientific) dispersed in cMEM was used as a 
marker for macropinocytosis.  Samples were collected and prepared for flow cytometry as 
described below. Alternatively, the efficacy of cytochalasin D and nocodazole on, 
respectively, actin or microtubule disruption was assessed by immunohistochemistry (see 
later for details).  
siRNA studies 
The mechanisms of uptake of 50 nm SiO2 NPs were assessed by using siRNA directed 
towards specific endocytic targets. Briefly, 13000 cells/well were seeded in 24-well plate 
(Greiner Bio-One BV). 24 h after seeding, HeLa were washed in serum free MEM for 20 
minutes and then each well was incubated with 250 µl of a mix composed by 45 µl 
oligofectamine (Thermofisher), 9 pmol of siRNA (Silencer® Select, Thermofisher) and Opti-
MEM (Thermofisher). A scramble siRNA was used as negative control. After 4 hours, 125 µl 
of MEM supplemented with 30% v/v Fetal Bovine Serum were added on cells and cells 
grown further at 37 °C, 5% CO2. 72 h after silencing, cells were incubated with 100 μg/ml 
nanoparticle-corona complexes dispersed in serum free MEM prepared as described above 
for the time indicated and then analysed by flow cytometry or fluorescence imaging.   
Plasmid transfection with AP180 
The construct containing the GFP-tagged C-terminal of Ap180 expressed under a 
constitutive promoter was kindly provided by Yvonne Vallis and Harvey T McMahon 
(Cambridge University, UK).50 HeLa were transfected with 0.2 ng of plasmid DNA, using 0.6 
μl Fugene (Promega) as transfection reagent in cMEM. After 24 h, cells were washed in 
serum free MEM and incubated with nanoparticle-corona complexes, as described 
previously. Cells were then washed and samples prepared for imaging as described later. 
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Flow cytometry analysis 
Flow cytometry was used to measure the fluorescence intensity of cells incubated with 
fluorescent 50 nm SiO2 NPs, LacCer, Dextran or LDL. After the required exposure time, cells 
were washed once with cMEM and twice with PBS in order to remove the nanoparticles and 
markers not internalized. HeLa cells were harvested using 0.05% trypsin–EDTA, collected, 
centrifuged and resuspended in PBS for the measurement. Cell fluorescence was recorded 
using a Cytoflex Flow Cytometer (Beckman Coulter, Woerden, the Netherlands) with a 488 
nm laser. Data were analyzed using Flowjo data analysis software (Flowjo, LLC). Cell debris 
and cell doublets where excluded by setting gates in the forward and side scattering double 
scatter plots. A total of at least 20000 cells were acquired per sample and each sample was 
performed in triplicate.  
Immunohistochemistry  
Immunohistochemistry was performed in Hela cells plated on glass coverslips inserted in 
24-well plates and experiments were performed as described above. For probing 
nocodazole efficacy on microtubule polymerization, HeLa cells were incubated for 1 h with 
a mouse primary antibody against human α-Tubulin (Merck Millipore, Netherlands) 
followed by 1 h incubation with a Alexa Fluor®488 goat anti-mouse secondary antibody 
(Thermofisher Scientific). Cytocalasin D efficacy on actin polymerization was assessed by 
selectively staining F-actin with TRITC-Phalloidin (Sigma-Aldrich). After each step of 
antibody incubation, cells were washed 3 times with PBS. Nuclei were stained with 0.2 
μg/ml DAPI (4',6-diamidino-2-phenylindole) and glass slides were mounted with Mowiol 4-
88 mounting medium (EMD Chemical, Inc, CA, USA). Image acquisition was performed using 
a Leica TCS SP8 fluorescent confocal microscope (Leica Microsystems, Wetzlar, Germany) 
with a 405 nm laser for DAPI excitation, a 488 nm laser for Alexa Fluor®488, and a 552 nm 
laser of TRITC. Images were processed using ImageJ software (http://www.fiji.sc).  
mRNA expression 
The expression levels of a silenced proteins were determined by RT-PCR using the primers 
listed in Table S1, Supplementary Information. 72 h after transfection, 4 wells were merged 
and their total mRNA was isolated using an Invitrap® Spin Cell RNA Mini Kit (Stratec 
Molecular GmbH, Berlin, Germany) according to the instruction provided by the 
manufacturer. Reverse transcription of 2 µg mRNA into cDNA was performed using a 
Reverse Transcription System (Promega, Leiden, The Netherlands) in an Eppendorf 
Mastercycler gradient (the following cycle was used: 20 ˚C for 10 min, 42 ˚C for 30 min, 20 
˚C for 12 min, 99 ˚C for 5 min and 20 ˚C for 5 min). The transcription levels were measured 
by quantitative real time PCR (SensiMix™ SYBR kit, Bioline, Taunton, MA) in a ABI7900HT 
sequence detection system (Applied Biosystems, Foster City, CA) from cDNA (20 ng per 
sample). The Ct values were obtained using a SDS 2.4 software (Applied Biosystems). For 
each target, 4 replicate wells were prepared and the average Ct value and its standard 
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deviation were calculated. Results are expressed as fold-change of the averaged Ct values 
of negative control (Neg) related to Ct values of the sample investigated (S) as follows: 
Fold change = 2−(Mean Neg −Mean S )       (1) 
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Gene Forward (left) Reverse (right) 
CLTC TGAGAAAAGAAGAAGAACAAGCTACA ACACTGGGTCCTGCTGTCA 
CAV1 ACAGCCCAGGGAAACCTC GATGGGAACGGTGTAGAGATG 
RHOA GGAGCTAGCCAAGATGAAGC GCCAATCCTGTTTGCCATA 
CDC42 CATCGGAATATGTACCGACTGTT TGCAGTATCAAAAAGTCCAAGAGTA 
ARF6 TGAACACAAAGTTGCTAGATGCT TGCTGTGTTTCCCCCATC 
DNM2 CATCAACACGAACCATGAGG CTTGTTCAGCTGCGTGCTC 
FLOT1 ATTCTAACTCGCCTGCCAGA GCATCTGTGAGGGCTGAAG  
GRAF1 CAGGCACGGTCTTCGATAA GCCAGTCTTTCCGTTCAGAG 
LDLR GTGACAATGTCTCACCAAGCTC CACGCTACTGGGCTTCTTCT 
TFRC TGAAGAGAAAGTTGTCGGAGAAA CAGCCTCACGAGGGACATA 
RAC1 CTGATCAGTTACACAACCAATGC CATTGGCAGAATAATTGTCAAAGA 
ANKFY1 AAACTAGCAAATCGGTTTCAGC GAGACATAACACCCTTCTCACATC 
EPN1 GAGAGCAAGAGGGAGACTGG AAGACGTCAGCAAGGTCCAT 
SH3GL1 GGGGCTGAAGAAGCAGTTC TTGCTGGTGACATCCACCT 
SH3GL2 AGGCACTCCCAAACCTTCA CAGGTTCAAAGTCGTACAGAGC 
SH3GL3 GCAGAAATTCTTTCAAAAACCACT CCTCGGATCTTCGACACAGT 
BIN1 CGTGCAGAAGAAGCTCACC TGCTCATCCTTGGTCTCATCT 
PACSIN2 CCGGGCCCTGTATGACTAT TCCTCCATCTTGGTCAGCTC 
IST1 CTTAAACTATTGGAGAAAAAGAAAACG CCCAGCAGCCAGATAGTC 
FCHO2 GATACAAAAATTTGCTGAGTCAAAAG TGTCACATTCTTCAAATTCAATGAG 
 
Table S1. Primers used in this study for RT-qPCR. RT-qPCR was performed as described in the Experimental Section to 
determine the expression levels of some cell receptors (LDL and transferrin receptor), and a series of targets involved in 
different endocytic pathways. 
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Figure S1: Size distribution by intensity (diameter, d, nm) of 50 nm red silica nanoparticles in different media. Briefly, 300 
μg/ml silica nanoparticles were incubated for 1 hour at 37˚C in 12 mg/ml (low serum corona, LC) or 60 mg/ml (high serum 
corona, HC) human serum, centrifuged for 1 hour and resuspended in MEM to 100 μg/ml prior to characterization by 
Dynamic Light Scattering, DLS. Alternatively (lower panels), 100 μg/ml nanoparticles were dispersed in 4 mg/ml (low) or 
20 mg/ml (high) human serum and measured immediately in the presence of serum. The results show that corona coated 
complexes could be resuspended and formed homogenous dispersions, while especially in the samples with proteins left 
free in solution a second peak between 1-10 μm was also detected, possibly sign of some agglomeration or due to presence 
of large serum aggregates.  Red, blue and green curves represent three different size measurements of the same sample. 
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Figure S2: Uptake kinetics of silica nanoparticles in LDLR silenced HeLa cells in different media. Nanoparticle-corona 
complexes were formed by incubating 300 μg/ml 50 nm silica nanoparticles in human serum (HS - left) or human 
delipidised serum (HSD - right) at a concentration of 62 mg/ml (HC).  Nanoparticle-corona complexes were then isolated 
by centrifugation and incubated at a final concentration of 100 μg/ml of nanoparticles on HeLa cells silenced for the LDLR 
(siRNA LDLR, grey line) or control cells silenced for a scramble siRNA (Ctrl, black line). The results are the average and 
standard deviation over 3 replicates of the cell fluorescence intensity obtained by flow cytometry. A stronger reduction in 
the uptake is more evident at longer exposure times. 
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Figure S3: Silencing controls for a panel of targets of endocytosis. a) Expression levels of endocytic targets in silenced HeLa 
cells. HeLa cells were silenced as described in the Methods for reducing the expression of a series of genes (as defined in 
the labels) or with a control scramble siRNA. After 72 h silencing, RT-qPCR was used to quantify the expression of the 
different targets in the silenced cells (see Methods for details). Results are the fold change in comparison to cells silenced 
with a scramble siRNA, calculated from Ct values as described in the Methods. Data are the average of 5 independent 
experiments, each with 3 replicates for each condition, and the error bars represent the standard error of the mean. The 
results confirm the reduction of the expression levels of all of the targets investigated in the silenced cells. b) Uptake of 
labelled TF in silenced cells. HeLa cells silenced for the targets indicated were incubated for 10 min with 15 µg/ml 
fluorescently labelled TF in serum free MEM. Cell fluorescence was measured by flow cytometry and expressed as 
percentage compared to control cells treated with a scramble siRNA. Error bars represent the standard deviation over 3 
replicates. The results confirm excellent reduction of uptake of TF in cells silenced for the expression of the TF receptor, 
and a good uptake reduction in cells silenced for EPN1, a key protein in clathrin mediated endocytosis, which is the 
mechanism of TF internalization. However, even if RT-PCR suggests good silencing efficacy, only minor effects were 
observed in cells silenced for clathrin heavy chain and dynamin 2. This may be explained by compensation by other clathrin 
heavy chain and dynamin isoforms or potential effects on the expression levels of the TF receptor in cells silenced for 
these targets (see also panel d for similar effects on LDLR expression). Further tests are required to elucidate on this. Given 
these results additional tests with expression of AP180 and chlorpromazine were added to investigate the role of clathrin 
mediated endocytosis in silica uptake. c) Western blot of clathrin heavy chain (CLTC) in HeLa cells silenced for CLTC and 
with a scramble siRNA (ctrl). The WB confirms excellent CLTC protein reduction in the silenced cells. d) Expression levels 
of LDLR in HeLa cells silenced for a panel of targets of endocytosis. HeLa cells were silenced for the targets indicated. RT-
qPCR was used to quantify the expression levels of LDLR in cells silenced for each of the targets in order to monitor 
eventual effects of silencing on LDLR. Results are the fold change in comparison to cells silenced with a scramble siRNA, 
calculated from Ct values as described in the Methods. Data are the average of 6 independent experiments, each with 3 
replicates for each condition, and error bars represent the standard error of the mean. The results suggest that silencing 
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some of the endocytic targets such as CLTC and DNM2 causes an increase in expression of the LDLR. e) Uptake of LDL in 
silenced cells. HeLa cells silenced for the targets indicated were incubated for 4 hours with 1 µg/ml fluorescently labelled 
Dil-LDL in serum free MEM. The results are the average and standard deviation of three independent experiments of the 
cell fluorescence measured by flow cytometry, normalized by the uptake in control cells treated with a scramble siRNA. 
Similarly to what observed for TF uptake in panel b, the results suggest that while silencing LDLR caused very strong 
reduction of LDL uptake, silencing some of the targets involved in clathrin mediated endocytosis (which is the mechanism 
of uptake of LDL) and in particular CLTC and DNM2 did not cause LDL uptake reduction. This may be explained by the effect 
on LDLR expression observed in cells silenced for these targets in panel d. 
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Figure S4 Uptake of silica nanoparticles in HeLa cells silenced for a panel of endocytic targets. HeLa cells silenced for a 
series of endocytic targets (as indicated in the labels) were exposed for 14 hours to 100 μg/ml 50 nm silica nanoparticles 
dispersed in 4 mg/ml human serum (HS) in situ. The results are the average and standard deviation over 3 replicates of 
the median cell fluorescence measured by flow cytometry, normalized by uptake in cells silenced with a scramble siRNA. 
Both controls and samples were incubated with the same dispersion of nanoparticles. The results show that in these 
conditions, where no effects on uptake were observed after silencing the expression of LDLR, also none of the other targets 
investigated showed substantial effects in reducing particle uptake. 
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Figure S5 Silencing controls for a panel of BAR domain curvature proteins. a) Expression levels of BAR domain proteins in 
silenced HeLa cells. HeLa cells were silenced as described in the Methods for reducing the expression of a series of genes 
(as defined in the labels) or with a control scramble siRNA. After 72 h silencing, RT-qPCR was used to quantify the 
expression of the different targets in the silenced cells (see Methods for details). Results are the fold expression in 
comparison to cells silenced with a scramble siRNA, calculated from Ct values as described in the Methods. Data are the 
average of 3 independent experiments, each with 4 replicates per condition, and the error bars are the standard error of 
the mean, SEM. b) Western blot of BIN1 in HeLa cells silenced for BIN1 and with a scramble siRNA (ctrl). RT-PCR confirms 
excellent reduction of expression for all silenced targets and the WB confirms also the reduction of BIN1 protein levels in 
BIN1 silenced cells. 
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Figure S6 a) Expression levels of LDLR in HeLa cells silenced for a panel of BAR domain curvature proteins. HeLa cells were 
silenced for the targets indicated. RT-qPCR was used to quantify the expression levels of LDLR in cells silenced for each of 
the targets in order to monitor eventual effects of silencing on LDLR. Results are the fold expression in comparison to cells 
silenced with a scramble siRNA, calculated from Ct values as described in the Methods. Data are the average of 2 
independent experiments, each with 4 replicates, and error bars represent the standard error of the mean. The results 
suggested only minor effects on the expression of the LDLR, with a mild increase for cells silenced for BIN1 and FCHO2. b) 
Uptake of LDL in silenced cells. HeLa cells silenced for the targets indicated were incubated for 4 hours with 2 µg/ml 
fluorescently labelled Dil-LDL in serum free MEM. The results are the average and standard deviation over 3 independent 
experiments, each with 3 replicates per conditions, of the cell fluorescence measured by flow cytometry, normalized by 
the uptake in control cells treated with a scramble siRNA. The results show increased uptake in cells silenced for FCHO2 
This may be explained by the effect on LDLR expression observed in cells silenced for this target in panel a. Importantly, 
no effects were observed in BIN1 silenced cells, while LDL uptake was lower in cells silenced for GRAF1, suggesting a 
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In order to improve the current success of 
nanomedicine, a better understanding of how nano-
sized materials interact with and are processed by cells 
is required. Typical in vitro nanoparticle-cell interaction 
studies often make use of cells cultured at different cell 
densities. However, in vivo, for their successful delivery 
to the target tissue, nanomedicines need to overcome 
several barriers, such as endothelial and epithelial cell 
barriers. Unlike sub-confluent or confluent cell cultures, 
cell barriers are tight cell monolayers, expressing a series 
of specialized tight junction proteins between adjacent 
cells to limit paracellular transport and ensure close cell-
to-cell interactions. A clear understanding on how 
development of cells into a cell barrier may affect uptake 
of nano-sized drug carriers, is still missing. To this aim, 
here, human primary umbilical vein endothelial cells 
(HUVEC) are used as a model cell line to form endothelial 
cell barriers. Then, nanoparticle uptake is assessed in the 
developed endothelial barriers and compared to the 
uptake in sub-confluent or confluent HUVEC cultures. 
The results clearly show that the organization of cells 
into a cell barrier leads to a differential gene expression 
of endocytic markers, and – interestingly - this is 
accompanied by reduced nanoparticle uptake levels. 
Transport inhibitors are used to characterise the 
mechanisms involved in the uptake. However we show 
that some of them can strongly compromise barrier 
integrity, thus impairing the interpretation of the 
outcomes, and overall, only a partial inhibition of 
nanoparticle uptake could be obtained. 
Keywords: endothelial cells; HUVEC; 
barrier; uptake mechanisms, 
nanoparticle 
Chapter 6: Effect Of The Development Of a  
Cell Barrier on Nanoparticle Uptake  
in Endothelial Cells 




Nano-sized materials have been shown to be promising tools as drug carriers for the 
delivery of drugs, proteins and siRNAs because of their ability to exploit cellular mechanisms 
to be internalized by cells.1–6 In particular nanomedicines have drawn a lot of interest for 
their potential as cancer therapeutics.7 Nano-sized carriers can in fact be used for passive 
targeting because of their capacity to reach the tumor tissue via the so called enhanced 
permeation and retention (EPR) effect.7–10 At the same time, they can also be decorated 
with targeting moieties and be directed specifically to tumors via active targeting. However, 
the presence and efficacy of EPR in humans is currently being debated11–13 and recent 
debates have pointed out the - sometime - limited targeting efficiency of nanomedicines.14–
17 This has been accompanied by a growing realization that a better understanding on how 
nano-sized carriers are recognized and processed by cells could help improving further 
nanomedicine design for a more effective targeting.18–20 
In order to reach their target, nano-sized carriers and drugs need to overcome a series of 
barriers both at organ, tissue and cellular levels.21–23 Among these, endothelial cells 
constitute one of the very first barriers that nanomedicines need to overcome in order to 
reach the targeted organ following administration into the blood stream.24,25 In order to 
control access to the underlying tissue and impair the passage of pathogens and undesired 
molecules, endothelial cells are typically organized in cellular barriers expressing tight 
junctions among cells, and with a clear spatial and functional separation between their 
apical and basolateral membranes.26 As a result, endocytic pathways are differentially 
expressed between the two sides of the cell monolayer.27 In order to reach the underlying 
tissue, nano-sized drug carriers may be able to use paracellular transport (if the barrier 
integrity is compromised or if specially designed to do so)28,29 or – more often - they need 
to enter the cells by using the pathways expressed on the apical membrane and later be 
transcytosed from the basal membrane.30,31 Other pathways that drugs can use to cross 
barriers may include specific transport proteins for smaller molecules, or simple diffusion 
across the cells for small lipophilic compounds. Overall, transport of (larger) nano-sized drug 
carriers across the endothelium is particularly challenging in the case of specialized 
endothelial barriers protecting organs such as - for instance - the brain, where the blood 
brain barrier constitutes a well-known example of one of the tightest barriers to drug 
delivery.32–35 
Because of all of these reasons, organized cell layers expressing tight junction proteins may 
constitute in vitro models that better reflect the barriers nanomedicines encounter in vivo 
in comparison to cells at different degrees of confluency, which are often applied for 
nanoparticle cell behaviour studies.6,18,36,37 Examples of nanoparticle studies using cell 
barriers are found in literature, especially for epithelial cells, such as for instance the skin, 
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intestine, lung and liver hepatocytes.38–40 Less examples can be found in the case of 
endothelial cells, often focused on the endothelial blood brain barrier,35,41 but not only.40,42 
In general, optimizing cell culture conditions for ensuring the in vitro development of an 
intact cell barrier, without gaps among cells, can be particularly challenging.41 In some cases 
it has been observed that the development of a cell barrier is accompanied by reduced 
nanoparticle uptake levels, for instance in epithelial cell barriers.40,43–46 In the case of 
endothelial cells, however, a clear view on the effect of the development of a cell barrier on 
nanoparticle uptake and the cellular mechanisms involved is still missing. 
Within this context, the aim of this study was to investigate how the differentiation of cells 
into a cell barrier in vitro affects nanoparticle uptake and behaviour in endothelial cells. For 
this purpose, we have chosen primary HUVECs (Human Umbilical Vein Endothelial Cells) as 
model (non-specialized) endothelial cells to develop endothelial cell barriers.47 Several 
nanoparticle cell interactions studies have already used this as a model endothelial cell 
line,48,49 including some examples in which cells were developed into barriers.50–52 After 
carefully optimizing cell culture conditions to ensure proper formation of a cell monolayer 
expressing tight junction proteins, we tested the effect of barrier formation on the uptake 
of 50 nm amorphous silica as a representative model nanoparticle.53 Thus, nanoparticle 
uptake kinetics in the barriers was directly compared to that in sub-confluent and confluent 
cells. Finally, protocols to use common chemical inhibitors of endocytosis on the cell 
barriers were carefully optimized with appropriate controls, paying special attention to the 
effect of these compounds on barrier integrity. The optimized protocols were then used for 
a preliminary study on the endocytic mechanisms involved in the uptake of 50 nm silica in 
the endothelial cell barriers. 
 
Results and discussion 
HUVEC barrier characterization and optimization 
HUVEC cells were chosen as a model system to develop endothelial cellular barriers. Prior 
to nanoparticle studies, extensive work was performed in order to optimize the culture 
conditions for the development of a cell barrier expressing tight junction proteins. Different 
coatings such as rat tail collagen type-I or type-3 and 4, gelatin and fibronectin are typically 
used to improve adherence and growth of cells, including endothelial cells and 
HUVECs.35,41,54–56 Rat tail collagen type-1, fibronectin and gelatin were tested and, as 
expected, they all allowed increased HUVEC adherence in comparison to uncoated surfaces, 
but with no obvious differences among them (see example in Supplementary Figure S1, for 
collagen type-1). Thus, we selected rat tail collagen type-I (as in many other studies with 
endothelial cells)35,41 for further optimization of cell growth conditions.  
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Trans-Epithelial Electrical Resistance (TEER), permeability assays and imaging of tight 
junctions were combined in order to monitor the development of cell barriers in the 
different conditions tested (Figure 1 and Supplementary Figures S2-S8). As a first step, the 
barriers formed after seeding HUVECs at different starting cell densities (3000 and 50000 
cells cm-2) were compared. Imaging of ZO-1 (zonula occludens-1) and CD31 (cluster of 
differentiation 31, also known as PECAM1, platelet endothelial cell adhesion molecule), two 
common tight junction proteins in endothelial cells, was used to monitor cell barrier 
development at different days after seeding.26  
In the first days, tight junction proteins were distributed intracellularly all over the cell. Only 
7 days after seeding 3000 cells cm-2, or 4 days after seeding 50000 cells cm-2 tight junctions 
were clearly visible in the margins between cells (Figure 1a and Supplementary Figures S2 
and S3), suggesting development of a cell barrier. 3D z-stack images at confocal microscopy 
clearly confirmed this (Supplementary Movie S1 and projection in Figure 1c). It is important 
to notice that light microscopy seemed to indicate cell confluency already at earlier times, 
when fluorescence microscopy showed that proper tight junctions were not formed yet. 
This indicates that confluency alone is not a good parameter to assess the development of 
a cell barrier. At later days after seeding, HUVECs started to overlap in multiple layers and 
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Figure 1. Characterization of the optimized HUVEC barriers. 3000 cells cm-2 HUVEC were plated on collagen coated glass 
coverslips (a-c) or Transwell inserts (d-e) and their growth was monitored for different days after seeding. a and c: confocal 
images of a HUVEC barrier (7 days after seeding) stained with anti-ZO-1 (red) or anti-CD31 (green) antibodies. Blue: DAPI 
stained nuclei. Scale bar: 20 µm. b: light microscopy image of the same culture. Scale bar: 50 µm. c: z- stack projection by 
confocal microscopy of a 7 day barrier (the corresponding movie is included in Supplementary Information). Scale bar: 10 
µm. d: Apparent permeability (Papp) of FITC-Dextran (4 kDa, 200 µg ml-1) at different times after seeding cells on polyester 
Transwell inserts. The fluorescence intensity of FITC-Dextran in the basal chamber was used to calculate the apparent 
permeability as described in the Experimental Section. Results are the average value and standard deviation of 2 different 
inserts. The results obtained with Transwells without cells are also included (CTRL). e: Trans Epithelial Electrical Resistance 
(TEER) at different times after seeding cells on polyester Transwell inserts. Results are the average TEER value and standard 
deviation obtained from two different inserts which were measured over time for the entire experimental period. 
Trans-Epithelial Electrical Resistance (TEER) assays were also used to further characterize 
the development of cell barriers in the different conditions tested (Figure 1e and 
Supplementary Figure S4, including comparisons for barriers formed on filters of different 
materials). For this purpose, we selected 12 mm Transwell® inserts with a polyester filter of 
0.4 μm pore size. Even though these measurements are very difficult to control 
quantitatively (see Supplementary Figure S5 as an example), the measured TEER values 
were comparable to what reported in literature for HUVECs in similar studies57–59 and the 
trend observed was in all cases the same: TEER values increased as cell barriers formed in 
the first days after seeding, reaching a plateau roughly after 7-8 days or 2-4 days, for cells 
seeded at the lower and higher cell densities, respectively. These timescales are in 
agreement with what observed by imaging of tight junction proteins and light microscopy 
(Supplementary Figures S2 and S3). After that, for the lower cell density, the TEER values 
started to decrease, probably as a consequence of loss of barrier integrity and cell death (as 
clearly visible in light microscopy images before and after washing in Supplementary Figure 
S6, and also the fluorescence images of Figures S2). In the case of cells seeded at the higher 
cell density, after the plateau and a similar decrease, a second apparent peak in TEER could 
be observed. Also in this case, however, light microscopy images before and after washing 
the cell cultures (Supplementary Figure S7) showed strong cell death and compromised 
barrier integrity. This clearly excluded the possibility to interpret this second peak as an 
indication of an intact barrier (the observed formation of multiple cell layers in these 
overgrown barriers, as shown in Supporting Figure S3 day 9, may in part explain this second 
increase).  
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Overall, the TEER results showed that by starting with a lower cell density (3000 cells cm-2) 
and waiting longer for barrier development, slightly higher TEER values could be obtained, 
suggesting a better barrier development in these conditions (Supplementary Figure S4). 
The apparent permeability (Papp) of 4kDa FITC-Dextran across the developing cell layer was 
also used to monitor the development of a cell barrier (Figure 1d and Supplementary Figure 
S4, with an example of a corresponding calibration curve in Supplementary Figure S8). The 
values obtained were comparable with what was determined in literature for similar 
systems.60–63 The results indicated that when 3000 cells cm-2 were seeded (Figure 1d), 
HUVEC permeability progressively decreased over time until 7 days after seeding, when it 
reached a minimum value corresponding to 40% of the permeability of a Transwell without 
cells (see also normalized results in Supplementary Figure S4c). Again, this timescale is 
comparable to what determined by TEER measurements and microscopy. On the other 
hand, the Papp of HUVECs seeded at high cell density (Supplementary Figure S4d) was 
already low since the beginning and fluctuated around the same values (40 to 60%) for all 
the experimental period (probably a smaller probe would be needed to be able to measure 
a decrease in apparent permeability in these conditions). 
 
Figure 2. Expression levels of genes coding for endocytic proteins in HUVEC barriers in comparison to sub-confluent cells. 
HUVEC were seeded at a density of 3000 cells cm-2 and cultured for three or seven days. RT-qPCR was performed as 
described in the Experimental Section to determine the expression levels of genes coding for some cell receptors (LDL and 
transferrin receptors), and for a series of targets involved in clathrin mediated endocytosis (CME), caveolae-mediated 
endocytosis, macropinocytosis, and other clathrin and caveolae independent mechanisms (Others) (see also 
Supplementary Table S1 for details). Results represent the average and standard deviation over 2 replicates of the fold-
change in gene expression levels in HUVEC barriers (day 7) compared to sub-confluent cells (day 3), calculated as detailed 
in the Experimental Section. 
Taken all-together, tight junction staining, TEER and Papp assays suggested that seeding 
lower cell numbers and waiting for longer times allowed HUVEC to form tight junctions, 
which resulted in a high electrical resistance and a low permeability to molecules in about 
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7 days after seeding. We selected these optimized conditions for the following studies to 
assess the behaviour of nanoparticles on the developed cell barriers. 
In order to test the effect of the development of a cell barrier on uptake and transport 
mechanisms, we also compared the expression levels of genes coding for key proteins 
involved in different endocytic pathways in sub-confluent HUVEC and in the optimized cell 
barriers (3 and 7 days after seeding 3000 cells cm-2, respectively). Similar approaches were 
used to characterize an in vitro model of the blood brain barrier endothelium.42 The results 
clearly showed that in all cases the mRNA expression levels of the selected endocytic targets 
were lower when cells were differentiated in a cell barrier compared to sub-confluent cells 
(Figure 2). Similarly, the gene expression levels of the same targets were also measured in 
confluent cells (25000 cells cm-2 seeded one day before the experiment). Cell counting 
confirmed that cell numbers in these confluent layers were comparable to the cell numbers 
in the optimized cell barriers (7 days after seeding 3000 cells cm-2) (Supplementary Figure 
S9). Also in this case, the results showed that the gene expression levels of the selected 
endocytic targets were lower when cells were developed into a cell barrier (Supplementary 
Figure S10). Overall, this further confirmed that the optimized protocols allowed us to 
obtain a well-differentiated endothelial cell barrier. At the same time, the results clearly 
indicated that cell confluence alone does not guarantee the development of a cell barrier. 
Nanoparticle uptake by HUVEC barriers 
Having observed reduced expression of genes coding for key endocytic proteins in the 
optimized endothelial cell barriers, we then studied eventual consequences for 
nanoparticle uptake. This was done by directly comparing nanoparticle uptake levels in the 
optimized cell barriers and sub-confluent or confluent HUVEC cultures. To this aim we used 
red fluorescently labelled 50 nm silica as a well characterized model in nanoparticle uptake 
studies.53 It is well established that once nanoparticles are dispersed in biological fluids, 
biomolecules from the surrounding environment adsorb on their surface, forming the so 
called nanoparticle corona.47,53,64 More recently, it has also emerged that cell receptors can 
recognize and interact with the proteins adsorbed in this layer.65–67  
Thus, in order to use a more relevant biological media for exposure to human endothelial 
cells, the nanoparticles were dispersed in a cell culture medium supplemented with human 
serum rather than the usual FBS. The use of a medium with human serum during exposure 
to the nanoparticles did not cause any major effect on cell viability and barrier integrity, in 
comparison to barriers maintained in standard FBS supplemented medium (data not 
shown). Dynamic Light Scattering was used to confirm that stable dispersions could be 
obtained in the conditions used for exposure to cells for up to 24 hours (see Supplementary 
Figure S11, after 24 hours incubation at 37 ˚C, 5% CO2 in cell culture medium supplemented 
with human serum, HS EBM-2).  
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Figure 3. Nanoparticle uptake and intracellular trafficking in HUVEC barriers. a: confocal microscopy image of a HUVEC 
barrier (seven days after seeding 3000 cells cm-2) exposed for 24 hours to 100 µg ml-1 50 nm red SiO2 nanoparticles. Red: 
nanoparticles, Green: LAMP-1, Grey: ZO-1, Blue: DAPI stained nuclei. Scale bar: 50 μm. b-c: Median cell fluorescence 
intensity as obtained by flow cytometry of HUVEC exposed for increasing times to 100 µg ml-1 50 nm red SiO2 nanoparticles 
dispersed in EBM-2 medium supplemented with 4 mg ml-1 human serum. Uptake levels in HUVEC barriers (seven days 
after seeding 3000 cells cm-2) are compared to those in (b) subconfluent HUVEC (three days after seeding 3000 cells cm-2) 
and (c) confluent HUVEC (one day after seeding 25000 cells cm-2). The results are the average median fluorescence 
intensity of three replicates and error bars (included for all data points) are the standard deviation. 
A direct comparison of nanoparticle uptake levels obtained in independent experiments, 
performed using same batches of nanoparticles and serum, confirmed good control and 
reproducibility of both the model cell barriers, as well as of the nanoparticle dispersions and 
exposure to cells (Supplementary Figure S12). As expected, the cell fluorescence intensity 
increased with incubation time as a consequence of nanoparticle uptake. Confocal 
microscopy confirmed nanoparticle uptake in the cell barriers and, as previously observed 
in different cell types for the same material,3,68 nanoparticle accumulation into the 
lysosomes (Figure 3a). 
As a next step, we compared the uptake of silica nanoparticles on sub-confluent cells and 
the optimized cell barriers (3 and 7 days, respectively, after seeding 3000 cells cm-2) for up 
to 48 hours (Figure 3b). Interestingly, the results showed that nanoparticle uptake in the 
cell barriers was lower than in sub-confluent cells. In order to exclude that this was simply 
due to the higher cell number (thus lower dose of nanoparticles per cell) or to the lower 
surface area when cells are tightly packed into a barrier, we compared nanoparticle uptake 
in the cell barriers (7 days after seeding 3000 cells cm-2) and in confluent cells with similar 
cell density (25000 cells cm-2 seeded one day before the experiment). As previously shown, 
cell numbers were comparable in the two conditions (Supplementary Figure S9). Also in this 
case, uptake in the cell barriers was lower than in confluent cells (Figure 3c). Importantly, 
the observed lower uptake was not unique to these specific nanoparticles, since similar 
results were obtained also with silica of bigger size (200 nm) and nanoparticles of a different 
material (carboxylated polystyrene of 40 and 200 nm) (see Supplementary Figure S11 for 
DLS characterisation, S13 for confocal microscopy and S14 and S15 for uptake studies). This 
result suggested that the lower uptake was not due to specific physico-chemical properties 
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of a particular nanoparticle type, rather depended on the development of cells into a cell 
barrier. 
Nanoparticle uptake mechanism in HUVEC barriers 
As a final step, we studied in more detail the mechanisms involved in nanoparticle uptake 
in the HUVEC barriers. The mechanisms that cells use to internalize nanoparticles still 
remain unclear in many cases, also because of the difficulty in characterizing transport 
pathways in cells and the limits of the different methods typically used to address this 
question.18 RNA interference can be used to block selectively the expression of key proteins 
involved in different endocytic mechanisms, thus determining their role in nanoparticle 
uptake. However, it is known that primary cells, as also HUVEC, in most cases are very 
difficult to transfect and silence (see example in Supplementary Figure S16).69,70 
For this reason, we used chemical inhibitors to block different uptake pathways thus 
determine their involvement in the uptake of the 50 nm silica nanoparticles (Figure 4). 
Chemical inhibitors are often used because they are relatively simple to use and their effect 
is very fast. However, it is known that their efficacy can vary in different cell types and they 
can also be very toxic, thus careful controls need to be performed in order to demonstrate 
their efficacy and exclude toxicity.18,37 To this aim, protocols were optimized on the 
developed barriers by verifying the effect of the inhibitors on the uptake of control markers 
and by immunostaining of actin and microtubules. Eventual effects on barrier integrity were 
monitored by light microscopy (The results of the optimization studies for each of the 
compound tested are included in Supplementary Figures S17 to S21. Additionally, the 
results of Figure 4 after normalization for uptake levels in control cells without drugs are 
also given in Supplementary Figure S22).  
Overall, HUVECs seemed to be particularly sensitive to all the drugs tested and most of the 
times the integrity of the cell barrier was impaired after exposure to the inhibitors (Figure 
4), thus limiting the interpretation of the outcomes. With chlorpromazine, a compound 
commonly used to block clathrin mediated endocytosis (CME),37,71 we obtained a decrease 
of only 30 to 50% at the different exposure times in the uptake of labelled low density 
lipoprotein (LDL), which is known to be internalized via CME (Figure 4a and normalized 
results in Supplementary Figure S22a). Furthermore, addition of chlorpromazine clearly 
resulted in loss of barrier integrity (Figure 4b), while lower drug concentrations were not 
effective in blocking the uptake of LDL (Supplementary Figure S17a). Using these conditions, 
around 40% inhibition of 50 nm silica nanoparticle uptake was observed at all exposure 
times in the compromised barriers in the presence of chlorpromazine (Figure 4c and 
normalized uptake results in Supplementary Figure S22b). 
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Figure 4. Uptake mechanisms in HUVEC barriers. HUVEC barriers (seven days after seeding 3000 cells cm-2) were exposed 
to 5 µg ml-1 chlorpromazine (CP) (a-c), 5 µM nocodazole (NZ) (d-f), 0.5 µg ml-1 cytochalasin D (CytoD) (g-i), 2 mg ml-1 methyl-
β-cyclodextrin (MBCD) (j-l), or 30 µg ml-1 dynasore (Dyn) (m-o). Left panels: controls for drug efficacy: uptake by flow 
cytometry of 2 µg ml-1 BODIPY-LDL (a and m), and 1 µg ml-1 of BODIPY LacCer (j) in control cells (Ctrl) and cells exposed to 
chlorpromazine, dynasore and MβCD respectively; confocal images were used as positive controls for nocodazole and 
cytochalasin D after staining the cells with fluorescent antibodies against tubulin (d) or actin (g) (scale bar: 30 µm). Middle 
panels: light microscopy images of HUVEC barrier morphology after exposure to each inhibitor (scale bar: 50 µm). Right 
panels: effect of the drugs on nanoparticle uptake. HUVEC barriers were exposed to 100 µg ml-1 50 nm red SiO2 
nanoparticles in EBM-2 supplemented with 4 mg ml-1 human serum for the indicated times in the presence or absence of 
the different drugs. Results are the average and standard deviation of three replicates. The same results after 
normalization for the uptake in control cells without inhibitors are given in Supplementary Figure S22. 
Nocodazole and cytochalasin D were then used to block microtubule and actin 
polymerization, respectively: these drugs are used often as inhibitors of macropinocytosis, 
but microtubule and actin are known to play a role also in other pathways, including 
CME.18,37 Immuno-staining confirmed that both drugs had strong effects on microtubule 
and actin polymerization (Figure 4d and 4g). However, as observed for chlorpromazine, also 
these drugs caused evident disruption of the cell barrier (Figure 4e and 4h). This is perhaps 
not surprising considering their effects on microtubules and actin, which are essential to 
maintain cell shape and structure. In these conditions, maximum 20% inhibition of 50 nm 
silica nanoparticle uptake was observed in the compromised barriers in the presence of 
nocodazole and 30 to 40% inhibition at increasing exposure times in the presence of 
cytochalasin D (Figure 4f and 4i, respectively and normalized uptake results in 
Supplementary Figures S22c and S22d). 
Next, methyl-β-cyclodextrin (MβCD) was used to sequester cholesterol from the plasma 
membrane. Cholesterol depletion is often used to block caveolae mediated endocytosis, 
however, it has been shown to affect also several other pathways.18 Uptake of fluorescently 
labelled lactosylceramide (LacCer), a common compound that requires cholesterol for its 
internalization,37 was used to verify MβCD efficacy. As opposed to the other drugs tested, 
in this case we could optimize protocols to achieve a very strong inhibition of LacCer uptake 
without compromising barrier integrity (Figure 4k). With the optimized conditions, LacCer 
uptake was strongly reduced up to 80% when MβCD was added (Figure 4j and normalized 
uptake results in Supplementary Figures S22e) and this reduction was even stronger at 
longer exposure times. However, no or only maximum 20% reduction of 50 nm silica 
nanoparticle uptake was observed upon cholesterol depletion in the cell barriers (Figure 4l 
and normalized uptake results in Supplementary Figures S22f).  
Finally, we optimized protocols to expose the cell barriers to dynasore, a drug that 
suppresses dynamin-dependent endocytic pathways by inhibiting the GTPase activity of 
dynamin.72 With the optimized conditions, the uptake of LDL, which is known to require 
dynamin for its internalization, was reduced by up to 70% at increasing exposure times 
(Figure 4m and normalized uptake results in Supplementary Figures S22g). Importantly, also 
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in this case the cell barrier integrity was maintained (Figure 4n). However, exposure to 
dynasore had only a minor effect on the uptake of 50 nm silica nanoparticles (roughly 10-
15% inhibition at all exposure times) (Figure 4o and normalized uptake results in 
Supplementary Figures S22h). 
As a final step, the same compounds were tested also on confluent cells in order to 
investigate eventual differences in uptake mechanisms between the barriers and confluent 
cells (Supplementary Figure S23). The results showed that only with cytochalasin D a small 
reduction of uptake could be observed (around 25% at all exposure times, as shown in 
Supplementary Figure S23h and S23i) and similarly with chlorpromazine at the longer 
exposure times (around 25% after 5 hours, as shown in Supplementary Figure S23b and 
S23c). This may suggest that different mechanisms are involved in comparison to what 
observed in cell barriers. However, further studies need to be performed to fully clarify this, 
and new methods need to be developed to fully characterize uptake mechanisms, especially 
for the cell barriers. 
In conclusion, the concentrations of the different drugs tested needed to be optimized in 
order to achieve a good inhibition without affecting barrier integrity. In several cases this 
was not possible and the barrier was strongly compromised by exposure to some of these 
compounds. Exposure to chlorpromazine, nocodazole and cytochalasin D resulted in loss of 
barrier integrity and a partial reduction of 50 nm silica nanoparticle uptake in the 
compromised barriers. In the case of MßCD and dynasore, instead, we could achieve an 
optimal inhibition of the uptake of control markers, while preserving barrier integrity. 
However, 50 nm silica uptake was essentially unaffected by the two treatments. The lower 
effect on nanoparticle uptake could also be related to the presence of proteins in solution 
during exposure to nanoparticles, which may limit drug efficacy due to protein adsorption. 
As for the other compounds, higher drug concentrations led to loss of barrier integrity, 
making it again very challenging to conclude on the applicability of these compounds and 
more in general on the uptake mechanisms in the barriers. Overall, the partial reduction of 
uptake observed with these compounds may suggest the involvement of multiple 
pathways. However, given the strong effects on barrier integrity, it is difficult to conclude 
whether the same mechanisms are actually involved in the uptake of these nanoparticles in 
the fully developed cell barriers. Given that on confluent cells the results were slightly 
different than what observed in the barriers, and only cytochalasin D gave a (smaller) 
reduction of nanoparticle uptake, one may also hypothesize that even though the barrier 
integrity is compromised, the cells do retain some different behaviour. However, the results 
clearly indicated that overall different methods need to be developed to study uptake 
mechanisms in cell barriers, thus to be able to fully address this kind of questions. 
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Conclusions 
The aim of this study was to determine the effect of the development of cells into a cell 
barrier on nanoparticle uptake in endothelial cells in comparison to standard cell cultures 
at different degrees of cell densities as commonly applied for in vitro studies. Different 
methods have been combined to monitor cell growth and to optimize the development of 
HUVEC endothelial cell barriers, varying conditions such as the presence of a coating, and 
the starting cell density. Barrier formation was confirmed via TEER measurements, 
permeability assays and imaging of tight junction proteins in the different conditions tested. 
Interestingly, a change in the expression levels of genes coding for several endocytic 
markers was also observed with the optimized conditions, further confirming the 
development of a differentiated cell barrier.  
Thanks to the optimized growth conditions, we could determine that the development of a 
cell barrier affects nanoparticle interactions with cells. In particular, we found that 
nanoparticle uptake was lower in the endothelial cell barriers than in sub-confluent cells. 
Importantly, this behaviour did not depend on the specific physico-chemical properties of a 
particular nanomaterial, since the same results was obtained with nanoparticles of different 
sizes and different materials. This suggested that the lower uptake was due to the 
development of cells into a cell barrier. Furthermore, the observed reduction of uptake was 
not simply due to the lower surface area of the cells in the barrier, since lower uptake was 
observed also in comparison to confluent cells of similar cell density. Importantly, these 
results also indicated that cell confluence alone does not guarantee the development of a 
cell barrier with proper tight junction expression.  
Various examples in literature showed a reduction in the endocytic activity of endothelial 
and epithelial cell types after differentiation74 or polarization.75,76 Here we show that the 
organization of HUVECs in a cellular barrier, which results into lower expression of genes 
coding for different endocytic markers, can also influence nanoparticle uptake levels.  
It is important to keep in mind that not only the gene expression levels, but also the amount 
and localization of receptors and endocytic proteins on the apical or basal membranes is 
known to be affected by barrier formation and this might be relevant for nanoparticle 
uptake routes in endothelial cells. Further studies (beyond the scope of this paper) should 
be performed to determine for instance if the observed lowered gene expression of 
endocytic targets is also accompanied by a different distribution of receptors on the apical 
membrane. Such effects could also explain the observed differences in nanoparticle uptake 
levels. Similarly, it would be interesting to study whether there is a link between the 
lowered gene expression and the partial reduction of uptake observed with the inhibitors. 
However, our results also clearly show that different methods need to be developed to 
study uptake mechanisms in cell barriers, thus also to be able to address similar questions. 
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Given the strong effect of the development of a cell barrier on nanoparticle uptake levels, 
other aspects could be further implemented to develop in vitro models that resemble more 
closely the endothelial cell barriers that nanomedicines encounter in vivo. For instance, 
improvements may include mimicking the extracellular matrix or adding myocytes and 
connective tissue, which are known to be fundamental in sustaining endothelial cells in vivo. 
The use of 3D cultures could further promote cell differentiation by allowing the formation 
of endothelial tubes.77 Similarly, the addition of a microfluidic system mimicking the blood 
flow and the resulting shear stress on the cells are also known to affect the expression of 
endothelial cell receptors.78 Nanoparticle-cell interactions and corona formation are also 
affected when nanoparticles are exposed to cells in flow conditions, as opposed to static 
cultures.55,79–83 Similar vessel-on a chip devices are being implemented84,85 and could 
provide useful insights in nanoparticle-cell studies, both for nanomedicine and nanosafety. 
Finally, here we also optimized protocols to use chemical inhibitors on the developed cell 
barriers and performed preliminary studies to try to characterize the mechanisms involved 
in the uptake. However, we found that preserving barrier integrity with these compounds 
is not always possible and overall only a partial reduction of uptake of 50 nm silica could be 
obtained in the compromised barriers. This may suggest that multiple pathways may be 
involved. However, clearly, other methods need to be developed and combined in order to 
be able to fully elucidate this and characterize how nanoparticles enter in similar endothelial 




Primary Human Umbilical Vein Endothelial Cells (HUVEC) from pooled donors (LONZA, 
Allendale, NJ, USA) were grown in standard cell culture flasks under standard conditions (37 
°C, 5% CO2) in Endothelial Basal Medium (EBM-2) supplemented with EGM-2 bullet kit 
(LONZA). All experiments were performed using cells from passage 2 to maximum 7 in order 
to limit cell senescence and loss of the primary cell characteristics. The medium was 
changed every 48 hours.  
Trans-Endothelial Electrical Resistance (TEER) 
Trans-Endothelial Electrical Resistance (TEER) measurements were performed in order to 
monitor the formation and integrity of the HUVEC cell barriers over time. HUVEC were 
seeded at a density of 3000 cells cm-2 or 50000 cells cm-2 on 12 mm Transwell® inserts 
(Corning, NY, USA) with a polycarbonate or polyester filter of 0.4 μm pore size. The filters 
were pre-coated with cold rat-tail collagen type-I (100 μg ml-1) (Corning, NY, USA ) for 1 hour 
at room temperature, washed three times with PBS and air-dried for 20 minutes before cell 
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seeding. As common in this kind of studies,41 in order to keep equivalent conditions for cell 
growth, the same procedure was followed to pre-coat also the plastic and glass substrates 
required for flow cytometry and fluorescence microscopy (see below). The basal and the 
apical chambers were both filled with cell culture medium pre-warmed at 37 °C (1.5 and 0.5 
ml respectively, for all experiments with Transwell inserts). In order to monitor the 
development of the cell barriers, the TEER was measured using an EndOhm-6 chamber and 
an EVOM2 Meter (World Precision Instruments, Sarasota, FL, USA) every day up to 10 days 
after seeding. The TEER values of a blank insert without cells (5-6 and 10-12 Ω for PC and PE 
filters, respectively) were subtracted from the obtained resistance values and the results 
were multiplied by the insert area (1.12 cm2) (thus the final values are expressed as Ω cm2). 
The measurement was performed on two inserts for each condition and was repeated at 
least two times for each insert. Results are the average and standard deviation over the two 
replicates. 
Para-cellular Permeability Assay 
In order to monitor cell barrier development, the leakage of a fluorescent probe (4 kDa FITC-
Dextran, Sigma-Aldrich St. Luis, USA) from the apical to the basal chamber of the Transwell® 
systems was monitored over time. Briefly, 3000 cells cm-2 or 50000 cells cm-2 were seeded 
on 12 mm Transwell® inserts as described above. FITC-Dextran (200 μg ml-1 in complete cell 
culture medium) was added to the apical chamber in Transwells with cells, as well as 
Transwells without cells (controls, CTRL) and the chambers were kept at 37 °C, 5% CO2. 
Every 20 minutes, 100 μl of medium was collected from the basal chamber and replaced 
with 100 μl of fresh medium for a total of 2 hours. The fluorescence intensity was measured 
immediately using a Gemini EM microplate spectrofluorometer (Molecular Devices, CA, 
USA) and the apparent permeability coefficient (Papp) of FITC-dextran was determined as 




          (1)  
where ∆Q ∆t-1 is the permeability rate (μg s-1), C is the initial concentration of FITC-dextran 
in the apical chamber (μg ml-1), and A is the surface area of permeable membrane inserts 
(cm2). Serial dilutions of FITC-dextran in complete EGM-2 medium (in the range 0 to 25 µg 
ml-1) were used to determine for each experiment a calibration curve of the fluorescence 
intensity as a function of concentration (see an example in Supplementary Figure S6). This 
was used to determine the transported mass ∆Q over the investigated time ∆t, taking into 
account the medium replacement in the basal chamber. Normalized data were obtained by 
dividing the Papp obtained on Transwells with cells with that obtained on Transwells without 
cells (100% Papp). 




Cell confluency and morphology were assessed regularly using light microscopy (Olympus 
IX50). Tight junction proteins were immunostained and their expression and distribution 
inside cells determined by confocal imaging. Briefly, 3000 cells cm-2 or 50000 cells cm-2 were 
seeded in a 24-well plate (Corning) on glass coverslips pre-coated with rat-tail Collagen 
Type-I as described above. At different days after seeding, cells were fixed with 
formaldehyde (4% v/v) solution for 15 minutes and permeabilized with Triton X-100 (0.1% 
v/v) for 5 minutes. Subsequently, cells were incubated with a polyclonal rabbit primary 
antibody against the tight junction protein ZO-1 (zonula occludens-1, Life technologies, NY, 
USA) and monoclonal mouse primary antibody against CD31 (cluster of differentiation 31, 
also known as PECAM1, platelet endothelial cell adhesion molecule, Dako, Glostrup, 
Denmark) for 1 hour at room temperature, followed by incubation in Alexa Fluor®488 goat 
anti-mouse (Life technologies, NY, USA) and Cy®5 goat anti-rabbit (Jackson Immuno 
Research Laboratories, Inc., PA, USA) secondary antibodies for 1 hour. The effect of 
nocodazole on microtubules was assessed by incubating samples with a mouse primary 
antibody against human α-Tubulin (Merck Millipore, Netherlands) for 1h followed by 
incubation with a Alexa Fluor®488 goat anti-mouse secondary antibody (Life technologies, 
NY, USA) for another hour. Efficacy of cytochalasin D on actin depolymerization was 
assessed by incubating samples with phalloidin conjugated with TRITC (Sigma-Aldrich St. 
Luis, USA), which stains F-actin selectively. After antibody incubation, cells were washed 3 
times with PBS. Nuclear staining was performed by incubating cells for 5 minutes with DAPI 
(4',6-diamidino-2-phenylindole). Subsequently, slides were mounted with Mowiol 4-88 
mounting medium (EMD Chemical, Inc., CA, USA). Images were taken using a Leica TCS SP8 
fluorescent confocal microscope (Leica Microsystems, Wetzlar, Germany) with a 405 nm 
laser for DAPI excitation, a 488 nm laser for Alexa Fluor®488, a 552 nm laser of TRITC and a 
638 nm laser for Cy5®. Images were processed using ImageJ software (http://www.fiji.sc). 
IMARIS V.7.6.4 software (Bitplane, St. Paul, MN) was used for 3D reconstructions of the z-
stack images and to generate the corresponding movie. In order to increase the visual clarity 
of the 3D images, the brightness and contrast of the tight junction protein channels (ZO-1 
and CD31) were adjusted. 
mRNA expression 
In order to determine the effect of barrier formation on cells, the expression levels of a 
series of genes coding for proteins known to be involved in different endocytic pathways 
were determined by RT-PCR using the primers listed in Table S1, Supplementary 
Information. HUVECs were seeded at a density of 3000 cells cm-2 and cultured for 3 or 7 
days as previously described. Additionally, to measure expression levels in confluent cells, 
cells were seeded at a density of 25000 cells cm-2 and cultured for 1 day. Then, total mRNA 
was isolated using an Invitrap® Spin Cell RNA Mini Kit (Stratec Molecular GmbH, Berlin, 
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Germany) according to the instruction provided by the manufacturer. Reverse transcription 
of mRNA (2 µg for both day 3 and day 7 cultures) into cDNA was performed using a Reverse 
Transcription System (Promega, Leiden, The Netherlands) in an Eppendorf Mastercycler 
gradient (the following cycle was used: 20 ˚C for 10 min, 42 ˚C for 30 min, 20 ˚C for 12 min, 
99 ˚C for 5 min and 20 ˚C for 5 min). The transcription levels were measured by quantitative 
real time PCR (SensiMix™ SYBR kit, Bioline, Taunton, MA) in a ABI7900HT sequence 
detection system (Applied Biosystems, Foster City, CA) from cDNA (20 ng per sample). The 
Ct values were obtained using a SDS 2.4 software (Applied Biosystems). For each target, 4 
replicate wells were prepared and the average Ct value and its standard deviation were 
calculated. Results are expressed as fold-change of the averaged Ct values of day 7 samples 
(Ct7) related to Ct values of control day 3 samples (Ct3) as follows: 
Fold change = 2−(Mean Ct7−Mean Ct3)       (2) 
The same formula was used to calculate the fold-change of Ct values of day 7 barriers 
related to Ct values of confluent cells. 
Nanoparticle characterization 
Red fluorescently labelled (Maximum excitation and emission wavelengths 569 and 585 nm 
respectively) silica nanoparticles (SiO2 nanoparticles) of 50 nm and 200 nm were purchased 
from Kisker Biotech (Steinfurt, Germany). Different batches (LOT numbers) of the same 
product were used among some of the different experiments presented. Fluorescently 
labelled red (580/605) and orange (540/560) carboxylated polystyrene nanoparticles (PS-
COOH nanoparticles) of 40 nm and 200 nm – respectively - were purchased from Invitrogen 
(Life Technologies, Carlsbad, CA, USA). In order to characterize the nanoparticle dispersions 
and monitor their stability throughout the duration of the experiments, nanoparticle size 
distributions were measured using Dynamic Light Scattering (DLS) with a Malvern Zetasizer 
Nano ZS. The same instrument was used also to measure zeta potential (ζ-potential). Briefly, 
nanoparticles (100 μg ml-1) were dispersed in PBS, dH2O or the cell culture medium (EBM-
2) supplemented with 4 mg ml-1 human serum (human serum from pooled donors, from TCS 
BioSciences Ltd Botolph Claydon, Buckingham, UK) at 20 ˚C and immediately measured, 
using disposable folded capillary cells (Malvern Instruments Ltd., Worcestershire, UK). 
Different batches of pooled human serum were used for some of the experiments 
presented. In order to monitor nanoparticle stability during exposure to cells, nanoparticles 
were incubated for 24 hours in complete culture medium in the same conditions as when 
exposed to cells (37 °C, 5 % CO2). Size measurements were averaged results from 5 runs of 
at least 3 measurements. 
Exposure to nanoparticles and flow cytometry analysis  
Cell fluorescence intensity was used as a measurement of nanoparticle uptake in HUVEC at 
different days after seeding and on the fully developed cell barriers. HUVEC were seeded in 
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24-well plates at a density of 3000 cells cm-2 and grown for 7 or 3 days, as described above. 
Additionally, cells were seeded at a density of 25000 cells cm-2 and cultured for 1 day. Then, 
HUVEC were exposed for different time periods to 50 nm red SiO2 (100 μg ml-1), 200 nm red 
SiO2 (200 μg ml-1), 40 nm red PS-COOH (2 μg ml-1) or 200 nm orange PS-COOH (3 μg ml-1). 
Given the different nanoparticle size, density and fluorescence, different mass 
concentrations were selected for each nanoparticle type in order to ensure good 
fluorescence signals in cells. Nanoparticles were dispersed at room temperature in cell 
culture medium containing human serum (human serum from pooled donors, from TCS 
BioSciences Ltd Botolph Claydon, Buckingham, UK). The final serum concentration was 4 mg 
ml-1, roughly corresponding to the protein concentration present in standard cell culture 
media prepared using 10% fetal bovine serum. Cells were exposed to the freshly made 
nanoparticle dispersions immediately after mixing, by replacement of the cell culture 
medium. In order to reduce variability due to the preparation of nanoparticle dispersions, 
cells were seeded and grown so that the same nanoparticle dispersion was used to incubate 
HUVEC which were grown for different days after seeding. After different exposure times, 
cells were washed with medium supplemented with FBS (10% v/v) and twice with PBS in 
order to remove nanoparticle excess and reduce the presence of eventual nanoparticles 
adhering outside the cell membrane. Thus cells were harvested using trypsin–EDTA (0.05% 
v/v). Cell fluorescence for nanoparticle experiments was recorded using a BD FACSArray (BD 
Biosciences, Erembodegem, Belgium) with a 532nm laser or – for the results in Figure 4c - 
using a Cytoflex Flow Cytometer (Beckman Coulter, Woerden, the Netherlands) with a 488 
nm laser. Data were analyzed using Flowjo® data analysis software (Flowjo, LLC). Double 
scatter forward and side scattering plots were used to set gates in order to exclude cell 
debris and cell doublets and select intact cells. For each experiment, a total of at least 15000 
cells were acquired per sample and each sample was performed in triplicate. The results in 
the Figures are expressed as the averaged median cell fluorescence intensity and standard 
deviation over the 3 replicates. At least 3 independent experiments were performed to 
confirm the results. 
Cell counting 
In order to determine the number of cells in confluent cultures and the optimized barriers, 
HUVEC were seeded in 24-well plates at a density of 3000 cells cm-2 and grown for 7 days, 
as described above. Additionally, cells were seeded at a density of 25000 or 50000 cells cm-
2 and cultured for 1 day. Then, cells were harvested using trypsin–EDTA (0.05% v/v) as 
described above and cell numbers were counted using a Neubauer hemocytometer or by 
flow cytometry, using a Cytoflex Flow Cytometer (Beckman Coulter, Woerden, the 
Netherland. The instrument allows to determine the number of cells in calibrated volumes). 
The results are the average and standard deviation over two replicate wells. 
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Studies with pharmacological inhibitors of endocytosis 
To investigate the role of different endocytic pathways and cellular structures in 
nanoparticle uptake in the cell barriers and confluent cells, cells were treated with 
pharmacological inhibitors and nanoparticle uptake in cells exposed to the different drugs 
was compared to that in untreated cells. Each inhibitor concentration was optimized in 
order to limit cell death during the experimental period and to maximize the drug efficacy. 
Briefly, 3000 cells cm-2 were seeded in a 24-well plate coated with rat-tail collagen type I 
and cultured for 7 days as described above in order to form cell barriers. Additionally, to 
study uptake mechanisms in confluent cells, cells were seeded at a density of 25000 cells 
cm-2 and cultured for 1 day. Then, cells were pre-incubated for 10 minutes in serum-free 
medium supplemented with the different inhibitors at the following concentrations: 
chlorpromazine hydrochloride (CP) (5 µg ml-1), methyl-β-cyclodextrin (MβCD) (2 mg ml-1), 
dynasore (Dyn) (30 μg ml-1) (all from Sigma-Aldrich St. Luis, USA), nocodazole (NZ) (5 µM) 
(Biovision, California, USA), cytochalasin D (CytoD) (0.5 µg ml-1) (Life technologies, NY, USA). 
Additional drug concentrations were tested for optimization of these protocols (as detailed 
in Supplementary Information, Figures S17 to S21). After the pre-incubation with the drug, 
50 nm red SiO2 nanoparticles dispersed in human serum (4 mg ml-1) where added to the 
cells in the presence of the drug. Alternatively, the uptake of fluorescently labelled 
endocytic markers was used as a control of the efficacy of the drugs. Fluorescently labelled 
Low Density Lipoprotein (BODIPY LDL, Life technologies, NY, USA) (2 µg ml-1 in serum free 
medium) was used as a marker for clathrin-mediated endocytosis. Uptake of BODIPY 
lactosylceramide/BSA complex (BODIPY LacCer; Life technologies, NY, USA) (1 µg ml-1 in 
serum free medium) was measured to verify the effect of cholesterol depletion. Samples 
were collected and prepared for flow cytometry as described above and the fluorescence 
intensity of at least 20000 cells was measured in triplicate for each time point using a 
Cytoflex Flow Cytometer (Beckman Coulter, Woerden, the Netherlands) with a 488 nm 
laser. Normalized uptake data were calculated by dividing the averaged median 
fluorescence of cells exposed to the nanoparticles or control markers in the presence of the 
inhibitors with the averaged median fluorescence of control cells exposed for the same time 
to the same nanoparticles or control markers without inhibitors. From the normalized 
uptake data, the percentage of reduction of uptake are calculated by subtraction (Uptake 
reduction % = 100% - normalized uptake %) 
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Supplementary Information  
Gene Forward (left) Reverse (right) 
CAV1 ACAGCCCAGGGAAACCTC GATGGGAACGGTGTAGAGATG 
CDC42 CATCGGAATATGTACCGACTGTT TGCAGTATCAAAAAGTCCAAGAGTA 
CLTC TGAGAAAAGAAGAAGAACAAGCTACA ACACTGGGTCCTGCTGTCA 
RHOA GGAGCTAGCCAAGATGAAGC GCCAATCCTGTTTGCCATA 
ARF6 TGAACACAAAGTTGCTAGATGCT TGCTGTGTTTCCCCCATC 
TFRC TGAAGAGAAAGTTGTCGGAGAAA CAGCCTCACGAGGGACATA 
DNM2 CATCAACACGAACCATGAGG CTTGTTCAGCTGCGTGCTC 
FLOT1 ATTCTAACTCGCCTGCCAGA GCATCTGTGAGGGCTGAAG  
LDLR GTGACAATGTCTCACCAAGCTC CACGCTACTGGGCTTCTTCT 
ARHGAP26 CAGGCACGGTCTTCGATAA GCCAGTCTTTCCGTTCAGAG 
RAC1 CTGATCAGTTACACAACCAATGC CATTGGCAGAATAATTGTCAAAGA 
ANKFY1 AAACTAGCAAATCGGTTTCAGC GAGACATAACACCCTTCTCACATC 
EPN1 GAGAGCAAGAGGGAGACTGG AAGACGTCAGCAAGGTCCAT 
 
Table S1. Primers used in this study for RT-qPCR. RT-qPCR was performed as described in the Experimental Section to 
determine the expression levels of some cell receptors (LDL and transferrin receptor), and a series of targets involved in 
different endocytic pathways. 
  




Figure S1. Effect of surface coating on cell growth. Representative light microscopy images of HUVEC plated at a 
concentration of 10000 cells cm-2 on 24 well plates uncoated (a) or coated with rat tail collagen Type-I (b). Scale bar 50 
µm. The presence of a collagen coating clearly improved cell adherence and cell growth.  
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Figure S2. HUVEC barrier formation from low cell density cultures. 3000 cells cm-2 HUVEC were plated on collagen coated 
glass coverslips and their growth was monitored for different days after seeding. Left: confocal images of HUVEC cells 
stained with anti-ZO-1 (red) or anti-CD31 (green) antibodies. Blue: DAPI stained nuclei (scale bar: 20 µm). Right: light 
microscopy images of the same cultures (scale bar: 50 µm). Tight junction staining showed barrier formation roughly 7 
days after cell seeding, then cells started to strongly overlap in multiple layers (as indicated by the white arrows) and areas 
with holes in the cell monolayer were observed, as a consequence of cell death.  




Figure S3. HUVEC barrier formation from high cell density cultures. 50000 cells cm-2 HUVEC were plated on collagen 
coated glass coverslips and their growth was monitored for different days after seeding. Left: confocal images of HUVEC 
cells stained with anti-ZO-1 (red) or anti-CD31 (green) antibodies. Blue: DAPI stained nuclei (scale bar: 20 µm). Right: light 
microscopy images of the same cultures (scale bar: 50 µm). Tight junction staining showed barrier formation roughly 4 
days after cell seeding, then cells started to overlap in multiple layers (as indicated by the white arrows) and areas with 
holes in the cell monolayer were observed, as a consequence of cell death.  
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Figure S4. Optimization of HUVEC barrier formation. HUVEC were seeded at two concentrations (3000 cells cm-2, (a) and 
(c) or 50000 cells cm-2, (b) and (d)) on Transwell® inserts made of polyester (PE) or polycarbonate (PC) and barrier 
formation was monitored for several days after seeding. a, b: Trans Epithelial Electrical Resistance (TEER) at different times 
after seeding. Results are the average TEER value and standard deviation obtained from two different inserts which were 
measured over time for the entire experimental period. c, d: Apparent permeability (Papp) of FITC-Dextran (4 kDa, 200 µg 
ml-1). The fluorescence intensity of FITC-Dextran in the basal chamber was used to calculate the apparent permeability as 
described in the Experimental Section. Results are the average value and standard deviation of 2 different inserts, 
normalized by the results obtained on Transwells without cells. Overall the results show that PE is a better substrate than 
PC for cell growth and barrier formation, and that seeding cells at lower density and waiting longer allowed HUVEC to 
develop into a cell barrier with high electrical resistance and a low permeability in about 7 days after seeding. 
  




Figure S5. Trans Epithelial Electrical Resistance (TEER) of HUVEC layers formed on polyester (PE) filters. 3000 cells cm-2. 
HUVEC were seeded on polyester Transwells as described in the Experimental Section and their TEER measured at the 
indicated times after seeding. Results are the average TEER value and standard deviation obtained from two different 
inserts which were measured over time for the entire experimental period. Even though in independent experiments the 
absolute TEER values were rather variable, the trend was consistent and in all cases, it showed a progressive increase of 
TEER at increasing days after seeding, with a peak reached 7-8 days after seeding, sign of barrier formation, followed by a 
progressive decrease as a consequence of cell death. 
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Figure S6. Integrity of HUVEC barriers formed from low cell density cultures. Representative light microscopy images 
before and after washing of HUVEC cell barriers formed from low cell density cultures, plated at a concentration of 3000 
cells cm-2 on 24 well plates and cultured for the indicated times (scale bar: 200 µm). Roughly 9 days after seeding, before 
washing the wells, many floating (dead) cells were clearly visible. Consecutively, after washing the wells, holes in the cell 
monolayer (as indicated by the white arrows) were visible. This overall indicated that in these conditions, roughly 9 days 
after cell seeding, barrier integrity was lost. 
  




Figure S7. Integrity of HUVEC barriers formed from high cell density cultures. Representative light microscopy images 
before and after washing of HUVEC cell barriers formed from high cell density cultures, plated at a concentration of 50000 
cells cm-2 on 24 well plates and cultured for the indicated times (scale bar: 200 µm). Roughly 8 days after seeding, before 
washing the wells, many floating (dead) cells were clearly visible. Consecutively, after washing the wells, holes in the cell 
monolayer (as indicated by the white arrows) were visible. This overall indicated that in these conditions, roughly 8 days 
after cell seeding, barrier integrity was lost. 
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Figure S8. Calibration curve for FITC-Dextran fluorescence. The fluorescence intensity of samples at increasing 
concentrations of 4 kDa FITC-Dextran was measured using a spectrofluorometer. Linear regression was used to obtain the 
relation between FITC-dextran concentration and fluorescence, from which the apparent permeability Papp was 
determined as described in the Experimental Section. A different calibration curve was made for each experiment (R2 
values ≥ 0.995 in all cases). 
  




Figure S9. Number of cells in HUVEC barriers and confluent cell cultures. HUVEC barriers and confluent cultures were 
prepared by seeding 3000 cells cm-2 (barrier) or 25000 cells cm-2 (confluent (a)), and cell numbers were counted 7 days 
(barrier) or 1 day (confluent) after seeding. Additionally, 50000 cells cm-2 (confluent (b)) were also seeded and cell 
numbers counted 1 day after seeding, as ulterior control. Cell numbers were counted using a hemocytometer (a) or by 
flow cytometry (b) as described in the Experimental Section. The results are the average and standard deviation of two 
replicate wells. The results confirmed that the optimized cell barriers and confluent cell cultures (confluent (a)) had 
comparable cell numbers. When the double of cells was seeded (confluent (b)), a double number of cells was counted 1 
day after seeding, further confirming accuracy in cell seeding and of the two methods used to count cell numbers. 
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Figure S10. Expression levels of genes coding for endocytic proteins in HUVEC barriers in comparison to confluent cell 
cultures. HUVEC were seeded at a density of 3000 cells cm-2 and cultured for seven days (barriers) or 25000 cells cm-2 
and cultured for one day (confluent cells). RT-qPCR was performed as described in the Experimental Section to determine 
the expression levels of genes coding for some cell receptors (LDL and transferrin receptors), and for a series of targets 
involved in clathrin mediated endocytosis (CME), caveolae-mediated endocytosis, macropinocytosis, and other clathrin 
and caveolae independent mechanisms (see also Supplementary Table S1 for details). Results are the average and 
standard deviation over 4 replicate wells of the fold-change in gene expression levels in HUVEC barriers compared to 
confluent cells. The results indicated that the gene expression of the selected endocytic targets in the cell barriers was 
lower than in confluent cells. 
  




Figure S11. Size distribution by intensity (diameter, d, nm) of 50 nm red SiO2 (a), 200 nm red SiO2 (b), 40 nm red PS-COOH 
(c) and 200 nm orange PS-COOH (d) as obtained by dynamic light scattering (DLS). Silica nanoparticles (100 µg ml-1) were 
dispersed in water, PBS, and EBM-2 supplemented with 4 mg ml-1 of human serum (HS EBM-2). For the 40 nm PS-COOH 
nanoparticles instead (c), in order to determine the size distribution at a nanoparticle to protein ratio closer to that used 
for cell experiments, 25 µg ml-1 nanoparticles were dispersed in EBM-2 supplemented with 50 mg ml-1 human serum. For 
the same reasons, the 200 nm PS-COOH nanoparticles (d) were dispersed to a final concentration of 36 µg ml-1 in EBM-2 
supplemented with 48 mg ml-1 human serum. Size distributions in HS EBM-2 were measured immediately, or after 24h of 
incubation of the dispersions at 37 ˚C, 5% CO2 (HS EBM-2 24h). The results showed that all dispersions remained stable 
for up to 24 hours in the conditions used for cell experiments. 
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Figure S12. Reproducibility of nanoparticle uptake levels in HUVEC barriers in independent experiments. Median cell 
fluorescence intensity as obtained by flow cytometry of HUVEC barriers (seven days after seeding 3000 cells cm-2) 
prepared in independent experiments (Exp 1-3) and exposed for increasing times to 100 µg ml-1 50 nm SiO2 nanoparticles 
dispersed in EBM-2 medium supplemented with 4 mg ml-1 human serum. (Exp 1 is from Figure 4f and Exp 2 is from Figure 
4l, while Exp 3 is an equivalent independent replica). In the three independent experiments, barriers were formed 
following the optimized protocols and were exposed to independent nanoparticle dispersions, prepared as described in 
the Experimental Section, using nanoparticles and human serum from the same batches. Results are the average and 
standard deviation over three replicates of the median cell fluorescence intensities. Overall the results show that when 
the same nanoparticle stock and human serum were used to prepare in independent experiments the nanoparticle 
dispersions, a very good reproducibility in nanoparticle uptake in the cell barriers was obtained. This indicated very good 
reproducibility of the barrier model, as also of the nanoparticle dispersions and all procedures for exposure to cells and 
measurement. 
  




Figure S13. Uptake and intracellular distribution of different nanoparticles in HUVEC barriers. HUVEC barriers (seven days 
after seeding 3000 cells cm-2) were exposed for 24 hours to 200 µg ml-1 200 nm SiO2 (a), 2 µg ml-1 40 nm PS-COOH (b) 
or 3 µg ml-1 200 nm PS-COOH (c) nanoparticles in EBM-2 medium supplemented with 4 mg ml-1 human serum. Red: 
nanoparticles, Green: LAMP-1, Grey: ZO-1, Blue: DAPI. Scale bar: 50 μm. 
  
 P a g e  | 197 
 
Chapter 6: Effect of the Development of a Cell Barrier 
on Nanoparticle Uptake in Endothelial Cells 
6 
Figure S14. Nanoparticle uptake levels in HUVEC barriers and subconfluent cultures. Median cell fluorescence intensity as 
obtained by flow cytometry of HUVEC exposed to different nanoparticles. HUVEC were grown for three (subconfluent) or 
seven (barrier) days after seeding (3000 cells cm-2) and exposed to 200 nm SiO2 (200 µg ml-1, a), 40 nm PS-COOH (2 µg 
ml-1, b) or 200 nm PS-COOH (3 µg ml-1, c) in EBM-2 medium supplemented with 4 mg ml-1 human serum for the indicated 
times. Results represent the average median and standard deviation of three replicates (for the 200 nm PS-COOH 
nanoparticles the far red fluorescence is plotted because the yellow fluorescence in subconfluent cells was out of scale 
due to the extremely high fluorescence intensity of these nanoparticles and high uptake levels). 
  




Figure S15. Nanoparticle uptake levels in HUVEC barriers and confluent cultures. Median cell fluorescence intensity as 
obtained by flow cytometry of HUVEC exposed to different nanoparticles. Confluent HUVEC (one day after seeding 25000 
cells cm-2) and HUVEC barriers (seven days after seeding 3000 cells cm-2) were exposed to 200 nm SiO2 (200 µg ml-1, a), 
40 nm PS-COOH (2 µg ml-1, b) or 200 nm PS-COOH (3 µg ml-1, c) in EBM-2 medium supplemented with 4 mg ml-1 human 
serum for the indicated times. Results represent the average median and standard deviation of three replicates. 
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Figure S16. Efficacy of silencing in HUVEC. Uptake of transferrin in HUVEC transfected with siRNA to block the expression 
of the transferrin receptor (TFRC) and of other targets involved in clathrin mediated endocytosis (CME). 25000 cells cm-2 
HUVEC were seeded and grown for 24h.  Silencing was performed following manufacturer’s instructions, using a fixed 
amount of TFRC siRNA and of oligofectamine transfection reagent (1x corresponding to 10 pmol siRNA and 1µl 
oligofectamine per well) for 24, 48 or 72h (a) or with increasing amounts of TFRC siRNA and transfection reagent (1x: 10 
pmol siRNA and 1µl oligofectamine; 2x: 20 pmol siRNA and 2µl oligofectamine; 3x: 30 pmol siRNA and 3µl oligofectamine) 
for 72 hours (b) Silencing was also performed on other CME targets for 48h with a fixed amount of siRNA and transfection 
reagent (2x: 20 pmol siRNA and 2µl oligofectamine) (c). Cells exposed to a negative siRNA in the same conditions were 
used as control. After silencing, cells were exposed to 15 µg ml-1 red fluorescent transferrin (TFR) in serum free medium 
for 10 minutes and their fluorescence measured by flow cytometry. The results are the averaged median intensity and 
standard deviation over three replicates, normalized by the results in control cells. In all cases transferrin uptake was 
reduced to a maximum of 50-60% in cells silenced for TFR in comparison to control cells, while up to 90% reduction can 
be obtained with the same method in cancer cells such as HeLa (data not shown). TFR uptake was barely affected in cells 
silenced for CME targets. This indicated low silencing efficacy in primary cells, in agreement with results in literature. 
  




Figure S17. Optimization of chlorpromazine (CP) dose on HUVEC barriers. HUVEC barriers (seven days after seeding 3000 
cells cm-2) were exposed to 1 or 5 µg ml-1 CP. Efficacy of CP (a) and effect of CP on nanoparticle uptake (b) were assessed 
by measuring the uptake of 2 µg ml-1 BODIPY LDL and 100 µg ml-1 50 nm red SiO2 nanoparticles in EBM2 supplemented 
with 4 mg ml-1 human serum, respectively, for the indicated doses and times in the presence or absence of CP. Results 
are the average and standard deviation of three replicates. Light microscopy images of HUVEC barriers (c) were taken to 
monitor the effect of CP on HUVEC barrier integrity after exposure for the indicated times to the different CP doses (scale 
bar: 100 µm). The results showed that in all conditions tested, exposure to CP resulted in loss of barrier integrity. 
Furthermore, at the lower dose tested, CP efficacy in blocking LDL uptake was minimal. Thus, 5 µg ml-1 CP was selected 
for further experiments on cell barriers, to ensure at least a partial inhibition, even if this dose led inevitably to loss of 
barrier integrity. 
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Figure S18. Optimization of nocodazole (NZ) dose on HUVEC barriers. HUVEC barriers (seven days after seeding 3000 cells 
cm-2) were exposed to 5 or 10 µM NZ. (a) Confocal images after staining the cells with fluorescent antibodies against 
tubulin were taken on untreated control barriers (Ctrl) and barriers exposed to the different doses of NZ for the indicate 
times (scale bar: 50 µm). Light microscopy images of HUVEC barriers (b) were taken after exposure for the indicated times 
to the different NZ doses to monitor the effect on HUVEC barrier integrity (scale bar: 100 µm). The results showed that 
even at the lower dose tested, exposure to NZ led to loss of barrier integrity. It is likely that loss of microtubules as induced 
by this compound leads inevitably to loss of barrier integrity (the tested doses are already much lower than what usually 
applied for this kind of compounds).36 
  




Figure S19. Optimization of cytochalasin D (CytoD) dose on HUVEC barriers. HUVEC barriers (seven days after seeding 3000 
cells cm-2) were exposed to 0.5 or 1 µg ml-1 CytoD. (a) Confocal images after actin staining (performed as described in the 
Experimental Section) were taken on untreated control barriers (Ctrl) and barriers exposed to the different doses of CytoD 
for the indicated times (scale bar: 50 µm). Light microscopy images of HUVEC barriers (b) were taken after exposure for 
the indicated times to the different CytoD doses to show the effect on HUVEC barrier integrity (scale bar: 100 µm). The 
results showed that even at the lower dose tested, exposure to CytoD led to loss of barrier integrity. It is likely that loss of 
actin as induced by this compound leads inevitably to loss of barrier integrity (the tested doses are already much lower 
than what usually applied for this kind of compounds).36 
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Figure S20. Optimization of methyl-β-cyclodextrin (MBCD) dose on HUVEC barriers. HUVEC barriers (seven days after 
seeding 3000 cells cm-2) were exposed to 1 or 2 mg ml-1 MBCD. Efficacy of MBCD (a) was assessed by measuring the 
uptake of 1 µg ml-1 BODIPY LacCer for the indicated doses and times in the presence or absence of MBCD. Results are the 
average and standard deviation of three replicates. Light microscopy images of HUVEC barriers (b) were taken after 
exposure for the indicated times to the different MBCD doses to monitor the effect on HUVEC barrier integrity (scale bar: 
100 µm). The results showed that in all conditions tested MBCD efficacy in blocking LacCer uptake was optimal, and barrier 
integrity was maintained. 
  




Figure S21. Optimization of dynasore (Dyn) dose on HUVEC barriers. HUVEC barriers (seven days after seeding 3000 cells 
cm-2) were exposed to 30 or 40 µg ml-1 Dyn. Efficacy of Dyn (a) and effect of Dyn on nanoparticle uptake (b) were assessed 
by measuring the uptake of 2 µg ml-1 BODIPY LDL and 100 µg ml-1 50 nm red SiO2 nanoparticles in EBM2 supplemented 
with 4 mg ml-1 human serum, respectively, in the presence or absence of Dyn. Results are the average and standard 
deviation of three replicates. Light microscopy images of HUVEC barriers (c) were taken after exposure for the indicated 
times to the different Dyn doses to monitor the effect on HUVEC barrier integrity (scale bar: 100 µm). The results showed 
that in all conditions tested Dyn efficacy in blocking LDL uptake was high, and barrier integrity was maintained. 
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Figure S22. Normalized uptake levels in HUVEC barriers exposed to different inhibitors. The same data of Figure 4 are 
shown here after normalization for the uptake in control cells without inhibitors. HUVEC barriers (seven days after seeding 
3000 cells cm-2) were exposed to 5 µg ml-1 chlorpromazine (CP) (a and b), 5 µM nocodazole (NZ) (c), 0.5 µg ml-1 
cytochalasin D (CytoD) (d), 2 mg ml-1 methyl-β-cyclodextrin (MBCD) (e and f), or 30 µg ml-1 dynasore (Dyn) (g and h). Left 
panels (a, e and g):  uptake by flow cytometry of 2 µg ml-1 BODIPY LDL (a and g), and 1 µg ml-1 of BODIPY LacCer (e) in 
control cells (Ctrl) and cells exposed to chlorpromazine, dynasore and MβCD respectively, as a control for drug efficacy. 
Right panels (b, d, f and h) and c: effect of the drugs on nanoparticle uptake. HUVEC barriers were exposed to 100 µg ml-
1 50 nm red SiO2 nanoparticles in EBM-2 supplemented with 4 mg ml-1 human serum for the indicated times in the 
presence or absence of the different drugs. The results are the average and standard deviation of three replicates, 
normalized by the uptake in control cells without inhibitors. 
  




Figure S23. Uptake mechanisms in confluent HUVEC cells. Confluent HUVEC cells (one day after seeding 25000 cells cm-2) 
were exposed to 5 µg ml-1 chlorpromazine (CP) (a-c), 5 µM nocodazole (NZ) (d-f), 0.5 µg ml-1 cytochalasin D (CytoD) (g-i), 
2 mg ml-1 methyl-β-cyclodextrin (MBCD) (j-l), or 30 µg ml-1 dynasore (Dyn) (m-o). Left panels: light microscopy images of 
confluent HUVEC cell morphology after exposure to each inhibitor (scale bar: 100 µm). Middle panels: effect of the 
inhibitors on nanoparticle uptake. Confluent HUVEC cells were exposed to 100 µg ml-1 50 nm SiO2 nanoparticles in EBM-
2 supplemented with 4 mg ml-1 human serum for the indicated times in the presence or absence (Ctrl) of the different 
inhibitors. Results are the average and standard deviation of three replicates. Right panels: the same nanoparticle uptake 








Chapter 7. General Discussion and Future 
Perspectives  
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Nano-sized materials are promising drug carriers, thanks to their ability to exploit cellular 
mechanisms to be internalized by cells and their improved biodistribution compared to 
conventional drugs.1–6  While several nanomedicines are already present in the clinic, it is 
recognized that a better understanding of the processes by which these drug delivery 
systems interact with the body and are internalized and trafficked by cells could contribute 
to advance further their success in the field.7–9 This thesis is a first step towards the attempt 
to clarify several aspects related to the recognition of nanomaterials by cells and to the 
endocytic mechanisms that are involved in their uptake.  
In particular, within a series of nanoparticles tested during my work (many more results 
were generated than those summarised in this thesis), I focused my investigation mainly on 
the in vitro study of 50 nm silica nanoparticles. These nanoparticles were selected because 
they constitute a model nanomaterial for which several aspects are already established.10,11 
In fact, silica nanoparticles are stable in complex biological media and therefore easy to 
study, and extensive information on their corona properties is already available.12 For 
instance, it has been shown that silica nanoparticles can form a corona that is specifically 
recognized by cell receptors, such as the LDLR, as I also studied and further expanded here 
(Chapter 5).13 This was found to be a crucial aspect to take into account for the 
characterization of the uptake mechanisms of nanomaterials by cells: in fact, during my 
investigation I could observe the involvement of certain molecular players only when a 
complex biological corona was formed and the LDLR receptor was engaged (Chapter 5, 
Figure 2 and Supplementary Figure S4). With other materials tested, such as carboxylated 
polystyrene nanoparticles, or with other exposure conditions for which the LDLR was not 
involved in the nanoparticle internalization, none of the molecular targets investigated gave 
a substantial contribution to the uptake. In these cases, only energy depletion confirmed 
the involvement of energy-dependent processes (data not shown). It would be interesting 
to understand better how different materials can play such a difference in nanoparticle 
recognition and to characterize the uptake mechanisms also in all those cases where only 
energy depletion seems to reduce the uptake. We should also consider, of course, that 
many other receptors other than the LDLR could be involved as well, and more studies are 
needed in order to identify them. Given the ambitious aims, starting from such a similar 
model system allowed me to gain first important insights into the mechanisms of 
nanomaterial uptake into cells, as I further summarise here.  
Overall, the investigation of the uptake of nanomedicines turned out to be particularly 
complex, even if many studies already explored this issue. In fact, there is still not a 
consensus on which cellular mechanisms drive the internalization of nanomedicines. The 
difficulties in the study of the uptake mechanisms of nanomaterials arise also from the fact 
that endocytosis represents a complex cellular process per se, with many molecules, 
feedback loops and signalling cascades involved. The endocytosis field is in continuous 
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evolution  and many processes and molecular details are still unknown. An overview of 
some of the pathways described is shown in Figure 1. In order to give a wider perspective 
on the endocytic mechanisms involved in the uptake of nanomedicines, in Chapter 2 I 
presented a detailed overview of the latest literature in the endocytosis field and I 
highlighted the importance of taking into account these recent findings in the study of the 
uptake of nanomedicines. 
 
Figure 1: Schematic representation of the most commonly described mechanisms of endocytosis. Red circles represent 
dynamin, while red lines indicate actin filaments. Reproduced from: Clathrin-independent pathways of endocytosis. Cold 
Spring Harbor perspectives in biology (2014).14 
Another aspect to take into account is that most classic approaches for the study of the 
endocytosis of nanomedicines (but also of proteins, toxins and any other cargoes) are based 
on methods to perturb the pathways of endocytosis. For instance, pharmacological 
inhibitors, RNA interference (RNAi) and gene editing approaches are used to knock down or 
transiently block the expression of key endocytic players. All these strategies provide a 
series of advantages and limits, as discussed extensively in Chapter 1.15,16 Among the others, 
the perturbation of a certain pathway or molecule might lead to compensation by another 
pathway or by another molecular player. For these reasons, I have stressed the importance 
to have proper controls to verify the effect of the selected treatment on the pathway of 
interest and exclude potential side effects. For example, in my study I have used 
fluorescently labelled low density lipoprotein (LDL) and transferrin (TF) as markers for 
clathrin-mediated endocytosis, dextran as a fluid phase marker for phagocytosis and for the 
CLEE/GEEC pathway, LacCer for cholesterol-dependent uptake. Moreover, thanks to recent 
findings that link the uptake of silica nanoparticles to the interaction between corona 
components and the LDLR,13 I have been able to use the LDLR expression as a further 
control. In fact, while performing RNAi on different molecular players of endocytosis 
(Chapter 5), I have tested whether the LDLR expression was altered before drawing any 
conclusion on the involvement of these targets in the uptake of the silica nanoparticles.  
As a first example of the difficulties associated with the characterization of uptake 
mechanisms, in Chapter 3 I extensively illustrated the challenges connected to the use of 
pharmacological inhibitors and their limits for the study of nanomedicine uptake. Even after 
an extensive optimization, a certain degree of variability between replicate experiments 
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could be observed when using these drugs, in particular when the effects of the inhibition 
on silica uptake were not particularly strong. This can be explained by the toxic effects that 
these compounds have on cells even for optimized conditions, or by other variables across 
experiments which are more difficult to control, such as small variations in the number of 
plated cells, in local cell density or in the nanoparticle dispersion. Because of the variability 
observed, I consider important to set relatively high thresholds on the inhibitory effect of 
certain treatments before drawing any conclusion on the mechanisms involved in the 
uptake. Based on the results obtained, I suggested a threshold of at least 40% inhibition, 
since a smaller decrease might just reflect an intrinsic sample variation. A further 
complication in the use of these inhibitors highlighted by this study is constituted by the 
fact that nanoparticle uptake must be performed in the presence of serum in order to allow 
corona formation, as it happens in biological contexts. As well established in the field, serum 
proteins or other biomolecules adsorb on nanomaterial surface once applied to a biological 
environment, forming a corona that gives them a new biological identity.17 While this 
phenomenon has to be taken into account when evaluating nanomedicine behaviour, the 
efficacy of some inhibitors (dynasore and methyl beta cyclodextrin) was fully lost in the 
presence of serum in situ, likely due to the interference of biomolecules with the drug. 
Further increasing drug concentrations mainly increased their cellular toxicity. Overall, the 
results obtained with these inhibitors and in the presence of serum in situ allowed us to 
draw only partial conclusions on the mechanisms of uptake. More in detail, perhaps the 
only clear results obtained are those with cytochalasin D, which point towards an actin 
driven mechanism (as summarised here again in Figure 2), and with nocodazole, which 
indicates the involvement of microtubules. The results obtained with EIPA suggest that 
macropinocytosis may be involved just at longer exposure times. Instead, the results 
obtained with chlorpromazine seem to exclude clathrin mediated endocytosis, even if other 
works in literature consider this mechanism as one of the main pathways involved in the 
uptake of nanoparticles smaller than 100 nm.6 Definitely, further studies using compounds 
not sensitive to the presence of proteins and the combination of different methods to 
characterize uptake pathways are required to draw conclusions on the endocytic 
mechanisms of nanomedicines.  
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Figure 2: Uptake in cells exposed to cytochalasin D for actin depolymerization. HeLa cells were exposed to different 
concentrations of Cytochalasin D (CytoD). A) Fluorescence (scale bar: 50 μm) and light microscopy images (scale bar: 150 
μm) of HeLa cells exposed for different times to 2,5 μg/ml CytoD, used as a control of drug efficacy; green: actin staining 
by TRITC-Phalloidin, and blue: DAPI stained nuclei.  B) Uptake by flow cytometry of 100 μg/ml red silica nanoparticles in 
cMEM in control cells (Ctrl) and cells exposed to 2,5 μg/ml CytoD; C) Viability by MTT test of HeLa cells exposed for 4 h to 
different doses of CytoD in cMEM. The viability data are normalized by results obtained in control cells without CytoD. 
Positive control (ctrl +) performed as described in the Methods. Flow cytometry data represent the average and standard 
deviation over 3 replicates of the median fluorescence intensity of at least 20000 cells. 
An alternative to avoid the interference of serum biomolecules on drug efficacy, while still 
characterize the uptake of nanomedicines with their corona, is to isolate the nanoparticle-
corona complexes and incubate them on cells in serum-free media, as done in Chapters 4 
and 5. Serum proteins not only interfere with the aforementioned compound activity, but 
they could also compete for the same cell receptors recognized by corona biomolecules 
adsorbed on nanoparticle surface. For the same reason, most studies of uptake pathways 
are performed by adding the labelled protein of interest to cells in serum free conditions, 
in order to avoid competition of free serum molecules, for instance when ligands such as 
the low-density lipoprotein (LDL) or transferrin (TF) are used to study the respective 
receptors in clathrin mediated endocytosis.18 Similarly here, when labelled LDL was 
incubated on cells in a medium containing serum (4 mg/ml), its uptake was reduced 
compared to when it was incubated in serum-free medium, due to the presence of 
unlabelled LDL in the serum that could compete for the binding to LDLR (Figure S3A, Chapter 
3). My results have also demonstrated a similar effect for the uptake of silica nanoparticles 
in conditions where the LDLR is involved (Figure 2, Chapter 4). In fact, when nanoparticles 
are incubated with proteins in situ, their uptake resulted to be very low. However, when 
the corresponding corona-nanoparticle complexes were isolated and then incubated on 
cells in serum-free medium, their uptake was higher (here showed again in Figure 3). 
 
Figure 3: Uptake kinetics of silica nanoparticles dispersed in different amounts of human serum. 100 µg/ml NPs was 
dispersed in low (LS) or high (HS) amount of human serum and incubated immediately on cells. Alternatively, 300 µg/ml 
nanoparticles was incubated in MEM supplemented with 12 mg/ml (LC) or 62mg/ml (HC) of human serum, isolated as 
described in Materials and Methods and incubated on HeLa cells at a final nanoparticle concentration of 100 µg/ml. Results 
represent one single experiment with 20000 event recorded by flow cytometry for each time point. Error bars are the 
standard deviation of biological triplicates. 
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In light of this, in order to be able to use compounds sensitive to the presence of serum, 
such as dynasore and methyl beta cyclodextrin, and in order to monitor the uptake kinetics 
of nanoparticles without the additional interference of free serum proteins, in Chatpers 4 
and 5 I have used isolated corona-nanoparticle complexes and incubated them in serum-
free medium on cells. 
With these premises, in Chapters 4 and 5 the mechanisms of nanomedicine recognition and 
uptake were studied with a special attention to the environment in which nanomedicines 
were dispersed and the resulting corona.17 As extensively discussed, the biomolecular 
corona and its composition can affect nanoparticle biodistribution and can alter their 
cellular recognition and uptake by cells.11–13,19–21 However, in literature there are many 
examples in which the uptake mechanisms of nanomedicines are studied in serum-free 
conditions or in normal cell culture media, such as media supplemented with foetal bovine 
serum, at concentrations which are pretty far from physiological ones. In Chapter 4 I 
explicitly studied to what extent the corona composition affects the mechanisms of uptake 
of nanomedicines by studying the uptake pathways of the same nanoparticles added to cells  
at different serum concentrations, such as standard in vitro serum content in cell media, 
and physiological serum concentration. My results clearly showed that certain pathways, 
such as clathrin mediated endocytosis, macropinocytosis and cholesterol-dependent 
pathways, were involved in the uptake just when low concentrations of serum were used 
(see Figure 4, Chapter 4). The same pathways were little or not at all involved in the uptake 
of the same nanomaterials when exposed to serum at more physiological concentrations. 
Similarly, in Chapter 5 I showed that also the recognition between the LDLR and the corona 
of silica nanoparticles, already demonstrated elsewhere,13 depends on the amount and 
composition of the serum used to form the corona (as shown again here in Figure 4). More 
specifically, the LDLR was not involved in the uptake of silica when low amounts of serum 
were used. It is important to stress that mass spectrometry in Chapter 4 confirmed the 
presence of apoB100 – a major ligand of LDLR - in the corona on silica nanoparticles in both 
serum conditions tested. This suggests that the presence of a certain protein in the corona, 
alone, does not imply its recognition by corresponding receptors.  A possible interpretation 
of this observation is that multiple proteins act in concert to engage with a specific receptor 
or that the availability of specific proteins for receptor binding depends also on the 
interactions of different biomolecules present on the surface of nanomaterials among 
them. More studies are needed to elucidate such aspects.  
Overall, these findings clearly highlight the importance of having a proper corona to engage 
with specific cellular receptors. For this reason, it remains to be defined how conclusions 
drawn from studies performed in serum free conditions or at serum concentrations far from 
physiological ones can be translated to in vivo conditions.  
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Another interesting aspect confirmed in my studies is that the relative abundance of 
proteins was different in corona formed in low and high serum amounts. In particular, 
apolipoprotein A-I was almost three times more abundant in the corona formed at low 
amount of serum, and apolipoprotein A-II almost two times, compared to the amount in 
the corona formed at high amount of serum. The opposite happened for the histidine-rich 
glycoprotein. Interestingly, a study on macrophages proposed that the presence of 
histidine-rich glycoprotein in the corona is associated to decreased uptake,22 which is in line 
to what observed in Chapter 4. This further suggests that the specific composition of the 
corona adsorbed on the nanoparticle surface can influence nanoparticle internalization. 
Further investigations will be necessary to understand the role of individual corona 
components in the different uptake mechanisms observed, as also the different uptake 
efficiency.  
 
Figure 4: Uptake of silica nanoparticles in LDLR silenced HeLa cells in different media. 100 μg/ml 50 nm silica nanoparticles 
were dispersed in situ in human serum (HS) or human delipidised serum (HSD) at a concentration of 4 mg/ml (low) or 20 
mg/ml (high) and incubated for 24h on HeLa cells silenced for the LDLR. Alternatively, 300 μg/ml 50 nm silica nanoparticles 
were dispersed in human serum (HS) or human delipidised serum (HSD) at a concentration of 12 mg/ml (LC) or 62 mg/ml 
(HC). The formed nanoparticle-corona complexes were then isolated and incubated at a final concentration of 100 μg/ml 
of nanoparticles for 24h on HeLa cells silenced for the LDLR. Data are expressed as percentage of control (cells silenced 
with a scramble siRNA). Both controls and samples were incubated with the same dispersion of nanoparticles. Error bars 
are the SD or three samples. 
Another interesting observation arising from the results presented in Chapter 4 and 5 is the 
potential involvement of multiple mechanisms at the same time. More specifically, the 
results presented in Chapter 4 (and summarised here again in Figure 5) suggested that the 
same nanoparticles enter cells via different mechanisms when coated by a different corona. 
At higher serum amount the uptake was partially dependent on dynamin, 
macropinocytosis, actin and microtubules, however with effects never stronger than a 40% 
uptake reduction. On the other hand, clearly clathrin mediated endocytosis and cholesterol 
didn’t appear to be involved in these conditions. Further investigations by RNAi in Chapter 
5 revealed that several classical endocytic players were involved, at least partially, in the 
uptake of silica in high serum content (Figure 2, Chapter 5): EPN1, involved in clathrin 
mediated endocytosis, CAV1 and FLOT1, involved respectively in caveolae and flotillin-
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mediated endocytosis, ARF6, CDC42 and RHOA, three GTPases involved in many pathways, 
RAC1 and ANKFY1, involved mainly in macropinocytosis (for further details on these targets, 
see Chapter 2). However, given that the silencing of RAC1 induced an upregulation of the 
LDLR, we have excluded this target from our conclusions. Importantly, my results clearly 
indicated that clathrin mediated endocytosis was not contributing to nanoparticle uptake, 
despite the LDLR is usually internalized by CME (see always Figure 2, Chapter 5).23 Few 
reports so far have highlighted that other pathways for LDLR internalization are possible, 
such as macropinocytosis, caveolae-mediated endocytosis or others, but mainly in cell types 
other than the HeLa cells used here.23–26 Therefore my results may suggest either that the 
LDLR-dependent uptake of nanoparticles is mediated by (perhaps several) pathways other 
than CME in HeLa cells, or that at least some of the nanoparticles are internalized trough 
pathways not mediated by the LDLR. Another possible interpretation of these results is that 
these nano-sized materials can trigger their internalization using less canonical or novel 
routes.  
Figure 5: Uptake mechanisms of silica nanoparticles in low and high amount of serum. 300 µg/ml nanoparticles was 
incubated in MEM supplemented with 12 mg/ml (LC) or 62mg/ml (HC) of human serum, isolated as described in Materials 
and Methods. Then samples were incubated on HeLa cells at a final nanoparticle concentration of 100 µg/ml in the 
presence or absence of 100µM EIPA, 10 µg/ml chlorpromazine, 2.5 mg/ml methyl-β-cyclodextrin (MβCD), 25 μg/ml 
dynasore, 2.5 µg/ml cytochalasin D or 5 µM nocodazole. Data are normalized for the fluorescence intensity of untreated 
cells. The results are the average of three independent experiments and error bars show the SD 
Within this context, in Chapter 5 I selected a panel of endocytic targets rarely investigated 
in this type of studies to study their potential involvement in nanoparticle uptake. In fact, 
in recent years research in endocytosis has been focused on several non-canonical clathrin 
independent pathways. These pathways are more difficult to observe and study, but might 
as well constitute a possible route of internalization for nanomedicines. In particular, in vitro 
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studies of nanoparticle-membrane interactions have shown that nanomaterials can induce 
several changes when interacting with lipid membranes, for example by inducing 
membrane deformation and bending.27,28 Most endocytic mechanisms utilize, among their 
regulators, a class of proteins containing domains with curved topologies (BAR domains), 
specialized in the recognition and induction of membrane curvature.29–31 Few studies 
however have focused so far on the molecular details required for membrane bending 
generation and vesicle formation in the uptake of nano-sized materials.27,28 Thus in Chapter 
5, I explored the possibility that nanomedicines can induce membrane bending and trigger 
their internalization by the recognition and induction of membrane curvature mediated by 
BAR-domain proteins.  
Interestingly, silencing the expression of several of the selected BAR domain proteins, 
among which BIN1, IST1, PACSIN2, did cause a marked reduction of silica nanoparticle 
uptake, up to 50% compared to controls (Figure 3, Chapter 5 and here again in Figure 6), 
thus stronger or comparable to the effects of some of the other (more classic) targets 
investigated. While this is just a first observation, these results clearly point towards an 
important role of curvature generation mechanisms in the uptake of nano-sized cargoes. 
 
Figure 6: Uptake of silica nanoparticle-corona complexes mediated by curvature proteins in HeLa cells. HeLa were 
transfected with the siRNA indicated. After 72 hours, 300 μg/ml silica nanoparticles were incubated for 1 hour at 37˚C in 
60 mg/ml human serum, centrifuged for 1h and the pellet was resuspended in serum free MEM. 100 μg/ml of 
nanoparticle-corona complexes were then incubated on HeLa cells for 14 hours, then cell fluorescence intensity was 
measure by flow cytometry. Data represent the average of 2 independent experiments and error bars represent the SD.  
Finally, while in all the Chapters described so far I have used mainly HeLa cells as a standard 
model cell line for the investigation of the uptake mechanisms of nanomedicines, in Chapter 
6 I studied whether organized cell layers may constitute in vitro models that better reflect 
some characteristics of the barriers nanomedicines encounter in vivo.6,7,16,32 Endothelial 
cells constitute undoubtedly one of the very first barriers that nanomedicines need to 
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overcome in order to reach the targeted organ following administration into the blood 
stream.33,34 Thus, in Chapter 6 I have studied the effect of cellular organization into a barrier 
in the uptake of silica nanoparticles. After an extensive optimization of the conditions to 
grow a HUVEC (Human Umbilical Vein Endothelial Cells) barrier in vitro, I could determine 
that the organization of cells interconnected by tight junction into to form a  barrier resulted 
into lower expression of different endocytic markers and affected the interactions of 
nanoparticle with cells. In particular, HUVEC barriers showed lower uptake compared to 
sub-confluent and confluent HUVECs. These results also indicated that confluency alone 
does not guarantee the development of a cell barrier with proper tight junctions .  Next to 
this first important outcome, in Chapter 6 I have also tried to study the endocytic 
mechanisms involved in the uptake of nanomaterials in these cell barriers. However, the 
transport inhibitors used for this purpose, in most cases, caused a loss of barrier integrity 
and therefore were not suited for this model system. This is another challenge in 
characterizing uptake mechanisms. Different techniques should be developed and 
optimized on similar cell barriers to be able to address this question.  
Given the strong effect of the development of a cell barrier on nanoparticle uptake levels, 
other aspects could be further implemented to develop in vitro models that resemble more 
closely the real complexity of endothelial cell barriers that nanomedicines encounter in vivo. 
This could be achieved, for instance, by mimicking the extracellular matrix or adding 
myocytes and connective tissue, which are known to be fundamental in sustaining 
endothelial cells in vivo, or using 3D cultures to further promote cell differentiation by 
allowing the formation of endothelial tubes.35 Similarly, the addition of a microfluidic 
system mimicking the blood flow and the resulting shear stress on the cells are also known 
to affect the expression of endothelial cell receptors,36 and all these factors can also affect 
nanoparticle uptake.37–42  
In conclusion, this project aimed at providing the basis for a more rational design of 
nanomedicines by studying in more detail how nanomaterials interact with cells. In 
particular, this thesis is a first step towards a more detailed description of the molecular 
mechanisms leading to the cellular interaction and internalization of nanomaterials. The 
results obtained open up the possibility that other mechanisms, beside the most classical 
ones, might be involved, with an important role for the mechanisms of membrane curvature 
generation for the uptake of nano-sized cargoes, such as nanomedicines. Further studies 
are needed to continue in this direction and elucidate the precise pathways and regulators 
of internalization, as well as to determine whether and how some of the findings 
summarised here translate to different cells, different nanoparticles and different exposure 
(corona) conditions.  
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Nederlandse Samenvatting 
Materialen in de nano schaal zijn veelbelovende geneesmiddel dragers, voornamelijk 
doordat ze cellulaire mechanismen kunnen gebruiken om op genomen te worden en door 
hun verbeterde distributie in het lichaam.1–6 Hoewel er al meerdere nano-medicijnen op de 
markt zijn, is het algemeen geaccepteerd dat een beter begrip over de interactie tussen 
nano-medicijnen en het lichaam, zoals hoe ze worden opgenomen en hoe transport in 
cellen plaats vindt, het veld kan bevorderen. 7–9 Deze scriptie is een eerste stap naar het 
verduidelijken van verschillende aspecten gerelateerd aan het herkennen van materialen 
op de nano schaal door cellen en de endocytose en exocytose mechanismen die hierin een 
rol spelen. 
Tijdens mijn werk heb ik me voornamelijk verdiept in de in vitro studie van 50 nm silica 
nano-deeltjes, een model waarvan verschillende aspecten al bekend zijn. 10,11 Silica nano-
deeltjes zijn stabiel in het complexe biologische medium en zijn daardoor makkelijk te 
bestuderen, en uitgebreide informatie over hun corona eigenschappen is al bekend.12 
Bijvoorbeeld, het is bekend dat deze deeltjes een corona kunnen vormen die specifiek 
herkend wordt door cel receptoren, zoals de LDLR (Low Density Lipoprotein Receptor), die 
ik bestudeerd heb in Hoofdstuk 5.13 Dit bleek een cruciaal aspect te zijn in het 
karakteriseren van de opname mechanismen door cellen: tijdens mijn onderzoek kon ik de 
betrokkenheid van zekere moleculaire spelers alleen zien als een complexe corona was 
gevormd en het de LDLR-receptor activeerde (Hoofdstuk 5, Figuur 2 en Supplementary 
Figuur S4). Andere geteste materialen, zoals gecaroxyleerd polystyreen nano-deeltjes van 
verschillende grootte, of condities waardoor LDLR geen rol speelt, gaf geen enige indicatie 
over de mechanismen die van invloed zijn bij opname (data niet weergegeven). We moeten 
wel in beschouwing nemen dat mogelijk andere receptoren, naast de LDLR, een invloed 
kunnen hebben op de opname, en dat nieuwe studies nodig zijn om deze mogelijk andere 
receptoren te identificeren bij alle gebruikte condities. Gezien dit ambitieuze doel, maakte 
het starten met een vergelijkbaar model het mogelijk om de eerste belangrijke inzichten in 
de mechanismen in de opname van nano-deeltjes te verkrijgen, die ik hieronder verder zal 
samenvatten. 
In het algemeen bleek onderzoek in de mechanismen in de opname van nano-deeltjes erg 
complex, ook al zijn er al veel studies op dit onderwerp losgelaten. Er is nog steeds geen 
consensus over welke cellulaire mechanismen nou echt de opname van nano-deeltjes op 
zich nemen. De moeilijkheid in het bestuderen van opname mechanismen stamt af van het 
feit dat endocytose een complex cellulaire proces is op zichzelf, waar veel moleculen, 
terugkoppelingen en signaal cascades een rol spelen. Het endocytose veld in zichzelf 
vernieuwd zichzelf continue (een overzicht van de beschreven routes is te zien in Figuur 1), 
en veel processen en moleculaire details zijn nog onbekend. Om een breed perspectief te 
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bieden over endocytosische mechanismen van invloed bij de opname van nano-deeltjes heb 
ik in Hoofdstuk 2 een gedetailleerd overzicht van dit veld beschreven. Waar ik ook het 
belang van recente vindingen in dit veld heb onderstreept voor de studie naar nano-deeltje 
opname. 
 
Figuur 1 Schematische weergave van de meest genoemde mechanismen van endocytosis. Gereproduceerd uit: Clathrin-
independent pathways of endocytosis. Cold Spring Harbor perspectives in biology (2014).14 
Een ander aspect waarmee rekening moet worden gehouden is dat de meest klassieke 
manieren voor het bestuderen van nano-medicijn opname endocytose routes verstoord. 
Bijvoorbeeld, inhibitie door farmacologische componenten, RNA-interferentie (RNAi) en 
gen modulatie worden gebruikt om bepaalde spelers in endocytose te blokkeren. Al deze 
methoden hebben voor en nadelen die uitgebreid zijn besproken in Hoofdstuk 1.15,16  In 
mijn project heb ik een combinatie van methoden gebruikt, inclusief endocytose inhibitors 
en RNAi voor specifieke endocytose spelers, met het doel om het effect van deze spelers op 
de opname van nano-deeltjes in kaart te brengen. In Hoofdstuk 3 heb ik de uitdagingen 
beschreven die men tegenkomt door het gebruik van een farmacologische inhibitor 
bibliotheek. Hoofdzakelijk de limieten die de hoek om komen kijken bij het gebruik hiervan 
in nano-medicijn opname studies. Zelfs na uitgebreid optimaliseren was de spreiding tussen 
experimenten zichtbaar, voornamelijk wanneer de inhibitie op de opname van silica niet 
erg sterk was. Dit kan worden verklaard door de toxische effecten die deze componenten 
op cellen hebben (zelfs onder geoptimaliseerde condities) of door andere verschillen tussen 
experimenten die moeilijk onder controle te houden zijn (zoals kleine verschillen in het 
aantal geplaatte cellen en de lokale cel dichtheid, of bijvoorbeeld subtiele verschillen in 
nano-deeltje dispersie). Door de gevonden variatie, vind ik het belangrijk om een hoge 
drempelwaarde te gebruiken voordat enige conclusies getrokken kunnen worden. 
Gebaseerd op behaalde resultaten, vind ik een drempelwaard van 40% inhibitie geschikt om 
resultaten te interpreteren, gezien een kleinere inhibitie het gevolg kan zijn van de 
gevonden variatie. 
Een verdere complicatie in het gebruik van deze inhibitors wordt belicht in deze studie door 
het feit dat bij nano-deeltje opname studies – benadrukt op meerdere plekken in deze 
scriptie – moet worden gedaan bij de aanwezigheid van serum, zodat de corona onder 
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fysiologische condities zich kan vormen. Zoals al bekend is in dit onderzoeksveld worden 
serum of andere biomoleculen geadsorbeerd op het oppervlak van nano-deeltjes wanneer 
deze deeltjes in een biologisch medium zijn geplaats. De corona die dan wordt gevormd 
geeft deze nano-deeltjes dan een nieuwe biologische identiteit.17 Hoewel we dit fenomeen 
niet kunnen vermijden wanneer we de interactie tussen nano-medicijnen en cellen of 
tussen nano-medicijnen en in vivo bestuderen, heb ik gevonden dat de effectiviteit van 
sommige inhibitors (dynasore and methyl beta cyclodextrin) compleet verdween door de 
aanwezigheid van serum in situ, waarschijnlijk een gevolg van eiwit interferentie met de 
geteste medicijnen. Het verder verhogen van de concentratie verhoogde voornamelijk hun 
cellulaire toxiciteit. Globaal gezien kunnen we met de behaalde resultaten met deze 
inhibitors alleen gedeeltelijk conclusies trekken over de opname mechanismen van nano-
medicijnen, helemaal bij de aanwezigheid van serum. De enige duidelijke resultaten 
behaald bij de aanwezigheid van serum zijn die van cytochalasin D, die wijst op een actine 
gedreven mechanisme (samengevat in Figuur 2), en met nocodazole, die een betrokkenheid 
van microtubulie suggereert, terwijl de resultaten behaald met EIPA de betrokkenheid van 
macropinocytosis suggereert bij een langere blootstelling. De resultaten behaald met 
chlorpromazine lijkt clathrin gemedieerd endocytosis uit te sluiten, ook al zijn er andere 
studies in de literatuur die dit mechanisme als een van de belangrijkste zien voor de opname 
van nano-deeltjes kleiner dan 100 nm.6 Uiteindelijk zijn andere studies met componenten 
die niet sensitief zijn voor de aanwezigheid van eiwitten en het combineren van 
verschillende methoden voor het karakteriseren van endocytoische mechanismen van nano 
medicijnen nodig om harde conclusies te kunnen trekken.  
 
 
Figuur 2 Opname in cellen blootgesteld aan cytochalasin D voor actine depolarisatie. HeLa cellen werden blootgesteld aan 
verschillende concentraties Cytochalasin D (CytoD). A) Fluorescentie (schaal: 50 μm) en licht microscoop fotos (schaal 150 
μm) van HeLa cellen blootgesteld voor verschillende duraties aan 2,5 μg/ml CytoD, gebruikt als controle voor medicijn 
effectiviteit; groen actine kleuring door TRITC-Phalloidin, en blauw: DAPI gekleurde nuclei. B) Opname door flow cytometry 
van 100 μg/ml rode silica nano-deeltjes in cMEM controle cellen (Ctrl) en cellen blootgesteld aan 2,5 μg/ml CytoD; C) 
Levensvatbarheid door de MTT test van HeLa cellen blootgesteld voor 4 uur aan verschillende doseringen van CytoD in 
cMEM. De levensvatbaarheid data are genormaliseerd door de resultaten behaald met controle cellen zonder CytoD. 
Positieve controle (ctrl +) uitgevoerd zoals beschreven in de methode sectie. Flow cytometry data representeert het 
gemiddelde en de standaarddeviatie van 3 herhalingen van de mediaan fluorescentie intensiteit van minstens 20000 
cellen. 
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Een alternatief om serum interferentie te vermijden, terwijl er nog wel een corona gevormd 
kan worden, heb ik gebruikt in Hoofdstukken 4 en 5. Hier heb ik nano-deeltje corona 
complexen geïsoleerd en geïncubeerd in cellen met serum vrije media. Serumeiwitten 
interfereren niet alleen met de eerder genoemde activiteit van de componenten, maar 
kunnen mogelijk ook concurreren voor dezelfde cellulaire receptoren die nano-medicijen 
gebruiken om opgenomen te worden. Dit soort competitie is de reden waarom er in de 
literatuur veel voorbeelden zijn van studies waar cellulaire routes zonder serum worden 
bestudeerd, bijvoorbeeld wanneer liganden zoals de low-density lipoprotein (LDL) of 
transferrin (TF) worden geïncubeerd met cellen voor het bestuderen van hun bijhorende 
receptoren in clathrin gemedieerde endocytosis.18 Ook hier was de opname van gelabeld 
LDL lager wanneer geïncubeerd met serum dan wanneer geincubeerd zonder serum (voor 
voorbeeld zie Figuur S3A in Hoofdstuk 3). Mijn resultaten laten een vergelijkbaar effect zien 
op de opname van silica nano-deeltjes wanneer de LDL receptor betrokken is (Figuur 2, 
Hoofdstuk 4). In feite, wanneer nano-deeltjes worden geïncubeerd met eiwitten in situ, is 
hun opname erg laag. Maar wanneer de corona nano deeltjes op dezelfde manier worden 
gevormd maar dan worden geïsoleerd en geïncubeerd op cellen in serum vrije conditie is 
hun opname hoger (Getoont in Figuur 3). Daarom, om componenten te kunnen gebruiken 
die sensitief zijn voor de aanwezigheid van serum, zoals dynasore en methyl beta 
cyclodextrin, en om hun opname kinetiek te kunnen monitoren zonder de interferentie van 
serumeiwitten, heb ik in Hoofdstuk 4 en 5 geïsoleerde corona-nano-deeltjes complexen 
geïncubeerd op cellen onder serum vrije condities. 
 
Figuur 3 Opname kinetiek van silica nano-deeltjes gedispergeert in verschillende hoeveelheden menselijk serum. 100 
µg/ml NPs werden gedispergeerd in laag (LS) of hoog (HS) hoeveelheid menselijk serum en meteen geïncubeerd op cellen. 
Als alternatief werden 300 µg/ml NPs geïncubeerd in MEM waaraan  12 mg/ml (LC) of 62 mg/ml (HC) menselijk serum is 
toegevoegd, geïsoleerd zoals beschreven in de materiaal en methode sectie en geïncubeerd op HeLa cellen met een nano-
deeltje concentratie van 100 µg/ml. De resultaten representeren één experiment met 20000 gebeurtenissen opgenomen 
door flow cytometry voor elk tijdspunt. Error balken zijn de standaarddeviaties van triplo’s. 
Met deze opzet, zijn in Hoofdstuk 4 en 5 de mechanismen van nano-medicijn herkenning 
en opname bestudeerd, met extra aandacht voor het milieu waarin de nano-medicijnen zijn 
gedispergeerd. Zoals eerder is genoemd, de blootstelling van nano-medicijnen in 
biologische vloeistoffen, zoals bloed, leid tot de formatie van een -bijna irreversibele- laag 
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van biomoleculen op het nano-deeltje oppervlak, de corona. De moleculaire corona en zijn 
compositie kan invloed hebben op de distributie van nano-deeltjes en kan hun cellulaire 
herkenning en opname veranderen.11–13,19–21 Echter, in de literatuur zijn er veel 
voorbeelden te vinden waar opname mechanismen van nano-medicijnen zijn bestudeerd in 
serum vrije condities of normale celcultuur medium, zoals media aangevuld met foetus rund 
serum, met concentraties die ver liggen van de fysiologische waardes. In Hoofdstuk 4, heb 
ik expliciet bestudeerd tot hoe ver de corona opname mechanismen beïnvloed, en 
inderdaad kon ik aantonen dat de routes die opname van nano-deeltjes verzorgen worden 
beïnvloed door de corona compositie, voornamelijk wanneer dezelfde nano-deeltjes 
worden blootgesteld aan verschillende serum concentraties, zoals standaard in vitro serum 
in cel medium, en fysiologische serum concentratie in vivo. Meer details, zoals bepaalde 
routes, zoals clathrin gemedieerd endocytosis, macropinocytosis en cholesterol 
afhankelijke routes, zijn verantwoordelijk voor de opname van nano-medicijnen alleen 
wanneer lage concentraties van serum zijn gebruikt (zie Figuur 4, Hoofdstuk 4). Dezelfde 
routes worden weinig of niet gebruikt in de opname van dezelfde nano-materialen wanneer 
blootgesteld aan meer fysiologische concentraties. Vergelijkbaar, in Hoofdstuk 5 laat ik zien 
dat de herkenning tussen LDLR en de corona van silica nano-deeltjes, al gedemonstreerd in 
dit artikel13, ook afhankelijk is van de hoeveelheid en de compositie van het gebruikte 
serum voor de formatie van de corona (te zien hier in Figuur 4).  
 
Figuur 4 Opname van silica nano-deeltjes in LDLR onderdrukt HeLa cellen in verschillende media. 100 μg/ml 50 nm silica 
nano-deeltjes zijn gedispergeerd in situ in menselijk serum (HS) of humaan lipide vrij serum (HSD) met een concentratie 
van 4 mg/ml (laag) of 20 mg/ml (hoog) en geïncubeerd voor 24 uur op HeLa cellen met onderdrukte LDLR-activiteit. Als 
alternatief 300 μg/ml 50 nm silica nano-deeltjes werden gedispergeerd in menselijk serum (HS) of humaan lipide vrij serum 
(HSD) met een concentratie van 12 mg/ml (LC) of 62 mg/ml (HC). De gevormde nano-deeltje-corona complexen werden 
geïsoleerd en geïncubeerd met een concentratie van 100 μg/ml nano-deeltjes voor 24 uur op HeLa cellen met onderdrukte 
LDLR-activiteit. Data is uitgedrukt als een percentage van de controle. Controle en monsters werden geïncubeerd met 
dezelfde dispersie als de nano-deeltjes. Error balken zijn de standaarddeviatie van 3 monsters. 
De LDLR was niet betrokken bij de opname van silica wanneer weinig serum werd gebruikt. 
Het is belangrijk om te onderstrepen dat de massa spectrometrie in Hoofdstuk 4 de 
aanwezigheid van ApoB100 – een ligand voor LDLR – in de corona van silica nano-deeltjes 
in beide gebruikte serum condities bevestigd, wat een indicatie is voor de aanwezigheid van 
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bepaald eiwit in de corona. Dat betekend niet dat het wordt herkent door zijn bijhorende 
receptor. Deze vindingen laten zien hoe belangrijk het is om de juiste corona te hebben om 
specifieke cellulaire receptoren te activeren. Om deze reden blijft het lastig om conclusies 
te trekken uit studies gedaan bij serum vrije condities of met serum concentraties ver van 
fysiologische waarden en die te vertalen naar in vivo condities. 
Een ander interessant aspect bevestigt in mijn studies is dat de relatieve overvloed aan 
eiwitten verschillen geeft in de gevormde corona tussen lage en hoge serum concentraties. 
In het bijzonder apolipoprotein A-I was bijna drie keer meer aanwezig in de corona ontstaan 
in de lage serum conditie, terwijl apolipoprotein A-II bijna twee keer, vergeleken met de 
corona gevormd bij de hoge serum conditie. Het tegenovergestelde gebeurde voor het 
histidine-rijke glycoprotein. Interessant genoeg, een studie van macrofagen stelde dat de 
aanwezigheid van histidine-rijke glycoprotein in de corona zorgde voor verlaagde opname, 
wat de resultaten in Hoofdstuk 4 bevestigd.22 Dit suggereert verder dat de specifieke 
compositie van de corona geadsorbeerd aan het oppervlak van het nano-deeltje een invloed 
uitoefent op de opname van dit deeltje. Verder onderzoek in deze richting is nodig om het 
effect van individuele corona componenten op de verschillende opname mechanismen te 
begrijpen. Gezien dit ook een effect heeft op opname efficiëntie. 
Aan de hand van deze resultaten, waren Hoofdstukken 4 en 5 bedoeld om de opname 
mechanismen van nano-deeltjes onder meer fysiologische relevante serum concentraties 
te karakteriseren. In beide hoofdstukken, door de combinatie van verschillende methoden, 
zijn de opname mechanismen van de deeltjes onderzocht. Belangrijker, in Hoofdstuk 4 
suggeren de resultaten (samengevat hier in Figuur 5) dat dezelfde nano-deeltjes de cellen 
binnen gaan via verschillende mechanismen wanneer ze een verschillende corona hebben, 
verder waren in alle condities meerdere mechanismen actief. Bij een hogere hoeveelheid 
serum was de opname gedeelte afhankelijk van dynamin, macropinocytosis, actin en 
microtubulie. Hoewel de reductie in opname nooit meer dan 40% was. Aan de andere kant, 
het is duidelijk dat clathrin gemedieerde endocytosis en cholesterol niet betrokken zijn bij 
de opname van deze nano-medicijnen. Verdere studies in Hoofdstuk 5 hield zich meer bezig 
met de klassieke endocytische spelers via RNAi. Hieruit kwam voort dat meerdere hierbij 
betrokken zijn, al is het gedeeltelijk, bij de opname van silica bij een hogere serum 
hoeveelheid (Figuur 2, Hoofdstuk 5): EPN1, betrokken bij clathrin gemedieerde endocytosis, 
CAV1, en FLOT1, betrokken respectievelijk bij caveolae en flotillin gemedieerde 
endocytosis, ARF6, CDC42 en RHOA, drie GTPases betrokken in meerdere routes, RAC1 en 
ANKF1, voornamelijk betrokken in macropinocytosis (voor verder detail zie Hoofdstuk 2). 
Onder deze spelers was een verhoging van de LDLR gezien alleen na inhibitie van RAC1. Wat 
kan betekenen dat we deze speler van onze conclusies kunnen excluderen. Bovenal, mijn 
resultaten geven een duidelijk indicatie dat clathrin gemedieerde endocytosis niet 
betrokken was bij nano-deeltje opname, zelfs als de route normaal betrokken zijn bij de 
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opname van LDLR (zie figuur 2, Hoofdstuk 5).23 Weinig artikelen zo ver hebben onderstreept 
dat andere routes voor LDLR opname mogelijk zijn, zoals macropinocytosis, caveolae 
gemedieerde endocytosis en anderen, al is dat voornamelijk in cel typen die afwijken van 
de HeLA cellen die hier gebruikt zijn.23–26 Daarom zijn deze resultaten, die suggereren dat 
LDLR afhankelijke opname van nano-deeltjes wordt gemedieerd door (misschien meerdere) 
routes anders dan CME in HELA cellen, of dat sommige van de nano-deeltjes worden 
opgenomen door andere routes niet gemedieerd door LDLR. Een ander mogelijk 
interpretatie van deze resultaten is dat nano-materialen hun opname kunnen initiëren via 
minder bekende routes. 
 
Figuur 5 Opname mechanismen van silica nano-deeltjes in lage en hoge hoeveelheid serum. 300 µg/ml nano-deeltjes 
werden geïncubeerd in MEM waarin 12 mg/ml (LC) of 62 mg/ml (HC) menselijk serum is toegevoegd. Geïsoleerd zoals 
beschreven in de materiaal en methode sectie. De monsters werden geïncubeerd op HeLa cellen met een nano-deeltjes 
concentratie van 100 µg/ml met de aanwezigheid of afwezigheid van 100µM EIPA, 10 µg/ml chloropromazine, 2.5 mg/ml 
methyl-β-cyclodextrin (MβCD), 25 μg/ml dynasore, 2.5 µg/ml cytochalasin D of 5 µM nocodazole. Data is genormaliseerd 
voor de fluorescentie intensiteit van onbehandelde cellen. De resultaten zijn het gemiddelde van drie experimenten en 
de error balken zijn de standaarddeviatie. 
In deze context is in Hoofdstuk 5 een paneel aan endocytische doelen, die amper 
onderzocht zijn in dit soort studies, geselecteerd voor hun mogelijke invloed op nano-
deeltje opname. In recente jaren heeft onderzoek in endocytosis zich gefocust op meerdere 
niet-gebruikelijke clathrin onafhankelijke routes. Deze routes zijn moeilijker om te 
bestuderen maar zijn wel mogelijke routes voor de opname van nano-medicijnen. In het 
bijzonder, zoals besproken in Hoofdstuk 5, in vitro studies van nano deeltje – membraan 
interacties laten zien dat nano-materialen meerdere veranderingen induceren, 
bijvoorbeeld het induceren van membraan kromming.27,28 De meest endocytische 
mechanismen gebruiken een klasse van eiwitten die domeinen bevatten met gebogen 
topografie, genoemd BAR-domeinen. Ze zijn gespecialiseerd in de herkenning en het 
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induceren van membraan kromming.29–31 Echter, een paar studies hebben gekeken op 
moleculair niveau wat nodig is voor membraan kromming en vesikel formatie voor de 
opname van nano-materialen.27,28 Dus in Hoofdstuk 5, gegeven de complexiteit van 
resultaten behaald in het karakteriseren van opname mechanismen, waarbij meerdere 
routes gebruikt worden, en gezien de vinding dat nano-deeltjes membranen kan verstoren, 
heb ik de mogelijkheid onderzocht dat nano-deeltjes membraan buiging en hun opname 
kunnen induceren door de herkenning en inductie van membraan kromming gemedieerd 
door BAR-domein eiwitten. 
Interessant genoeg, de inhibitie van bepaalde BAR-domein eiwitten, zoals BIN1, IST1, 
PACSIN2, resulteerde in een afname van nano-deeltje opname, tot 50% vergeleken met de 
controle (Figuur 3, Hoofdstuk 5 en hier in Figuur 6). Wat sterker of vergelijkbaar is met de 
resultaten van de ander onderzochte spelers. Hoewel dit alleen een eerste observatie is en 
verdere studies nodig zijn om de invloed van de kromming eiwitten op opname van nano-
deeltjes te karakteriseren, laten deze resultaten al wel zien dat de membraan kromming 
mechanismen een belangrijke rol kunnen spelen in de opname van nano-materialen. 
 
Figuur 6 Opname van silica nano-deeltjes-corona complexen gemedieerd door kromming eiwitten in HeLa cellen. HeLa 
cellen werden getransfereerd met de genoemde siRNA’s. Na 72 uur, 300 μg/ml silica nano-deeltjes werden geïncubeerd 
voor 1 uur 37˚C in 60 mg/ml humaan serum, gecentrifugeerd voor 1 uur waarna de pellet werd gesuspendeerd in serum 
vrij MEM. 100 μg/ml van nano-deeltje-corona complexen werden geïncubeerd op HeLa cellen voor 14 uur, daarna werd 
de cel fluorescentie intensiteit gemeten door flow cytometry. Data representeert het gemiddelde van 2 experimenten en 
de error balken zijn de standaarddeviatie. 
Uiteindelijk, hoewel in alle Hoofdstukken zover Hela cellen als standaardmodel gebruikt zijn 
voor het onderzoek naar de opname mechanismen van nano-medicijnen, heb ik in 
Hoofdstuk 6 gekeken of georganiseerde cel lagen een beter in vitro model zijn die beter 
sommige barrières weergeven die nano-medicijnen in vivo tegenkomen.6,7,16,32 Endotheliale 
cellen zijn één van de eerste barrières die nano-medicijnen moeten overkomen om hun 
doel orgaan binnen te gaan na toedieningen in de bloedsomloop.33,34 Dus in Hoofdstuk 6 
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heb ik gekeken naar het effect van de formatie van cellulaire barrières met cellen die zonula 
occludens (tight junctions) vormen op de opname van silica nano deeltjes. Na een 
extensieve optimalisatie van de condities om HUVEC (Menselijk Navelstreng ader 
endotheliale cellen) te groeien in een barrière in vitro, kon ik bepalen dat de formatie van 
cellen in een cel barrière resulteerde in een lagere expressie van verschillende endocytische 
markers en dat het een effect had op nano-deeltje interactie met cellen. In het bijzonder, 
HUVEC-barrières lieten een lagere opname zien vergeleken met geïsoleerde en niet 
gedifferentieerde HUVEC cellen. Deze resultaten laten ook zien dat confluentie alleen niet 
de formatie van een cel barrière garandeert met zonula occludens expressie. Naast deze 
eerste uitkomt, heb ik in Hoofdstuk 6 ook geprobeerd om endocytische mechanismen 
betrokken bij de opname van nano-materialen in cel barrières te bestuderen. Hoewel de 
transport inhibitors gebruikt voor dit doel vaak een verlies van barrière integriteit 
betekenen en daardoor niet geschikt zijn voor dit modelsysteem. Dit is een andere uitdaging 
in het karakteriseren van opname mechanismen, en verschillende technieken geschikt voor 
vergelijkbare cel monolagen moeten worden ontwikkeld om deze uitdaging aan te kunnen 
gaan. Gezien het sterke effect van een cel barrière op de opname van nano-deeltjes, kunnen 
andere aspecten geïmplementeerd worden om zo in vitro modellen te maken die dichterbij 
komen bij de complexiteit van endotheliale cel barrières gezien in vivo. Dit zou bijvoorbeeld 
kunnen worden gedaan door de formatie van een extracellulaire matrix of door de 
toevoeging van spiercellen en bindweefsel, waarvan bekend is dat ze fundementeel zijn 
voor het onderhouden van endotheliale cellen in vivo. Verder kunnen 3D structuren 
gebruikt worden voor de promotie van cel differentiatie door het faciliteren van de formatie 
van endotheliale buisjes.35  Vergelijkbaar, door de toevoeging van een microfluïde systeem, 
wat de bloedsomloop zou moeten voorstellen, zien we een effect op de expressie van 
endotheliale cel receptoren. Al deze factoren kunnen een effect hebben op de opname van 
nano-deeltjes.37–42 
In conclusie, in dit project heb ik geprobeerd een basis te geven voor een meer rationale 
ontwikkeling van nano-medicijnen. Dit voornamelijk door de interactie van nano-
materialen met cellen in meer detail in kaart te brengen. Deze scriptie is een poging om 
moleculaire mechanismen te beschrijven die leiden tot cel interactie en opname van nano-
materialen en geeft de mogelijkheid dat andere mechanismen, naast de klassieke, 
betrokken zijn. Verdere studies zijn nodig om routes en spelers hierin verder in kaart te 
brengen. Ook zijn verdere studies nodig om te kijken of de resultaten bepaald hier ook 
gelden voor andere cellen, andere nano-deeltjes en andere blootstelling (corona) condities. 
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